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Acute Myeloid Leukemia (AML), caused by the uncontrolled proliferation of the leukocytes 
of the myeloid lineage, is a cancer with a very high mortality rate. Present therapies to treat 
AML include chemotherapy and bone marrow transplant. These methods suffer from certain 
inherent limitations such as heavy cytotoxicity and innocent bystander effects in the case of 
the former and acute allograft rejection in the latter. Hence there is an urgent need for more 
effective therapeutic strategies. 
In this study, we have evaluated the efficacy of two such potential therapeutic drugs, namely 
Rapamycin (rapa) and Genistein (GEN) and have characterised their mechanism of action 
using high-throughput strategies. A combination of microarray and 4-plex iTRAQ based 
approach was adopted to study the effects of rapa on MV4-11 and THP-1 cells and an 8-plex 
iTRAQ based methodology was employed to profile the proteome of the MV4-11 and HL-60 
cells treated with GEN. 
We found that rapa had potent anti-proliferative effect on all the AML cell lines tested. We 
chose the cell lines with the lowest and highest IC50, MV4-11 and THP-1 respectively, for 
functional characterisation. High-throughput studies indicated that rapa regulates Cell cycle, 
IGF-1 and FGF signalling, death receptor signalling, protein ubiquitination and hypoxia 
signalling pathways. Functional studies showed that rapa did not induce apoptosis but 
effected a time-dependent G1 arrest, with the peak inhibitory effect at 16 h. Interestingly, rapa 
down-regulated IGFBP2, usually elevated in AML patients. Our study showed that rapa 
represses Skp2, an important constituent of the protein ubiquitination pathway. Working on 
this clue, we identified that the time dependent G1 arrest is in fact the result of the inhibition 
of Skp2, leading to the accumulation of p27, which in turn causes repression of Cdk2 and 
Cdk4. 
In the second study, we found that GEN had inhibitory effects on both the MV4-11 (IC50 
20µM) and HL-60 (IC50 30µM) cells. We discovered that GEN inhibited the constitutive 
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phosphorylation of FLT3 in the MV4-11 cells, which carry the FLT3-ITD (Internal Tandem 
Duplication) mutations. However, GEN had potent anti-leukemic effects on the HL-60 cells 
too, in spite of them possessing the wild-type version of the gene. 
 A purely proteomic-based approach, using the 8-plex iTRAQ strategy, was employed to 
understand the dynamics of GEN‟s effects on the two subsets of AML. We found that GEN 
down-regulated the mTOR pathway, thus arresting protein synthesis in the AML cells. GEN 
up-regulated Akt, leading to elevation in the reactive oxygen species (ROS) levels which in 
turn caused apoptosis. While HL-60 underwent a caspase- mediated cell death, the apoptosis 
in MV4-11 was caspase independent. GEN induced arrest at the G2/M phase of the cell cycle 
in HL-60 while it caused a moderate G1 arrest in MV4-11. We can attribute these differences 
in the mechanism of action of GEN to the FLT3 mutational status of the two cell lines. Hence, 
we conclude that GEN has an all encompassing anti-proliferative effect on AML irrespective 
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REVIEW OF LITERATURE 
The literature review section comprises of an in-depth examination of the biology of acute 
myeloid leukemia, the drugs rapamycin and genistein, and an evaluation of the advantages of 
combining high-throughput approaches and functional analyses to study the mechanism of 
action of drugs. 
 
1.1 Cancer 
Cancer is a disease which is defined by the uncontrolled growth and proliferation of a group 
of cells. Cancer has afflicted humans for a long time. It is the leading cause of death in the 
western countries, second only to heart disease. According to the American Cancer Society‟s 
reports, the disease accounts for nearly 23.1% of all deaths in the United States of America 
alone. In Singapore too, the statistics show a similar trend, with cancer causing 25.6% of all 
deaths (Look, et al., 2001), making it one of the leading causes of mortality.  
Cancer is a composite disease and is classified based on the individual organs and systems of 
the body where it develops. In clinical terms, cancer is defined as a collective term to include 
a large number of complex diseases, up to a hundred, that behave differently depending upon 
the cell types that they originate from. Cancers of the blood, liver, lung, breast, ovary, cervix, 
prostate, testis, colon, rectum, pancreas, lymph and kidney, are among the common 
manifestations of this disease.   
Metastasis refers to the spreading of cancer from its primary site of origin to other parts of the 
body. The lethal combination of uncontrolled cell proliferation and metastasis makes cancer 
cells highly dangerous. Most cancers, with the notable exception of leukemia, are 
characterised by the formation of a tumour, a lesion like growth of an abnormal cluster of 
cells. Tumours could be benign (harmless, non-metastatic), pre-malign, or malign (harmful, 
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cancerous, and metastatic). While benign tumours can be surgically removed with no serious 
harm, malignant tumours are very difficult to treat. 
Cancer is a genetic disease involving a multitude of genomic alterations such as single-
nucleotide substitutions, large-scale chromosomal rearrangements, amplifications and 
deletions. The development of cancer is a multistep process and is influenced by a variety of 
risk factors such as age, sex, life style, diet, genetic makeup, etc. The causal factors 
contributing to cancer development are diverse. It is often a culmination of multiple factors 
that interact over a long period of time. On the one hand, the risk factors include heredity, 
abnormal genetic regulation and genetic makeup of some individuals. On the other hand, in 
many cases, the onset of the disease may be due to certain cancer causing agents called 
carcinogens such as tobacco and ionising radiations (Sasco, et al., 2004). It has been found 
that some viruses such as the human papillomavirus also induce tumours (zur Hausen, 2009). 
One of the most lethal among the various types of cancers is acute myeloid leukemia.  
 
1.2 Acute Myeloid Leukemia  
The etymology of the term „leukemia‟ is derived from ancient Greek, „leukos‟ meaning white 
and „aima‟ meaning blood. It is the cancer of white blood cells (leukocytes). It is a 
hematopoietic stem cell disorder characterised by a block in differentiation of hematopoiesis, 
resulting in growth of a clonal population of neoplastic cells or blasts. It is broadly classified 
into 2 categories: 
1) Acute Leukemia: This is the result of rapid increase in the levels of immature blood cells. 
It is the most common type of leukemia in children. It progresses fast and hence requires 
immediate treatment. The malignant cells if left untreated, pose the risk of metastasising 
through the bloodstream into other organs of the body. 
2) Chronic Leukemia: This is characterised by the accumulation of relatively mature blood 
cells, over a period of months to years. In contrast with acute leukemia, chronic leukemia is 
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monitored over a period of time to ensure maximum effectiveness of the therapy. The 
frequency of affliction is greater among older people.  
Additionally leukemia is subdivided based on the type of white blood cells (WBC) affected. 
Hence there are two subdivisions based on this classification method, namely: 
a) Lymphocytic leukemia: The cancer develops in the lymphoid lineage of cells. 
b) Myelogenous (myeloid) leukemia: The cancer occurs in the myeloid lineage of cells. 
Hence by the combination of these two classification strategies, we recognise four types of 
leukemia (Table 1.1): 
 
Table 1.1: Classification of leukemia by lineage and tumourigenicity 
  
Affected cell lineage Acute Chronic 
Lymphocytic Acute lymphocytic leukemia Chronic lymphocytic leukemia 
Myelogenous 
(Myeloid) 
Acute myelogenous leukemia Chronic myelogenous leukemia 
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1.2.1 Biology of AML 
Acute Myeloid Leukemia (AML) is a cancer of the leukocytes of myeloid lineage, 
distinguished by uncontrolled proliferation of hematopoietic precursor cells with decreased 
rate of self destruction and impaired differentiation. They comprise a heterogeneous group of 
malignancies of hematopoietic progenitor cells with different genetic abnormalities, clinical 
characteristics, and variable outcomes with currently available treatments (Gilliland and 
Tallman, 2002). The diagnosis of AML is now established when at least 20% of the cells 
identified in the blood or bone marrow are blasts of myeloid origin. 
AML is principally classified based on the French-American-British (FAB) system, devised 
in 1976, which was later reviewed and revised in 1985. This is the most widely used system 
and the default methodology adopted to classify AML. AML is categorised eight-fold hence 
in Table 1.2. 
 
Table 1.2: French-American-British (FAB) system of classification of AML  
 
  
Category Morphology Incidence (%) 
M0  AML with no differentiation 3 
M1 AML without maturation 15-20 
M2 AML with granulocytic maturation 25-30 
M3 Hypergranular APML 5-10 
M3 variant Hypogranular variant APML  
M4 Acute myelomonocytic leukemia 25-30 
M5a Acute monoblastic leukemia 2-10 
M5b Acute monocytic leukemia  
M6 Erythroleukemia 3-5 
M7 Megakaryoblastic leukemia 3-12 
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The classification depends on accurate morphological and cytochemical quantitation of the 
degree of differentiation and level of lineage commitment. The classification of AML in this 
system is defined by the presence of greater than 30% myeloid blasts in the bone marrow 
(Smith, et al., 2004) and their reactivity with histochemical stains, including 
myeloperoxidase, Sudan black, and the nonspecific esterases α-naphthylacetate and 
naphthylbutyrate. 
An alternate system of classification is adopted by WHO which aims to demarcate distinct 
clinical entities within the spectrum of AML types as listed in Table 1.3. However this system 




Table 1.3: World Health Organisation (WHO) classification of AML 
 




AML with recurrent 
cytogenetic 
translocations 
AML with features of t(8;21)(q22;q22) 
AML with features of t(15;17)(q22;q12) 
AML with features of inv(16)(p13;q22) 





AML with MDS-related 
features 
AML with multi-lineage dysplasia 
AML arising in previous MDS 
10–15 
 
Acute myeloid leukaemia, 
unspecified 
AML minimally differentiated [M0] 
AML without maturation [M1] 
AML with maturation [M2] 
Acute myelomonocytic leukaemia [M4] 
Acute monocytic leukaemia [M5] 
Acute erythroid leukaemia [M6] 
Acute megakaryocytic leukaemia [M7] 
Acute basophilic leukaemia 
Acute panmyelosis with myelofibrosis 
40–50 
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1.2.2 Epidemiology of AML 
AML accounts for 30% of all adult leukemia incidences. The epidemiology of AML shows 
some interesting trends. The disease has an incidence of 3.7 per 100,000 persons in the U.S.A. 
However it has an age-dependent mortality of 2.7 to nearly 18 per 100,000 persons. 
According to the American Cancer Society, 31,500 individuals in the U.S. will be diagnosed 
with leukemia annually. An estimated 21,500 patients will die of this disease. The annual 
incidence rates in Europe were between 2 and 4 per 100,000. In Singapore, leukemia is the 
tenth most common cancer among males (http://www.singaporecancersociety.org.sg/lac-gci-
cancer-facts-n-figures.shtml). Although it is a relatively rare form of cancer, it has 
disproportionate survival rates in comparison to other cancer types. The incidence of acute 
leukemia is <3% of all cancers, and yet it constitutes the leading cause of death due to cancer 
in children and persons age <39 years (Deschler and Lübbert, 2006).  
The median age of patients afflicted with this disease is 65. The survival rates of patients are 
age dependent. In Europe, five year relative survival decreased markedly with age. While 
37% of patients between the 15–45 years age bracket survived, the rate among the oldest 




1.2.3 Aetiology of the disease 
There are many risk factors for AML. Age is an important factor among others as described 
earlier. It is a disease predominantly of later adulthood. Familial history of haematological 
disease is another factor. Genetic disorders including Down syndrome, Klinefelter syndrome, 
Patau syndrome, Ataxia telangiectasia, Shwachman syndrome, Kostman syndrome, 
Neurofibromatosis, Fanconi anemia, Li-Fraumeni syndrome, etc greatly increase the 
vulnerability to AML (Deschler and Lübbert, 2006). 
Exposure to toxic chemical agents such as benzene, pesticides, cigarette smoking, embalming 
fluids, herbicides and radiation such as ionising rays from nuclear bombs, and medical 
procedures are high risk factors (Deschler and Lübbert, 2006) (Smith, et al., 2004). In some 
cases even certain kinds of drugs and chemotherapeutic agents have proven to increase the 
susceptibility to AML depending on the dosage and patient characteristics. These include 
alkylating agents, anthracyclines, taxanes, fludarabine, chlorambucil and cyclophosphamide 
(Morrison, et al., 2002; Verma, et al., 2009). 
RNA retroviruses have been found to cause many neoplasms in many cancers including 
leukemia, albeit a clear link hasn‟t been identified yet. Parvovirus B19 seems to play a major 
role in the pathogenesis of AML (Kerr, et al., 2003). 
 
1.2.4 Genetic abnormalities in AML 
AML is characterised by many genetic translocations and mutations. They frequently occur in 
leukemia incidences. The Figure 1.1 lists the common mutations which predominate acute 
leukemias. Prominent among them is associated with t(1t5;17)(q22;q12) giving rise to the 
PML/RARα fusion in the case of acute promyelocytic leukemia. The AML1 and CBFβ 
components of the heterodimeric transcription factor core binding factor (CBF) are prone to 
translocations including t(8;21)(q22;q22) and inv(16)(p13q22). Activating point mutations in 
the genes such as RAS, FLT3, and c-KIT as well as loss of function mutations have been 
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frequently implicated in AML progression, survival and drug resistance (Gilliland and 
Tallman, 2002).  
 
 
                                  
 
 
Figure 1.1: Common genetic abnormalities associated with AML (adapted from (zur 
Hausen, 2009)) 
There are various genetic abnormalities including translocations and mutations which 











FLT3 (Fms-like tyrosine kinase 3), is a gene encoding a receptor tyrosine kinase belonging to 
the class III receptor tyrosine kinase family (RTKIII), which is 993 amino acids in length. It is 
expressed by immature hematopoietic cells and is crucial to the proliferation, differentiation 
and apoptosis of haematopoietic cells. In 1996, Nakao et.al identified that the FLT3 gene in 
certain AML cases possessed an internal tandem duplication in the juxtamembrane domain 
(Nakao, et al., 1996), rendering it constitutively active. It is the result of a head-to-tail 
duplication of 300–400 base pairs in exons 14 or 15. It is quite common in AML and occurs 
in around 24% of the cases. This mutation has not been detected in normal hematopoietic 
cells and is specific to AML. Subsequently it was reported that the point mutation D835 
occurs in the activation loop of FLT3. It is relatively rare in comparison to the ITD mutation 
and is known to be present in 7% of all AML cases. These mutations might confer perpetuity 
to the activated status of FLT3 by relieving it of its autoinhibitory function (Gilliland and 
Griffin, 2002). 
ITD mutations of FLT3 cause ligand-independent dimerisation and tyrosine 
autophosphorylation (Kiyoi, et al., 1998). Cells containing this mutation had an increased 
expression of STAT5 and RAS/MAPK pathways. The frequency of FLT3-ITDs in patients 
with AML increases with age, ranging from 5–15% in paediatric patients to 25–35% in 
adults.  FLT3 has been found to be associated with poor prognosis in a number of studies. 
Clinical studies showed that patients with FLT3-ITD mutations had significantly smaller 
survival rates and died earlier than patients with wild type FLT3 gene. Hence there is a 
suggestion to classify patients with FLT3-ITD mutations as having high-risk disease (Abu-
Duhier, et al., 2000) .  
 
1.3 Current treatment strategies for AML 
The acute nature of the disease makes it fatal if left untreated, over a period of days to weeks, 
depending on the blast count level in the peripheral blood. Hence immediate treatment is 
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essential. The current therapies for AML involve chemotherapy which combines therapeutic 
agents such as cytarabine (ara-C) and an anthracycline (daunorubicin or idarubicin) followed 
by multiple cycles of intensive post-remission therapy with elevated-dosage of ara-C 
(Gilliland and Tallman, 2002) (Mayer, et al., 1994). However, profound myelosuppression, 
frequent relapse of patients, poor response to therapy and development of resistance to the 
administered drugs are common deterrents to the treatment strategies.  
With the advent of all transretinoic acid (ATRA) and arsenic trioxide (ATO), curing acute 
promyelocytic leukemia (APL), a subtype of AML (M3 and variant) has become a reality. In 
the case of ATRA therapy, the strategy involves early addition of chemotherapy such as ara-C 
to ATRA treatment and maintenance therapy, which involves continuous chemotherapy and 
intermittent ATRA treatment. Such an approach has been proven to reduce the incidence of 
relapse in APL and increase the chances of a disease free survival to 75-85% (Fenaux, et al., 
1999). ATO when used alone in relapsed APL patients, a remission rate of greater than 80% 
and a 2-year survival rate of around 60% were observed. When ATO was used in 
combination with ATRA and gentuzumab, seven of eight patients achieved 100% remission. 
Six of eight patients remained in remission after 3 years (Quezada, et al., 2008). 
Alternate therapies in development include gemtuzumab ozogamicin, an anti-CD33 
monoclonal antibody chemically linked to the potent cytotoxic agent calicheamicin. This 
induces complete remission in CD33-positive AML (Sievers, et al., 2001). 
Mutation in the FLT3 gene is the single most common genetic alteration in AML. This makes 
it a very attractive target for therapy. The FLT3 mutations make the cells refractory to most 
conventional drugs, necessitating alternate therapies for such patients. This has driven 
researchers to specifically design and develop drugs specifically to combat AML with FLT3-




Table 1.4: FLT3 inhibitors in different stages of development 
 
Compound Company Receptor Responses 
CEP-701 
 
Cephalon FLT3 (wild-type 
and mutant) 
1 of 8 patients: 
5% blasts in bone 
marrow 
SU5416 Sugen FLT3 (wild-type 
and mutant) KIT, FMS 
and PDGFR 




SU11248 Sugen FLT3 (wild-type 
and mutant) KIT, FMS 
and PDGFR 





MLN518 Millenium FLT3 (wild-type 
and mutant) KIT and 
PDGFR 
8 patients, 2 out 




PKC412 Novartis FLT3 (wild-type 
and mutant) PKC, 
VEGFR and PDGFR 
1 of 8 patients: 
>50% reduction 
in marrow blasts 
L-000021649 Merck FLT3 (wild-type 
and mutant) and VEGFR 




FLT3 inhibitors such as PKC412 are being tested in combination with conventional 
chemotherapeutic agents such as ara-c, doxorubicin, idarubicin, etoposide and vincristine with 
encouraging results in cell lines carrying a FLT3 mutation. They do not exert similar 
inhibitory effects in cells with wild-type FLT3 gene (Furukawa, et al., 2007) (Odgerel, et al., 
2008).  
However, the above mentioned strategies are restricted to the treatment of a subset of the 
disease, such as a particular subtype or cells carrying a particular mutation. The most potent 
generic therapy thus far is hematopoietic stem cell transplantation (HSCT) from a human 
leukocyte antigen (HLA)-matched donor (Gilliland and Tallman, 2002). Autologous as well 
as allogeneic bone marrow transplantation is found to result in better disease-free survival and 
reduced rate of relapse than intensive chemotherapy with high-dose cytarabine and 
daunorubicin (Zittoun, et al., 1995) (Gorin, 1998). However the overall survival was found to 
be marginally better in chemotherapy. The treatment-related mortality of HSCT was 
approximately 20% as observed in randomised clinical trials. This offsets any advantage that 
this approach offers (Cassileth, et al., 1998). The inherent drawbacks in each of these current 
treatment methods, necessitates the search for an effective, less toxic and more directed 
therapy for AML. 
 
1.4 Rapamycin 
1.4.1 Discovery and physical properties 
Rapamycin (Rapa) also known as sirolimus, was first identified in 1975, as an antibiotic, 
produced by a strain of Streptomyces hygroscopicus, which was isolated from a soil sample 
collected from the Vai Atare region of Rapa Nui (commonly known as Easter islands). Rapa 
is a white crystalline solid with a melting range of 183° to 185°C. It is a lipophilic 
macrocyclic lactone, soluble in most organic solvents and virtually insoluble in water. It has a 
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molecular weight of 914. The structure of rapa was resolved with the aid of two-dimensional 






                               
                                            
 
 




Rapa was found to have strong anti-fungal action. It is a FDA approved immunosuppressant, 
and is capable of reversing acute active allograft rejection and enhancing long-term donor-
specific allograft tolerance  (Sehgal, 2003). Interestingly, it was observed that rapa showed 
promise as an anti-tumour drug. Studies pertaining to the anti-tumoural activity of rapa and its 
analogs (CCI-779, RAD001) and the possibility of using it as therapy for certain cancers are 
underway (Galanis, et al., 2005; Chan, et al., 2005; Agarwala and Case, 2010).  
 
1.4.2 Rapamycin as an immunosuppressant 
Rapa‟s immunosuppressive property was discovered when it was observed that it prevented 
experimental allergic encephalomyelitis and adjuvant arthritis and inhibited the production of 
antibodies. Rapa is a highly effective immunosuppressant in organ transplantation. This is due 
to rapa‟s unique mechanism of immunosuppression, favourable side effect profile with no end 
organ toxicity, and its synergistic action with other established immunosuppressants without 
overlapping toxicity (Sehgal, 2003). 
Rapa belongs to a class of macrolide immunosuppressants whose activity is based on their 
binding to specific cytosolic binding proteins called immunophilins. Rapa specifically binds 
to the immunophilin FKBP12 (FK506 binding protein of 12 KDa). Other members of this 
class include cyclosporine A and FK506 (Sehgal, 1998). 
 
1.4.3 Antifungal properties of rapamycin 
Rapa exhibits strong antifungal effects and was initially discovered by virtue of this property. 
A number of other immunosuppressants of the same classification as rapa including 
cyclosporine A and FK506 possess similar potency against fungi. Rapa is mainly active 
against Candida albicans with a minimum inhibitory concentration range from 0.02 to 0.2 
µg/ml, against ten strains. It is also effective against Microsporum gypseum and Trichophyton 
granulosum, C. neoformans, C. albicans, Candida stelloidea, A. fumigatus, 
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Aspergillus flavus, Aspergillus niger, Fusarium oxysporum, and Penicillium sp. It was found 
to be more potent than amphotericin B, the established fungicidal agent in use. Overall, rapa 
exerted its antifungal activity via FKBP12 and TOR homologs in C.albicans (Wong, et al., 
1998; Cruz, et al., 2001). 
 
1.4.4 Mechanism of action of rapa 
Rapamycin is a known inhibitor of the mammalian Target Of Rapamycin (mTOR) pathway. 
The mechanism of this inhibition has been well established. 
1.4.4.1 Structure of the mTOR protein 
mTOR is known by several other names such as FK506-binding protein (FKBP12), 
rapamycin- associated protein (FRAP), rapamycin and FKBP12 target (RAFT1), rapamycin 
target (RAPT1), and sirolimus effector protein (SEP). The TOR proteins were identified 
originally in yeast, by virtue of mutations of two rapa target genes, which helped yeast escape 
the cell cycle arrest caused by rapa. The mammalian counterpart of this protein was identified 
subsequently to be a 289 kDa protein that has C-terminal homology to phosphatidylinositol-3 
kinase (PI3K) and is therefore a member of the PI3K-related kinase family. Further studies 
revealed that rapa forms a complex with the immunophilin FKBP12 (Sabatini, et al., 1994). 
This complex then forms a ternary complex with mTOR. This binding leads to inhibition of 
the function of the mTOR protein, an atypical serine/threonine protein kinase. The structure 
of mTOR has been elucidated (Figure 1.3). It contains up to 20 tandem repeats of the HEAT 
domain (a protein-protein interaction structure of two tandem anti-parallel α-helices found in 
huntingtin, elongation factor 3, PR65/A and TOR) repeats at the N-terminal region, followed 
by FAT (FRAP, ATM, and TRRAP, all PIKK family members) domain. The ternary complex 
formation is due to the presence of the FRB (FKBP12/rapamycin binding) domain. The 
kinase domain lies sandwiched between the FRB and the FATC domains, at the C-terminus of 
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the protein. The HEAT domain mediates protein-protein interactions, and the FATC domains 

















































1.4.4.2 Functional roles of mTOR 
mTOR controls a number of functions related to cell growth, among which are cell cycle 
checkpoint regulation, translation, transcription, and protein kinase C signalling. The actions 
of mTOR are defined by its upstream and downstream effectors. Two very important mTOR 
downstream effectors are S6K1 (p70 ribosomal protein S6 kinase1) and 4E-BP1 (eIF4E 
binding protein 1). Usually, S6K1 and 4E-BP1 are bound to eIF3 (eukaryotic initiation factor 
3) which renders them inactive. However, in response to stimulatory agents such as growth 
factors, mTOR binds to eIF3 and phosphorylates S6K1 and 4E-BP1. This releases S6K1 from 
eIF3, thus activating the kinase. The active S6K1 promotes translation and growth by 
phosphorylating cellular substrates such as S6. 4E-BP1 inhibits cap dependent mRNA 
translation via binding to the translation initiator eIF4E (eukaryotic translation initiation 
factor 4E). The phosphorylation of 4E-BP1 by mTOR frees it from eIF4E, relieves its 
inhibitory effect and stimulates translation initiation. Hence, active mTOR enhances cell 
growth by promoting protein translation, and increasing cell mass (Schmelzle and Hall, 
2000). A key regulating partner of mTOR is the PI3K/Akt pathway. It interacts with growth 
factors and their receptors as well as other mitogenic stimuli. PI3K is usually activated in 
response to growth factors such as IGF-1. 
 
1.4.5 Rapamycin as an anti-cancer agent 
Hyper activity of mTOR is known to promote cancer. Rapa binds to mTOR by means of the 
FKBP12-rapa complex and inhibits the kinase action of mTOR. This abrogates the 
phosphorylation of S6K1 and 4E-BP1, which leads to arrest in the translation of proteins 
needed for cell cycle progression and cell growth. This confers rapa with profound anti-




Rapa is hence a promising cure for cancer. A number of analogs of rapa such as CCI-779, 
RAD 001 and AP23573 are undergoing clinical trials for various cancers such as prostrate, 
breast, non- small cell carcinoma, glioblastoma and melanoma (Chan, et al., 2005) (Galanis, 
et al., 2005) (Mita, et al., 2008) (Johnson, et al., 2007) (Johnston, et al., 2010) (Hainsworth, et 
al., 2010), with encouraging results.  
There have been very few studies investigating the anti-leukemic effects of rapa. The work by 
Récher et al (Récher, et al., 2005) attributes an anti-leukemic effect to rapa in blast cells. 
There are reports which suggest aberrant regulation of mTOR in leukemia, hence making it an 
attractive target for rapa mediated therapy (Panwalkar, et al., 2004) (zur Hausen, 2009). In 
spite of these studies, a thorough understanding of the regulatory effects of rapa on other 
molecules and pathways are still vague and not much is known about the perturbations caused 
by the drug treatment on the cell as a whole. All the previous studies pertaining to the anti-
proliferative effects of rapa employed the traditional approach of investigating individual 
pathways, in this case just the mTOR and PI3K/Akt. We were interested in studying the effect 
of rapa on AML at the global level, by mapping all the transcriptomic and proteomic 
modulations caused by the drug. Such a study would go a long way in illustrating the 
mechanism of action of rapa in AML in its totality and in expanding our cognizance of the 
repertoire of its targets.  
 
1.5 Genistein 
1.5.1 Physical properties 
Genistein (GEN) is a member of the family of chemicals called isoflavones, which are a class 
of estrogen like compounds found in soy. GEN is a natural tyrosine kinase (TK) inhibitor. In 
the search for specific inhibitors for tyrosine kinases, it was isolated from the fermentation 
broth of Pseudomonas sp.  
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Gen is the simplest of the isoflavonoid compounds of Leguminosae on a biosynthetic level 
(Dixon and Ferreira, 2002). Chemically known as 5, 7-Dihydroxy-3-(4-hydroxyphenyl)-4H-
1-benzopyran-4-one or 4', 5,7-Trihydroxyisoflavone, its chemical formula is C15H10O5n 











                                       
 
 Figure 1.4: Chemical structure of genistein   
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1.5.2 Versatility of GEN 
The major dietary sources of isoflavonoids are soy products, with one gram of soy protein 
containing nearly 250 mg of GEN. Processed soy products such as miso and soy sauce 
contain lower levels of GEN than tofu, which is the major source of isoflavones in the Asian 
diet. 
The structure of GEN is similar to the potent estrogen estradiol-17β. In particular the phenolic 
ring and the distance (11.5 A) between its 40- and 7- hydroxyl groups share profound 
similarity. These features enable GEN to bind estrogen receptors and sex hormone binding 
proteins. It thus exerts both estrogenic and anti-estrogenic activity, the latter by competing for 
receptor binding by estradiol (Dixon and Ferreira, 2002). GEN is thus a phytoestrogen. 
GEN has been known to exhibit many interesting properties. Like many other members of the 
isoflavonoid family, GEN exerts broad-spectrum antimicrobial activity and is therefore 
believed to help the plant fight microbial disease (Erasto, et al., 2004). Higher dietary intake 
of GEN is found to be responsible for reduced incidence of cardiovascular disease (Hwang, et 
al., 2001). It also seems to improve plasma lipids, resulting in lowered LDL cholesterol, the 
ratio of total cholesterol to HDL cholesterol, and the ratio of LDL to HDL cholesterol, in pre-
menopausal women (Merz-Demlow, et al., 2000). An isoflavone rich diet also helps alleviate 
post-menopausal stress in women in addition to potentially reducing the risk of cardiovascular 
disease and osteoporosis (Alekel, et al., 2000). Interestingly GEN exhibited anti-cancer 
properties. 
 
1.5.3 Anti-cancer properties of GEN 
It is known that a significant correlation existed between an isoflavone rich soy-based diet 
and reduced incidence of breast cancer or mortality from prostate cancer in humans. A 
pioneering epidemiological study on Singapore Chinese women by Lee et al, (Lee, et al., 
1991) showed that soy consumption directly correlated with reduced risk of breast cancer. In 
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another study, neonatal administration of GEN to rats proved to be effective in the control of 
chemically-induced mammary gland tumour. The study also confirmed that GEN in the diet 
at „physiological level‟ greatly enabled cell differentiation, possibly by the up-regulation of 
the EGF pathway, with no observed toxic effects on the reproductive tracts of females. GEN 
is also known to reduce the risk of prostate cancer in men. Dietary GEN regulates sex steroid 
receptor and growth factor ligand and receptor mRNA expression, with a high degree of 
specificity (Lamartiniere, et al., 2002). It induces cell growth inhibition in prostate cancer 
through the suppression of telomerase activity by reducing the expression of human 
telomerase reverse transcriptase and c-myc and increasing the expression of p21, in a study 
0performed on the prostate cancer cell line LNCaP (Ouchi, et al., 2005). 
GEN has been show to have antioxidant effects and free radical scavenging properties. It thus 
protects cells against reactive oxygen species by inhibiting the expression of stress–response 
related genes and hence reduces carcinogenesis (Banerjee, et al., 2008) .  
The prospects of developing GEN as a therapy for cancer is very bright and clinical trials are 
underway in this direction. There have been efforts to explore the possibility of enhancing the 
effects of GEN by means of combining it with prevailing chemotherapeutic agents. GEN has 
exhibited synergistic effects in inhibiting AML cells when combined with a chemotherapeutic 
agent such as cytosine arabinoside ara-c (Shen, et al., 2007). Interestingly, chemo-resistant 
colon cancer cells have been observed to respond to a combination of GEN and 5-fluorouracil 
in vitro (Hwang, et al., 2005). 
 
1.5.4 GEN as a potential therapeutic agent for AML  
GEN‟s potential as an anti-leukemic agent is of much interest to researchers. A number of 
studies have evaluated the effect of GEN on AML cell lines and in mouse models of 
leukemia. Most of these studies confirm that GEN indeed inhibits the proliferation of AML 
cells in vitro (Traganos, et al., 1992; Raynal, et al., 2008) . 
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A recent study by Sanchez et al., has detailed the mechanism by which GEN induced 
differentiation in AML cells as a ROS-independent process, mediated by the Raf-
1/MEK/ERK axis, involving the PI3K pathway. The differentiation process is coupled and 
co-regulated with G2/M arrest, but uncoupled to the pro-apoptotic action of the drug 
(Sánchez, et al., 2009). 
A high-throughput study by Shen et al., profiled the transcriptional changes induced by GEN 
treatment on the AML cell lines HL-60 and NB-4 (Shen, et al., 2007). The study observed 
that GEN down-regulated genes belonging to the MAPK pathway. The mode of inhibition 
employed by GEN includes cell cycle: G2/M arrest and apoptosis in varying degrees. Nude 
mice with established tumours showed a decrease in tumour volume when GEN was 
administered and an enhanced tumour reduction when GEN was combined with ara-c (Shen, 
et al., 2007). Thus the prospect of using GEN as a therapy for AML is highly promising. 
Yet, unravelling the proteomic aspects of the dynamics of GEN action on AML is necessary 
for complete cognizance of its mechanism of action. A study by Zhang et al., attempted to 
map the proteome level changes caused by GEN in HL-60 cells, employing a two 
dimensional- gel electrophoresis (2D-GE) approach. However, they could conclusively 
identify only 14 proteins with altered levels from the study (Zhang, et al., 2007). This might 
be due to the inherent shortcomings of 2D-GE technique for protein separation and 
identification. Hence there is a great need to use a robust and advanced technology-based 
method to study the proteome of GEN-treated AML cells.  
 
1.5.5 GEN- a potent tyrosine kinase inhibitor 
GEN was reported to inhibit tyrosine-specific protein kinases in a landmark study by 
Akiyama et.al in 1987 (Akiyama, et al., 1987). It was identified that GEN had a highly 
specific inhibitory effect on tyrosine kinases, but little or no effect on the activity of serine 
and threonine kinases and other ATP analogue-related enzymes in vitro. The inhibitory effect 
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of GEN has been manifested in its inhibitory activity on c-src and v-abl, with an IC50 values 
of 7.4 and 22.2 µmol/L (2 and 6 µg/mL), respectively and EGFR‟s PTK activity at an IC50 of 
2.6 µmol/L (Peterson, 1995). On the other hand, it does not have a generic inhibitory effect on 
all PTKs equally, and some of them such as p94 PTK are unaffected, underlining the 
specificity of GEN (Feller and Wong, 1992). Such high specificity is an interesting dimension 
to its characteristics. 
Among the number of genetic abnormalities occurring in AML patients, FLT3-ITD is the 
most prominent, as detailed in section 1.2.4. FLT3 is a tyrosine kinase. Considering GEN‟s 
powerful inhibitory action on a number of PTKs, it is highly interesting to speculate on the 
effect of GEN on FLT3. However we could not find any previous study pertaining to this. 
Most of the studies described in section 2.4.4 establishing the anti-leukemic effects of GEN 
were performed on HL-60 and other cell lines possessing the wild-type FLT3 gene. None of 
the studies include MV4-11 or any other AML cell line with an ITD mutation. Since FLT3 
mutations have a major role in leukemogenesis and resistance to drugs, it would be interesting 
to test whether GEN can exhibit anti-proliferative effects on cell lines possessing FLT3-ITD 
mutations as compared to those with the wild-type version of the gene. The fact that the drug 
has a potent PTK inhibitory effect makes it logical to expect a wide spread regulation at the 
proteomic level. 
 
1.6 High-throughput approaches to mechanistic studies of drugs 
The high-throughput approach of profiling the molecular response of cells to rapa therapy at 
both the transcriptomic and proteomic levels would provide a holistic perspective on the 
repercussions of drug treatment on the cell. The fact that we can profile the expression of 
most of the genes encoded by the human genome using microarray analyses is a boon to 
researchers (Bild, et al., 2006) (Clarke, et al., 2004) (Comuzzi and Sadar, 2006). Similarly, 
the advent of proteomic profiling technologies such as iTRAQ™ is catapulting translational 
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research into a whole new era and is paving the way for accelerated innovations in the field of 
cancer research (Hattori, et al., 2006) (Qian, et al., 2008). Such a two pronged approach, 
profiling the molecular level changes of mRNA and protein expression as a consequence of 
drug treatment has been proven to be effective in understanding the mechanism of action of 
drugs (Li, et al., 2007; Frolov, et al., 2003) (Nunoda, et al., 2007). Transcriptomic techniques 
can survey the expression levels of thousands of genes and can capture even the low copy 
number transcripts. On the other hand proteomic strategies, although not as sensitive as their 
transcriptomic counterparts, have the advantage of mirroring the protein levels, the eventual 
products of mRNA translation.  
 
1.6.1 Transcriptomic profiling and microarray technology 
The transcriptome of a cell is defined as the set of all messenger RNA (mRNA) molecules 
namely „transcripts‟ produced in it. The transcriptome of cells are not fixed entities. They are 
highly dynamic and mRNA expression varies in accordance to the treatment conditions that 
the cells are subjected to. Hence studying the transcriptome of cells would provide deep 
insights into the effect of the drugs, dosages and time points. 
Microarray is a very powerful technique to study the expression of thousands of genes 
simultaneously across samples, in response to treatment conditions. Hence one can obtain a 
global view of the transcriptome in one single shot. Microarrays have greatly aided cancer 
research by proving to be an invaluable tool to compare the expression levels of cancer vs. 
normal cells, classify tumours, obtain molecular signatures for cancer types, identify 
prognostic factors, conduct epidemiological studies and study the effects of drug treatment on 
cancer cells. 
Studies identifying tumour biomarkers have skyrocketed due to the advent of microarrays. 
Comparative profiling of refractory and responsive tumours has been done to identify 
prognostic factors for many different cancers including AML and ALL (Ross, et al., 2004).  
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The gene expression profiles have been very useful in classification of tumours into 
genetically distinct subtypes with different prognostic values, which would be of great value 
in making therapeutic decisions (Valk, et al., 2004). A recent study by Kadara et al, identified 
a 6-gene signature  that is capable
 
of predicting the survival of lung adenocarcinoma by 
comparison of differential gene expression profiles of  normal, immortalised, transformed, 
and tumourigenic lung epithelial cells (Kadara, et al., 2009). 
A lot of such high-throughput microarray studies have been done in the field of leukemia 
biology too. Nowicki et al, have compared the profiles of CML patients (in different stages of 
tumour progression) with non-cancerous samples and identified a molecular signature for 
CML. The study also identifies that the gene expression patterns depend on the particular 
disease stage of the patient. Distinct expression signatures for the individual lineages of the 
leukemic blasts have been identified using microarrays. The study demonstrates the 
usefulness of gene expression monitoring in cancer classification and suggests the extension 
of this strategy for discovering and predicting cancer classes for other types of cancer, 
independent of previous biological knowledge (Golub, et al., 1999). Class prediction of AML 
into different subtypes is done by virtue of the characteristic gene expression profile of each 
of the subtype. Different genetic mutations and translocations are also identified by this 
method. NPM1 and FLT3-ITD gene mutations in AML have been shown to give rise to 
distinct gene clusters in AML. Hence the study of gene expression at a global level has 
greatly enhanced cancer research in general and leukemia studies in particular. 
 
1.6.2 Affymetrix Genechip analysis 
Genechip
® 
is a product from Affymetrix which is one of the major providers of microarray 
solutions. DNA microarray is composed of thousands of DNA probes arranged as an array on 
a solid surface to interrogate the abundance and/or binding ability of DNA or RNA target 
molecules. The DNA probes that are used in a DNA microarray are usually amplified cDNA 
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fragments or synthesised oligonucleotide sequences that have sequences that complement the 
target sequences (Zhu, 2003).  
The samples under study are labelled fluorescently. When samples are hybridised on the 
DNA microarray, the DNA probes will capture the nucleic-acid target molecules through 
sequence complementation. The strength of the fluorescent signal from the captured target is 
commensurate to the abundance of the target molecules and/or the binding compatibility 
between the probe and target molecules. A laser scanner is then used to capture this 
fluorescence and analyse it quantitatively. A microarray chip would contain thousands of such 
probes and hence can be used to analyse the expression pattern of a large number of genes in 
parallel. 
Affymetrix human whole-genome microarrays can monitor the expression levels of upto 
47,000 genes, including 38,500 well characterised genes and UniGenes. This in total amounts 
to more than 54,000 probe sets and 1,300,000 distinct oligonucleotide features. Each 
transcript is analysed by 11 probe pairs, each of which consists of a perfect match 25-mer 
oligonucleotide (PM) and a 25-mer mismatch oligonucleotide (MM), wherein a single base 
pair mismatch is in the central position. The PM/MM design is used for identification and 
subtraction of nonspecific hybridisation and background signals (Schinke-Braun and Couget, 
2007). 
GeneChip® is a specialised microarray that uses in silico synthesized DNA oligonucleotides 
as probes to detect the sequence similarity and abundance of target-DNA or -RNA molecules 
through complementary-sequence binding. The fabrication of chips is a highly standardised 
procedure. So are the target preparation, hybridisation, and processing protocols. This ensures 
consistency, high quality, reduced variability between samples, limited batch effects, ease of 
data mining and downstream analysis. 
The arrays are manufactured by an innovative light-directed chemical synthesis process, 
which combines solid-phase chemical synthesis with photolithographic fabrication techniques 
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employed in the semiconductor industry. High-density oligonucleotide arrays are constructed 
using a series of photolithographic masks to define chip exposure sites, followed by specific 
chemical synthesis steps, with each probe in a predefined position in the array. Several such 
probe arrays are synthesised in parallel on a large glass wafer, hence enhancing the 
reproducibility and cost effectiveness. The wafers are then packed into injection-moulded 
plastic cartridges, which protect them from the environmental contaminants and serve as 
chambers for hybridisation. (http://www.ohsu.edu/xd/research/research-cores/gmsr/project-
design/array-technology/affymetrix-genechip-arrays.cfm) 
Genome expression analysis necessitates a wide, unbiased survey of the transcriptome. Hence 
it is imperative to provide a true global coverage of a complex genome in a single microarray 
and Genechip® succeeds in this respect. The technology has found wide acceptance and is 









              
 












1.6.3 „Proteomics‟- scope and definition  
 Proteome, as the name suggests, is the set of all the proteins expressed in a cell. The term 
„proteome‟ was used for the first time in 1995, to describe the protein complement of a 
genome (Blackstock and Weir, 1999). „Proteomics‟ can succinctly be defined as the study of 
protein properties (expression level, post-translational modification, interactions etc.) on a 
large scale to obtain a global, integrated view of disease processes, cellular processes and 
networks at the protein level (Blackstock and Weir, 1999).The goal of proteomics is, a 
comprehensive quantitative description of protein expression and its changes under the 
influence of biological perturbations such as disease or drug treatment (Anderson and 
Anderson, 1998).  In many cases, transcriptomic data are not enough for a clear identification 
of a therapeutic target, mainly because proteins are the targets for the drug‟s mode-of-action. 
The effects seen on the gene expression level are only a response to drug effects on the gene 
level. However, it has been observed that there is not always a direct correlation between gene 
expression and protein expression patterns (Müllner, et al., 1998). Therefore, a major focus of 
current research in drug discovery and mechanism studies is to map the expression patterns of 
drug effects on the cell at both the nucleic acid and the protein levels.  
 
1.6.3.1 Mass spectrometry- the magic wand of proteomics 
In the past decade, the study of proteomics has blossomed into an extremely useful technique 
enabled by advances in the field of mass spectrometry. Mass spectrometry is a powerful 
analytical technique that is used to identify unknown compounds, to quantify known 
compounds, and to elucidate the structure and chemical properties of molecules. It has 
developed into an essential tool for biologists and chemists due to its versatility. It has several 
unique features spawning several applications including accurate molecular weight 
measurements: sample confirmation, sample purity determination, verification of amino acid 
substitutions, and detection of post-translational modifications; reaction monitoring: enzyme 
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reactions monitoring, chemical modification, protein digestion; amino acid sequencing: 
sequence confirmation, characterisation of peptides and protein identification; 
oligonucleotide sequencing; protein structure: protein folding studies enabled by 
monitoring H/D exchange and macromolecular structure determination. 
A typical mass spectrometer consists of three parts 1) Ioniser   2) Ion Analyser   3) Detector 
(http://www.chemguide.co.uk/analysis/masspec/howitworks.html). The sample atom is 
ionised, usually to cations by the gain of a proton. The ions are sorted and separated 
according to their mass and charge. The separated ions are then detected and tallied, and the 
results are displayed on a chart. The ionisation methods include Electrospray Ionisation (ESI), 
Matrix Assisted Laser Desorption Ionisation (MALDI), Fast Atom Bombardment (FAB), 
Chemical Ionisation (CI), and Electron Impact (EI). 
(http://www.astbury.leeds.ac.uk/facil/MStut/mstutorial.htm).  
ESI and MALDI are the two techniques most commonly used to ionise proteins. ESI ionises 
the analytes out of a solution. It is hence coupled to liquid-based separation tools. MALDI, on 
the other hand, sublimates and ionises the samples out of a dry, crystalline matrix via laser 
pulses. MALDI-MS is the preferred technique to analyse relatively simple peptide mixtures, 
whereas integrated liquid-chromatography ESI-MS systems (LC-MS) are better suited to 
analyse complex samples (Aebersold and Mann, 2003).  
 
1.6.3.2 Proteome profiling techniques- an overview 
The study of the proteome has helped solve many mysteries surrounding cancer and other 
human ailments (Jungblut, et al., 1999). This has been accelerated by the advent of a number 
of excellent techniques which enable a global study of the proteome. One can anticipate a 
modification of the expression of the proteins in a system in response to a perturbation such 
as drug treatment. Hence the proteomic profiling tool should be capable of capturing the 
relative difference caused by the drug in comparison to a reference control state.  The most 
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popular of these techniques include 2- Dimensional Electrophoresis (2-DE), SILAC (Stable 
Isotope Labelling with Amino acids in Cell culture), ICAT (Isotope Coded Affinity Tag), 
iTRAQ (Isobaric Tag for Relative and Absolute Quantitation), etc. In general, these 
techniques involve protein labelling/separation followed by mass spectrometry based 
identification of the peptides. Each of these methods has its own inherent advantages and 
disadvantages. 
2-DE involves separation of proteins on the basis of their isoelectric points and sizes. The first 
dimensional separation is achieved by isoelectric focussing (IEF), while the proteins are 
separated by mass using SDS-PAGE in the second dimension, in a direction 90˚ from the 
first. The resultant protein spots are excised and analysed by mass spectrometry. The 
strengths of this technique include identification of hundreds of proteins simultaneously and 
discernment of post translational modifications. However the pitfalls of this method are low 
reproducibility, limited dynamic range of isoelectric points and molecular weights, decreased 
rate of detection of low-abundance proteins and hydrophobic proteins. 
ICAT is a method to relatively quantify cysteine containing peptides from tryptic digests of 
protein extracts and identify them using mass spectrometry. In this approach, two samples are 
labelled with a heavy and light pair of chemically identical tags that differ in the isotopic 
composition and contain a thiol-reactive and a biotin moiety. The thiol reactive group enables 
attachment to cysteine residues. Control and treated samples can be labelled with the heavy 
and light reagents respectively to enable relative quantification of the trypsin digested 
proteins. Although this method offers significant advantages over 2-DE in terms of 
reproducibility and automation of procedure, it cannot identify proteins without cysteine 
residues.  
SILAC is a simple and straightforward approach for in vivo incorporation of a label into 
proteins for mass spectrometry (MS)-based quantitative proteomics. It relies on metabolic 
incorporation of a given 'light' or 'heavy' form of the amino acid into the proteins of actively 
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dividing cells in culture. Hence in an experiment two cell populations whose proteomes are to 
be quantified and compared, are cultured with the „light‟ and „heavy‟ versions of the same 
media. After a number of cell divisions, each instance of this particular amino acid will be 
replaced by its isotope labelled analogue. The cells are then combined, lysed and the 
differentially regulated proteins are quantitatively identified by mass spectrometry. SILAC is 
gaining popularity as the method of choice for accurately determining level of changes of 
proteins and PTMs. It has the inherent advantage of reduced sample complexity, increased 
efficiency and reproducibility owing to the introduction of the stable isotope early on in the 
procedure, while the cells are still dividing. However the success of the method is subject to 
100% incorporation of the isotopic label. Also, the method currently suffers from the high 
cost of the labelled amino acids. 
Hence in our study, we have used a method called iTRAQ which could be automated and 
whose power of identification is not restricted to any particular subset of proteins.  
 
1.6.3.3 Isobaric Tag for Relative and Absolute Quantification (iTRAQ) 
iTRAQ is a stable isotope labelling method for relative and absolute quantification of 
proteins. It involves the usage of reagents which were designed as isobaric tags consisting of 
a charged reporter group that is unique to each of the four reagents. The multiplexing 
capability of the method can be doubled to eight, by the usage of 8-plex iTRAQ reagents. The 
reagents contain a peptide reactive group, and a neutral balance portion to maintain an overall 
mass of 145 (305 in the case of 8-plex) (Zieske, 2006).  
The 4-plex experimental design consists of labelling samples with four independent isobaric 
reagents which upon fragmentation in MS/MS would produce four unique reporter ions of 
m/z= 114-117 (Figure 1.8 a). The second generation of iTRAQ reagents can label 8 samples 
in one shot. The reporter ion masses are 113.1–119.1 Da and 121.1 Da (Figure 1.6 b). The 
mass at 120.1 is omitted in order to avoid contamination from phenylalanine immonium ion 
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(m/z 120.08). The peptide reactive group was designed to react with all primary amines which 
results in enhanced peptide coverage for any given protein. The reporter region was selected 
in the low mass area in order to keep the additive mass to the fragments negligible and hence 
eliminate any effect in either MS or MS/MS modes. This would also mean elimination of any 
interference with other immonium or fragments ions, enabling enhanced degree of confidence 
in interpretation (Zieske, 2006). In the case of the 8-plex strategy, the overall mass of the 
balance group was increased to provide for the additional channels. All mass differences are 














Figure 1.6: Illustration of (a) 4-plex and (b) 8-plex iTRAQ reagent chemistry   
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The samples are independently reduced, alkylated, and enzymatically digested with trypsin. 
The ensuing pool of peptides from each sample is then labelled with one member of the 
multiplex set. The labelled peptides are then combined and subsequently analysed by LC-
MS/MS. Quantitation is accomplished by comparison of the peak areas and the resultant peak 
ratios for the four MS/MS reporter ions. The isobaric nature of the reagents helps to pool the 
labelled peptides without increasing the complexity of the MS analysis. The workflow of the 








   (b) 
 
Figure 1.7: Workflow of (a) 4-plex and (b) 8-plex iTRAQ procedure   
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1.6.3.4 Critical evaluation of the iTRAQ technique 
The iTRAQ technology offers certain significant improvements over other existing strategies 
for proteomic profiling. These include 1) Higher reproducibility due to the fact that the 
peptides from the same protein show similar relative quantification patterns in addition to 
biological replicates showing consistent conformity. 2) Higher confidence and quality of data 
because of the amine specificity of the isobaric tags which makes most peptides in a sample 
acquiescent to this labelling strategy with no loss of information from samples involving post-
translational modifications. 3) Ease of cross comparison and improved statistical validation 
within experiments, enabled by the multiplexing capability of these reagents (Zieske, 2006). 
However the technique does have its own inherent pitfalls. Though it has enhanced sensitivity 
for quantitation, it is more susceptible to errors in precursor ion isolation. This indicates that 
the reliability of the technique could be hampered by mass spectrometer interference (Gan, et 
al., 2007). Yet, the method offers significant advantages which outweigh the negatives.  
 
1.6.3.5 iTRAQ as a tool for oncoproteomic investigation 
iTRAQ, in the recent years has especially proven to be a very effective tool for 
oncoproteomic evaluation. In many studies pertaining to cancer, it is imperative to compare 
the proteomic profiles of normal tissue/cell samples to their cancerous counterparts. This 
would shed light on the proteins which are abnormal in the tumour cells. On the same lines, in 
order to understand the effects of a drug on cancer, it is essential to compare the profiles of 
the treated and untreated cells.  
Sensitive protein expression analysis has been difficult because amplification of proteins, 
unlike DNA or RNA is impossible. Relative quantification of proteins using iTRAQ is hence 
a bright prospect. Several studies have employed this strategy for oncoproteomic studies. 
Pierce et al, used an eight-plex iTRAQ based method to compare the activity of 6 
leukemogenic tyrosine kinases (Pierce, et al., 2008). This technique was also exploited to 
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study the exact mechanism responsible for the anti-proliferative effects of the highly 
promising drug imatinib on chronic myeloid leukemia. The comparative profiling was 
performed across highly precious and relatively scarce clinical samples. The fact that iTRAQ 
could successfully identify a significantly large number of proteins bears testimony to the 
sensitivity and efficacy of the technique (Griffiths, et al., 2007). 
The time dependent effects of butyrate, a fatty acid fermentation by-product, on colorectal 
cancer were critically evaluated by profiling the proteome of butyrate treated cells using 
iTRAQ 4-plex strategy. The multiplexing capability of iTRAQ proved invaluable in enabling 
the cross comparison across various time points within the same experiment. This eliminated 
the errors introduced by batch effects which seriously compromises the accuracy of the data 
(Tan, et al., 2008). 







AIMS OF THE STUDY 
Cancer is a highly multifactorial disease. It is an umbrella term encompassing a huge gamut 
of ailments, which are characterised by uncontrolled proliferation of cells belonging to 
various body parts. This plurality is in fact the biggest hurdle in developing therapies to cure 
cancer. It is hence close to impossible to identify that elusive „magic pill‟ that can cure 
cancer. Yet we endeavour to mitigate the deadly effects of the disease by developing lasting 
cures for certain types of cancer. In this respect, this thesis work attempts to add to the 
existing knowledge of AML and leukemia therapy. 
We understand today that cancer is a result of a complex interplay of signalling and metabolic 
pathways acting in a deregulated state. Any drug designed to cure cancer would target these 
aberrant pathways. Hence, in order to design therapeutic agents for cancer treatment it is 
essential to understand the molecular mechanisms employed by the drug. 
While there have been a number of studies in this direction, they suffer from the common 
fallacies of highly specified objectives and technology oriented constraints. We have studied 
the molecular mechanism of action of two drugs, with bright prospects as cure for AML. We 
have employed a combination of transcriptomic and proteomic based approaches to overcome 
the aforementioned pitfalls encountered in such studies. Such a top-down strategy hence 
provides a snapshot of the various pathways modulated by the drugs in AML. 
The main aims of the project are: 
1) Assess the prospects of using Rapamycin and Genistein as therapies for AML on a cell line 
based model of the disease. 
2) Identify the pathways modulated by these drugs in AML using high-throughput strategies 
such as mRNA expression analysis and proteomics, in combination or alone. 
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3) Validate these findings using methods such as real-time PCR and western immunoblotting, 
to ascertain the veracity of the data. 
4) Characterise the various novel pathways identified by the study by employing appropriate 
functional assays. (This is more like solving a jigsaw puzzle that is the mechanism of action 
of the drug, piece by piece, now that all the information that we need is at hand!) 
This is the first concerted effort to extensively use high-throughput studies to study the effect 
of Rapa and GEN on AML. The study uncovers crucial information pertaining to the action of 
these drugs, which is fundamental in understanding its mode of action. The knowledge 
gleaned from this study provides a strong case for rapa and GEN to be considered for further 
clinical studies on human subjects and would pave the way for the successful alleviation of 









MATERIALS AND METHODS 
The Materials and Methods section encompasses detailed descriptions of all the methods 
employed and the protocols followed while performing the experiments. It also provides the 
source of all reagents and biological materials used in the research. 
 
3.1 Cell Culture 
The entire study was performed on immortal cell lines derived from AML patients. The cell 
lines used in this study are listed as follows and their FAB subtypes are indicated: MV4-11 
(acute monocytic leukemia, FAB M5), THP-1 (acute monocytic leukemia, FAB M5), HL-60 
(acute promyelocytic leukemia, FAB M2), HEL (erythroleukemia, FAB M6) and Kasumi-1 
(FAB M2). All the cell lines were cultured in complete RPMI media supplemented with 10% 
FCS in a humidified incubator at 37˚C with 5% CO2. Cells were grown in T-75 tissue culture 
flasks and aseptic conditions were strictly maintained. Cells were cultured according to the 
growth kinetics and doubling rates of each cell line.  
 
3.2 In vitro cytotoxicity assay 
Rapa was purchased from Calbiochem (Darmstadt, Germany) and dissolved in DMSO. 
10mM stock solutions were made. GEN was purchased from Sigma- Aldrich (St.Louis, MO, 
USA) and stock solutions of 100mM were prepared. The aliquots were stored at -20˚C. 
Working solutions of the drugs were prepared by diluting the stock with RPMI (without 
FCS). The final concentration of DMSO in the in vitro assays was maintained at <0.05%. 
In vitro cytotoxicity assays were performed using the MTS (3-(4, 5-dimethylthiazol-2-yl)-5-
(3- carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt assay reagent) - 
CellTiter 96® AQueous One Solution Cell Proliferation Assay (Promega, Madison, WI, 
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USA) to assess the inhibitory effect of rapa and GEN on the AML cells. It is a colorimetric 
assay for determining the number of viable and proliferating cells. It contains an electron 
coupling agent phenazine ethosulfate (PES), in addition to the above mentioned tetrazolium 
compound, fortifying the stability of the solution. The MTS tetrazolium compound is reduced 
by live cells into a coloured formazan product by the NADPH or NADH produced by 
dehydrogenase enzymes in metabolically active cells. Hence the colour change of the culture 
media is a direct indicator of the number of living cells and hence the cytotoxicity of the drug. 
Cells were seeded at a concentration of 2  105 cells/ml in 96-well plates and treated with 
increasing dosages of rapa for 48 h. The final volume was maintained at 100 µl. 20 µl of the 
MTS reagent was added to each well and the plate was incubated at 37˚C for 1-4 h. The 
absorbance of each well was measured at 490nm with a 96-well plate reader. The CalcuSyn 
software (Biosoft™) was used to calculate the IC50 dosage of rapa for each of the cell line 
used.  
In the case of GEN treatment, the cytotoxicity was assessed using the trypan blue exclusion 
dye (Sigma-Aldrich). It is a vital dye which stains dead cells blue. Cells were treated with 
GEN at various dosages such as 10 µM, 20 µM and 40 µM, and for different time points 
including 0h, 24h, 48h and 72h. The dye was then loaded on to a small aliquot of the cells and 
counted under a microscope. The total number of viable cells in the treated and control cells 
were calculated to assess the cytotoxicity of GEN, accounting for the dilution introduced in 
the previous step by mixing the dye with the cell. 
 
3.3 Transcriptomic analysis using microarray 
3.3.1 RNA extraction 
The MV4-11 and THP-1 cells were cultured at a seeding density of 2  105 cells/ml. The 
MV4-11 cells were treated with 50nM and 500nM of rapa while the THP-1 cells were treated 
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with 500nM of the drug for 48 h. The control was subjected to treatment with the same 
amount of DMSO used to dilute the drug, to normalise the effects of DMSO on the cells. 
The cells were harvested after 48 h of drug treatment and RNA was extracted using the 
RNeasy kit (Qiagen, GmbH, Hilden, Germany). The manufacturer‟s instruction was followed 
and pure RNA was eluted out using a binding column to remove DNA and protein 
contaminants. The RNA was quantified using the NanoDrop® ND-1000 UV-Vis 
Spectrophotometer (Nanodrop Technologies, Wilmington, DE, USA). The RNA was stored at 
-80˚C. 
The quality of the RNA was assessed using the RNA 6000 Nano LabChip kit on the Agilent 
2100 Bioanalyzer (Agilent Technologies, Inc., Palo Alto, CA, USA). The Agilent 2100 
Bioanalyzer is a microfluidics-based platform for sizing, quantification and quality control of 
DNA, RNA, proteins and cells on a single platform. This instrument offers several significant 
advantages over the traditional methods of RNA quality detection using gel electrophoresis. It 
enables rapid quality checking possible with a sample preparation and running time of only 
30-40 min. It also has multiplexing capabilities, allowing up to 10-12 samples in one chip.  
The data is highly reproducible and the quality of the output is very neat. The method is very 
easy to adopt. Hence it was used in our experiment.  
The RNA 6000 Nano kit was employed. The electrodes were decontaminated with 
RNaseZAP® (Ambion/Applied Biosystems, Austin, TX, USA). The chip priming station was 
set up in the required position for RNA analysis. After equilibrating the reagents to room 
temperature, the gel matrix was filtered through a spin column by centrifugation. The filtered 
gel matrix would be in excess. It can be stored at 4˚C and should be used within a month after 
preparation. 1 µl of the dye concentrate is then added to a 65µl aliquot of filtered gel matrix. 
After thorough mixing, it is subjected to centrifugation at 13,000 g for 10 min at room 
temperature. The gel-dye mix is then added to a new RNA Nano chip, which is placed in the 
correct position on the chip priming station. The gel-dye mix is added in a particular sequence 
on the chip, as mentioned in the user manual supplied by the manufacturer and the chip is 
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pressurised using the syringe on the chip priming station. This is followed by addition of 
RNA Nano marker to the ladder and sample wells. Heat denatured RNA ladder is then added 
to the ladder well. 1 µl of the RNA samples whose quality is to be tested are then added to the 
sample wells. The sample is vortexed using the special vortex provided and the chip is 
analysed within 5 min of preparation on the bioanalyzer. 
 
3.3.2 Affymetrix Genechip analysis 
The gene expression profiling was done using the Affymetrix Human Genome U133 2.0 
arrays (GeneChip®, Affymetrix, Santa Clara, USA). The samples were prepared and run as 
biological replicates, strictly adhering to the Affymetrix GeneChip
®
 Expression Analysis 
Technical Manual for the eukaryotic sample and array processing. The general flow of work 
is illustrated in Fig 3.1. 
The GeneChip® Human Genome U133A 2.0 Array is a single array comprising of 14,500 
well-characterised human genes and 18,400 transcripts. The salient features of this chip are 
many. It provides transcripts of well substantiated genes. It involves 22,000 probe sets and 
500,000 distinct oligonucleotide features. 
Sequences used in the design of the array are obtained from databases such as GenBank®, 
dbEST, and RefSeq. The sequence clusters were fashioned from the UniGene database and 
then refined by analysis and comparison with a number of other publicly available databases. 
Oligonucleotide probes complementary to each corresponding sequence are synthesised in 
situ on the array. Eleven pairs of oligonucleotide 25-mer probes are used to measure the level 
of transcription of each sequence represented on the GeneChip Human Genome U133A 2.0 
Array (HG-U133A 2.0). The GeneChip arrays are manufactured by a very sophisticated 
process wherein synthesised photolithographic masks are used to direct light onto the surface 
of a wafer. The oligonucleotide probes are then synthesised on the surface one base at a time. 
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The samples were prepared as suggested by the manufacturer strictly adhering to the 
instructions provided. 2µg of RNA was used as the starting material for each of the samples. 
The samples which were hybridised to the chips are as follows: MV4-11- 50nM rapa, MV4-
11- 500nM rapa; THP-1- 500 nM rapa. All the samples were prepared as biological 
duplicates. 
One-cycle target labelling procedure was followed. Poly-A RNA Controls (Spike-in Controls) 
were added to the sample to include exogenous positive controls to monitor the labelling 
process. Double stranded cDNA is synthesized and cleaned up to remove all possible nucleic 
acid and other contaminants. This is followed by preparation of biotin-labelled cRNA by in 
vitro transcription. The cRNA thus obtained is again cleaned up and its quality and integrity is 
verified using the Agilent 2100 Bioanalyzer. The cRNA is subjected to fragmentation for 
target preparation. This is done to obtain optimal assay sensitivity. The fragmented cRNA is 
again tested using the Bioanalyzer for complete and proper fragmentation. Once the 
efficiency of the process is verified, the sample is hybridised onto the chip. This is performed 
by injecting the samples processed for hybridisation (hybridisation cocktail) into the HG 
U133 2.0 array, which is then sealed and incubated in a rotating hybridisation chamber set at 
60 rpm at 45˚C for 16 hr. The volume of the cocktail prepared depends on the format of the 
array. In this case we used the 10 Format (Midi) array. The hybridised arrays were washed 
and stained with the SAPE station (Streptavidin Phycoerythrin) on the GeneChip
®
 Fluidics  
station 450 using the appropriate protocols. The stained arrays were scanned using the 
GeneChip® Scanner 3000 7G.  
Figure 3.1 illustrates the process of preparing samples for Affymetrix genechip analysis in a 








Figure 3.1: Workflow of Genechip array sample processing and array scanning   
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3.4 Data analysis 
The microarray data was deposited in the public database ArrayExpress. The accession 
number is E-MEXP-2170 and is open for public use. The raw image files were generated by 
scaling the global factor to 500 using the Affymetrix GeneChip
®
 Operating Software 1.2 
(GCOS). The quality of the microarray data was verified by checking the parameters such as 
sig (3‟/5‟) value of house-keeping controls, which have been inserted as an internal control of 
quality control by the manufacturers. The spiked in control levels were assessed to judge the 
labelling and hybridisation efficiencies. 
Scatter plots of each of the replicates were generated to confirm the reproducibility of 
duplicate chips. The data was subsequently analysed using Genespring 7.3.1 (Silicon 
Genetics, USA). It provides a complete suite of statistical and visualisation tools for 
microarray data analysis. The data was normalised on „Per Chip: Normalise to 50th percentile‟ 
and „Per Gene: Normalise to specific samples‟ basis. The normalised data was filtered for 
„Flags: Present or Marginal‟ and „Fold Change cut off of +/-1.5‟. 
One-way ANOVA was performed to obtain statistically significant genes with p-value<0.05. 
The genes were classified according to their „Gene ontology‟.  Hierarchical clustering was 
performed to visualise the expression difference among the different treatment conditions and 
across the two cell lines.  
 
3.5 isobaric Tag for Relative and Absolute Quantification (iTRAQ) labelling 
The proteomic profiling of rapa treated cells was done using the 4-plex iTRAQ™ labelling 
strategy (Applied Biosystems, Life Technologies Corporation, Carlsbad, CA, USA) while the 
proteome of the GEN treated cells was probed using an 8-plex iTRAQ method. The 
difference between the methods as suggested by their nomenclature lies in the fact that the 8-
plex method essentially doubles the number of samples that can be studied in a batch 
experiment. It has 4 more tags to accommodate these extra samples. 
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3.5.1 Protein extraction and sample preparation for iTRAQ labelling 
The proteome profiles of cells treated with rapa and GEN were generated using the iTRAQ 
labelling technique. The cells were harvested and lysed for protein extraction with 0.5M 
Triethylammonium bicarbonate Buffer (TEAB), pH 8.5 containing 1% SDS and protease 
inhibitor. The cells were pelleted and incubated with this lysis buffer at room temperature for 
15 min and at 100˚C for 20 min. Protein separation was achieved by centrifuging at 4˚C for 1 
h at 14,000 rpm, and the supernatant was separated. The samples were quantified using the 
RC DC™ Protein Assay (Bio-Rad, Hercules, CA, USA). 100µg of each sample was used for 
the iTRAQ labelling. 
The protein samples were diluted 10 times with 0.5M TAEB, pH 8.5 and subjected to 
reduction with 5 mM tris-(2-carboxyethyl) phosphine (TCEP) at 60 °C for 1 h followed by 
alkylation with 10 mM methyl methanethiosulfonate (MMTS) for 10 min. Cysteine blocking 
was performed on the sample, each of which was diluted to 0.05% (w/v) SDS. The samples 
were then trypsinised with 25 µl trypsin at 37˚C for 16 h.  
Following this, each tryptic digest was labelled for 1 h with one of the four isobaric amine-
reactive tags for the 4-plex study. The pattern adopted for labelling the tags for the rapa study 
is as depicted in Table 3.1: 
 
Table: 3.1: iTRAQ labelling plan for rapa treated samples 
 





114 MV4-11- Control 
115 MV4-11- 50nM rapa 
116 THP-1- Control 
117 THP-1- 500nM rapa 
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For the GEN study, an 8-plex method was adopted. Hence the samples were prepared as 
biological duplicates and labelled with one of the eight isobaric tags for 2 h using the 
labelling pattern as shown in Table 3.2: 
 
Table: 3.2: iTRAQ labelling plan for GEN treated samples 
 
LABEL SAMPLE 
113 MV4-11- Control 1 
114 MV4-11- Control 2 
115 MV4-11- 20 µM 1 
116 MV4-11- 20 µM 2 
117 HL-60- Control 1 
121 HL-60- Control 2 
118 HL-60- 30 µM  1 







3.5.2 Cation exchange, purification and desalting of labelled samples 
These iTRAQ-derivatised samples (4 or 8, based on the protocol followed) were then pooled 
and passed through a strong cation exchange (SCX) cartridge as recommended by the 
manufacturer (AB SCIEX, Foster City, CA, USA). The bound peptides were eluted with 5 % 
NH4OH in 30 % methanol. This eluate (from the ion exchange step) was desalted using a C18 
column Sep-Pak cartridge (Millipore, Billerica, MA, USA). It was then subjected to vacuum-
drying, and reconstituted for 2D-LC (two dimensional liquid chromatography). The 
reconstitution was done using 20μl of 5 mM KH2PO4 buffer containing 5 % ACN, pH 3.0. 
 
3.5.3 2D-LC separation of Labelled Peptides 
 The iTRAQ-labelled peptide mixtures were separated using an Ultimate
™
 dual gradient LC 
system (Dionex-LC Packings, Sunnyvale, CA, USA) provided with a Probot™ MALDI 
spotting device. The 2-D LC separation was performed in the following manner. The labelled 
peptide mixture was dissolved in 2% ACN with 0.05% TFA. It was then injected into a 0.3  
150-mm strong cation exchange column (FUS-15-CP, POROS 10S) (Dionex-LC Packings, 
Sunnyvale, CA, USA) for separation. This constituted the first dimension of separation. In the 
case of the 8-plex study, the sample was initially reconstituted to 50 μl, of which 12 µl was 
injected by microliter pickup injection into a 0.5 × 23.5 mm strong cation-exchange (SCX) 
NanoEase™ trap column (WATERS Corp., Milford, MA, USA) for first dimensional 
separation. The Mobile phase A used was 5 mM KH2PO4 buffer, pH 3, 5% ACN, and mobile 
phase B used was 5 mM KH2PO4 buffer, pH 3, 5% ACN, 100 mM KCl, respectively. A 
steady flow rate of 6 µl/min was maintained. A total of nine fractions were obtained using 
step gradients of mobile phase B: unbound, 0–5, 5–10, 10–15, 15–20, 20–30, 30–40, 40–50, 
and 50–100%. The eluting fractions were captured alternatively onto two 0.3  1-mm trap 
columns (3-µm C18 PepMapTM, 100 Å) (Dionex-LC Packings) and washed with 0.05% TFA 
followed by gradient elution in a 0.2  50-mm reverse phase column (monolithic polystyrene-
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divinylbenzene) (Dionex-LC Packings).In the case of the 8-plex study, the reverse phase (C18) 
and trap columns were both purchased from Waters Corporation. The mobile phases used for 
this second dimensional separation were 2% ACN with 0.05% TFA (A) and 80% ACN with 
0.04% TFA (B). The gradient elution step was 0–60% B in 15 min at a flow rate of 2.7 
µl/min. The LC fractions were mixed directly with MALDI matrix solution (7 mg/ml α-
cyano-4-hydroxycinnamic acid and 130 µg/ml ammonium citrate in 75% ACN) at a flow rate 
of 5.4 µl/min via a 25-nl mixing tee (Upchurch Scientific, IDEX Health & Science, Oak 
Harbour, WA, USA) before they were spotted onto a 192-well stainless steel MALDI target 
plate (Applied Biosystems, Life Technologies Corporation) using a Probot Micro Precision 
Fraction Collector (Dionex-LC Packings) at a speed of 5 s/well. 50 fmol of ACTH peptide 
(m/z = 2465.199) was spiked into each well as internal standard.  
 
3.5.4 Mass Spectrometry Analysis and Database search 
3.5.4.1 4-plex iTRAQ study 
The 4700 Proteomics Analyzer mass spectrometer (Applied Biosystems) was used in the 
analysis of the samples on the MALDI target plates for the 4-plex study. Nitrogen at a 
collision energy of 1 kV and a collision gas pressure of 1  10-6 torr was used to do the 
MS/MS analyses. The peptide and protein identifications were performed by using the GPS 
Explorer™ software version 3.6 (Applied Biosystems, Life Technologies Corporation) to 
create and search files with the MASCOT search engine (version 2.1; Matrix Science). The 
International Protein Index (IPI) human database (version 3.30, 67,922 sequences) was used 
for the search, and this was restricted to tryptic peptides. 
One thousand shots were accumulated for each MS spectrum. For MS/MS, 6,000 shots were 
combined for each precursor ion with signal to noise (S/N) ratio greater or equal to 100. For 
precursors with S/N ratio between 50 and 100, 10,000 shots were acquired. The resolution 
used to select the parent ion was 200. No smoothing was applied before peak detection for 
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both MS and MS/MS, and the peaks were deisotoped. For MS/MS, only the peaks from 60 to 
20 Da below each precursor mass and with S/N ≥ 10 were selected. Peak density was limited 
to 30 peaks per 200 Da, and the maximum number of peaks was set to 125. Cysteine 
methanethiolation, N-terminal iTRAQ labeling, and iTRAQ-labeled lysine were selected as 
fixed modifications; methionine oxidation was considered as a variable modification. One 
missed cleavage was allowed. Precursor error tolerance was set to 100 ppm; MS/MS fragment 
error tolerance was set to 0.4 Da. Maximum peptide rank was set to 2. iTRAQ quantification 
was performed using the GPS Explorer™ software and normalized among samples. iTRAQ 
ratios were calculated based on the cluster areas of the iTRAQ reporter fragment peaks (114, 
115, 116, and 117), and the calculation of ratios included only peptides identified with C.I. 
percent above cut-off thresholds as described below. The average iTRAQ ratio and standard 
deviation were determined using the GPS Explorer™ software (version 3.6).  
 
3.5.4.2 8-plex iTRAQ study 
In the case of the iTRAQ study, mass spectrometry was performed on a 4800 MALDI-
TOF/TOF Analyser (Applied Biosystems/MDS Sciex) operating in positive mode. The laser 
intensity was adjusted to 4000 for MS and 4300 for MS/MS acquisition. One thousand shots 
were accumulated in each spot. MS spectra were acquired between m/z 800-3000.  The 7 
precursor ions with the highest peak intensity of each spot with at least S/N of 50 were 
automatically selected for MS/MS acquisition. MS/MS was performed using air as the 
collision gas at collision energy of 1 kV and collision gas pressure of ~1.4 × 10
-6
 Torr, with an 
accumulation of 5000 shots for each spectrum. 
ProteinPilot™ 2.0.1 (Applied Biosystems, Life Technologies Corporation) was employed for 
protein identification which uses the Paragon™ algorithm to perform database searches. The 
IPI database version 3.65 was the relevant human protein repository used for the search. 
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Redundancy was eliminated by grouping the identified proteins using the ProGroup algorithm 
in the software.  
A decoy database search strategy was adopted to estimate the false discovery rate (FDR) for 
peptide identification. A corresponding randomized database was generated using the 
Proteomics System Performance Evaluation Pipeline (PSPEP) feature in the ProteinPilot™ 
Software 2.0.1. The results were then exported into Microsoft Excel for manual data 
interpretation. 
 
3.5.5 Determination of the significant cut-off threshold for fold-change 
To determine the cut-off threshold for the fold change of proteins identified from the iTRAQ 
study to be considered as significantly regulated, two equal amounts of six-protein mixtures 
(Applied Biosystems)  were trypsin digested and labelled with the iTRAQ reagents (Tan, et 
al., 2008). The standard deviation (S.D) of all the ratios of the labelled peptides was computed 
to be 0.15. Thus by using a 1 + 2 S.D formula the fold-change cut-off thresholds were set as 
1.3 for up-regulated proteins and reciprocally 0.77 for down-regulated proteins. This strategy 
was adopted for the 8-plex iTRAQ GEN study. 
In the case of the 4-plex rapa study, the S.D of the ratios of the proteins identified from the 
iTRAQ study was computed to be 0.12. Hence cut-off thresholds of 1.24 and 0.80 were 
applied for up and down-regulated proteins respectively. 
 
3.5.6 Estimation of false positive rate to determine cut-off score 
A randomized database generated using IPI human database Version 3.31 (generated using a 
Pearl script downloaded from http://www.matrixscience.com/help/decoy_help.html) was 
used, in addition to the IPI human database for the purpose of weeding out false positives 
from the iTRAQ results. The false positive rate was calculated by comparing the peptide hits 
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obtained from these 2 databases at different ion score C.I % (peptide). The minimum ion 
score C.I % was set such that no more than 5% false positive rate is achieved. Based on this 
cut-off threshold, all the proteins identified from the random database search were matched to 
a single-peptide. Hence, proteins identified from the human database that are matched to at 
least 2 peptides are statistically confident. For single-peptide matched proteins, only those 
with ion score C.I % greater than the highest C.I % attained from the random database search 
were considered as significant. 
For the 8-plex study, the ProteinPilot™ software was used for the data visualisation. Among 
the various parameters used to classify the data, the unused score is of significance. An 
unused score greater than 2 corresponds to a confidence of greater than 99%. This 
corresponds to an accepted false discovery rate (FDR) of 1%. Hence this cut-off score was 
used to pick proteins of high confidence. 
 
3.6 Quantitative Real-Time PCR validation of microarray and iTRAQ data 
The microarray and iTRAQ data were validated using quantitative real-time PCR technique. 8 
genes of interest were chosen from the microarray data for this purpose. The criteria applied 
in the choice of these genes were two-fold. They were selected on the basis of their level and 
direction of fold change and their potential implications in explaining the mechanism of 
effects of rapa on MV4-11 and THP-1 cell lines.  
cDNA was synthesised from total RNA using the High-Capacity cDNA Archive Kit (Applied 
Biosystems). The RNA was reverse transcribed using reverse transcriptase enzyme. 2 µg of 
RNA was converted to cDNA using the following procedure. The 2 RT master mix was 




















2 µg of RNA was diluted to 25 µl and was mixed with the 2 RT master mix. The mixture 
was placed in a thermocycler set to the following conditions (Table 3.4): 
 
Table 3.4: PCR program for reverse transcription reaction 
 
 Step 1 Step 2 
Temperature 25˚ C 37˚ C 
Time 10 min 120 min 
 
 
The cDNA was stored at -20˚C. The qRT-PCR was performed on the ABI Prism 7000 
thermocycler. SYBR Green (Applied Biosystems) was the choice of fluorescent detection 
system used. Primers were designed using the Primer Express® Version 2.0 program and the 
sequences are listed in Table 3.5. β2M gene was used as the endogenous control for the study 
as its levels remain unchanged due to rapa treatment. Equal amount of cDNA was used in all 
the reactions and the samples were run on ABI PRISM® 7000 Sequence Detection System. 
SYBR Green reagent (Applied Biosystems) was the employed to quantify the expression 
Component Volume (µl) /Reaction 
10X Reverse Transcription Buffer 5 
25X dNTPs 2 
10X random primers 5 
MultiScribe™ Reverse Transcriptase 2.5 
Nuclease-free H2O 10.5 
Total per Reaction 25 
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levels of the selected genes. The data was analysed using the ABI PRISM® 7000 SDS 








Forward Primer Reverse Primer Product 
(bp) 
FOS TCACCCGCAGACTCCTTCTC AGTGACCGTGGGAATGAAGTTG 102 
FRAT1 TCCTCGGTTCAAGGTCACTGTT ACCGGCAGAACCTGGCTACT 71 
IGFBP2 CGGAGCAGGTTGCAGACA GTTCTCCACCAGGCCTCCTT 56 




TGFβI CTGTCCAGCAGCCCTACCA TCCGTGCGGTCCGTGTA 90 
TIEG GCTCAACTTCGGTGCCTCTCT CTTTTGGCCTTTCAGAAATCATTT 71 





3.7 Pathway Analysis 
The genes and proteins showing significant differences in fold change values from the 
microarray and iTRAQ studies were analysed using the Ingenuity Pathway Analysis software 
(Ingenuity® Systems, Redwood city, CA, USA), Version 5.5.1 (IPA). It is highly useful to 
study the pathways and networks each candidate gene or protein is involved in. 
An excel file containing the list of genes/proteins showing up/down regulation due to rapa 
treatment was uploaded into IPA. The software maps each of the gene/protein to the 
repository of information in the Ingenuity Pathways Knowledge base. Molecular networks 
regulated by the drugs in AML were obtained using these focus genes and proteins. The 
canonical pathways and functions were also ranked based upon their significance.   
The gene ontology analysis for the proteomic profile was done using STRAP, an open source 
software tool for protein annotation. (http://cpctools.sourceforge.net). Protein lists were 
submitted as text documents, upon which GO was generated for each protein.  
 
3.8 Protein Extraction for western blot analysis 
AML cells were treated with the drugs and harvested. The time of harvest was specific to 
individual experiments. The cells were washed twice with ice-cold PBS and lysed with buffer 
containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% Triton X-100, protease inhibitor 
and phosphatase inhibitor cocktails (Roche, Basel, Switzerland). The cells were incubated 
with the lysis buffer for 30 min on ice. The mixture was then centrifuged for 30 min at 4˚C at 
14,000 rpm. The supernatant was carefully extracted and stored at -80˚C. Aliquots were 




3.9 Western Blot 
 The protocol suggested by the company was followed to perform western immunoblotting. 
The antibodies were purchased from the commercial vendors listed in Table 3.6. The 
expression level of the loading control actin was used to ensure equal loading in each well. 
The proteins were separated on 12% SDS-PAGE gel. The proteins thus separated were then 
transferred on to PVDF membrane (Bio Rad, Hercules, CA). The membrane was activated by 
methanol treatment for 15 sec, prior to the transfer protocol. The transfer was conducted in a 
cold room, on ice for 90 min at a constant voltage of 100V. The membrane was then blocked 
with 5% milk (in 1 PBS-T) for 1 h at room temperature with gentle shaking. In some cases 
overnight blocking at 4˚C was performed. 
The membrane was then washed well with 1 PBS and incubated overnight with the primary 
antibody diluted to the appropriate quantity in 5% BSA. After vigorous washing, the 
membrane was incubated for 1 h at room temperature with the appropriate secondary 
antibody. This was followed by successive washing in 1 PBS-T. Table 3.6 summarises the 
conditions used for each antibody. The membranes were then incubated with HRP substrate 
Western Lightning (Perkin Elmer, Waltham, MA, USA) and the signals were detected on 




Table 3.6: Antibody dilutions and blocking conditions used for western immunoblotting 
 
Antibody  Source Dilution Blocking 
Actin BD Biosciences, Franklin Lakes 
(NJ, USA 
1:4000, 1 h- 
room temp 
1 h- room 
temp 
p-FLT3 Cell Signaling Technology 
(Danvers, MA, USA) 
1:500, 
Overnight- 4˚C 
2 h- room 
temp 
4E-BP1 Cell Signaling Technology 
(Danvers, MA, USA) 
1:1000, 
Overnight- 4˚C 
1 h- room 
temp 
p-4E-BP1 Cell Signaling Technology 
(Danvers, MA, USA) 
1:1000, 
Overnight- 4˚C 
2 h- room 
temp 
p70S6K Cell Signaling Technology 
(Danvers, MA, USA) 
1:1000, 
Overnight- 4˚C 
2 h- room 
temp 
Cyclin D1 Cell Signaling Technology 
(Danvers, MA, USA) 
1:1000, 
Overnight- 4˚C 
1 h- room 
temp 
Cyclin E Cell Signaling Technology 
(Danvers, MA, USA) 
1:1000, 
Overnight- 4˚C 
1 h- room 
temp 
Cdk 2 Santa Cruz Biotechnology (Santa 
Cruz, CA, USA) 
1:200, 
Overnight- 4˚C 
1 h- room 
temp 
Cdk 4 Santa Cruz Biotechnology (Santa 
Cruz, CA, USA) 
1:200, 
Overnight- 4˚C 
1 h- room 
temp 
p27 Santa Cruz Biotechnology (Santa 
Cruz, CA, USA) 
1:200, 
Overnight- 4˚C 
1 h- room 
temp 
Skp2 Invitrogen (CA, USA) 1:1000, 
Overnight- 4˚C 
1 h- room 
temp 
Akt Cell Signaling Technology 
(Danvers, MA, USA) 
1:1000, 
Overnight- 4˚C 
1 h- room 
temp 
IGFBP2 Abcam (Cambridge, MA, USA) 1:1000, 
Overnight- 4˚C 




BD Pharmingen (San Jose, CA, 
USA) 





Chemicon, Millipore (Billerica, 
MA, USA) 






3.10 Cell Cycle Analysis 
We used flow cytometry analysis to study the change in the cell cycle distribution of the cells 
after rapa treatment. The cells were treated with GEN and harvested at 0 h, 8 h, 24 h, 48 h and 
72h time points after drug treatment. Time points of 0 h, 8 h, 16h, 24 h and 48 h were adopted 
for the rapa study. The cells were washed twice with 1 PBS and fixed in ice cold 70% 
ethanol. The fixed cells were then stored at -20˚C until staining and analysis. 
The cells were stained with staining solution containing 0.1% Triton-X-100 in PBS, 200 
µg/ml of RNaseA and 20 µg/ml of propidium iodide (PI) for half an hour before flow 
cytometry analysis.  The DNA content of the samples was studied by running the samples on 
CyAn Flow Cytometer (Dako, Denmark). 50,000 relevant cells were collected in each 
sample. The DNA content distribution was obtained by analysis using the Summit 4.3 
software (Dako, Denmark). 
 
3.11 Caspase 3/7 Assay 
The MV4-11 and THP-1 cells were treated with rapa for 0 h, 12 h and 20 h time points. In the 
case of GEN treatment, the drug treated MV4-11 and HL-60 cells were incubated for 0 h, 24 
h, 48 h and 72 h and assayed for apoptosis as follows. The treatments were carried out in 96 
well plates. The cells were incubated with equal volumes of Caspase-Glo
®
3/7 reagent 
(Promega, Madison, WI, USA) for 1 h along with the necessary controls. The assay is 
designed as a homogenous, luminescence based method to study caspase 3/7 activity. The 
assay reagent contains the tetrapeptide sequence DEVD, provided in a solution pack 
optimized for caspase activity, luciferase activity and cell lysis. The Caspase 3/7 levels were 




3.12 Annexin V-FITC apoptosis detection 
MV4-11 and THP-1 cells were treated with rapa and harvested after 48 h. A time course study 
was done in the case of GEN treatment, involving the following time points: 0h, 8h, 24h, 48h, 
and 72h. The cells were stained with annexin V-FITC and propidium iodide (PI) to detect 
apoptosis. During apoptosis, the membrane phospholipid phosphatidylserine (PS) is 
translocated from the inner to the outer leaflet of the plasma membrane. Annexin V is a Ca
2+ 
protein which binds to PS with high-affinity and binds to cells with exposed PS. When 
Annexin V is bound to a fluorochrome FITC, the structure can be used to detect apoptotic 
cells on a flow cytometer. Double staining of cells with PI was done to select for early 
apoptotic cells, which would stain positive for Annexin V FITC but not for PI. Cells 
displaying double positive staining patterns represent dead or late apoptotic cells. Cells which 
stain only for PI and not for Annexin V FITC are necrotic. Double negative staining 
represents viable cells. 
The harvested cells were washed twice with ice cold 1 PBS and resuspended in 1 binding 
buffer at a concentration of 1106 cells/ml. 100 μl of the solution (1105 cells) was then 
transferred to a 5 ml culture tube (Dako). To this, 5 μl of Annexin V-FITC and 5 μl of PI were 
added, to ensure equal double staining. The cell-stain cocktail was vortexed gently and the 
ensuing mixture was incubated at room temperature for 15 min in the dark. 400 μl of 1X 
binding buffer was added to each tube and the sample was analysed by flow cytometry 
immediately. The flow cytometers used were CyAn (Rapa study) and BD FACS Calibur 
(GEN study). 50,000 relevant cells were collected in each case. The data was analysed using 
the FlowJo software (Version 7.6) (Tree Star, Inc.) and Summit v4.3 (Dako) to assess the 




3.13 Measurement of ROS levels in cells 
MV4-11 and HL-60 cells were treated with GEN for the following time points: 8h, 24h, 48h 
and 72h. The treatment was carried out in 6-well plates and the cells were seeded at a density 
of 2  105 cells/ ml. The cells were harvested at each time point and assayed for the inherent 
reactive oxygen species (ROS) levels using the ROS detection reagent 5-(and-6)-carboxy-
2′,7′-dichlorodihydrofluorescein diacetate (carboxy-H2DCFDA) (Molecular Probes, 
Invitrogen, Eugene, OR, USA). 
The derivatives of reduced fluorescein and calcein act as cell-permeant indicators for ROS 
detection. The unique property of the reduced and acetylated forms of 2′, 7′-
dichlorofluorescein (DCF) and calcein to become fluorescent upon removal of the acetate 
groups by intracellular esterases in the event of oxidation is used to mirror the ROS levels 
inside the cells. The carboxy derivative of fluorescein, carboxy-H2DCFDA, carries additional 
negative charges that improve its intracellular retention compared to noncarboxylated forms. 
A concentrated stock solution of the probe was prepared and kept tightly sealed. The probe 
was diluted shortly before use in pre warmed PBS. The harvested cells were resuspended in 
1PBS containing 5 µM of the probe dye. The cells were loaded with the dye by incubating 
them with the dye solution for 45 min at 37˚C. The cells were then incubated in the growth 
medium for 15 min to enable their recovery. Oxidation of the probe was detected by 
measuring the increase in fluorescence intensity using the CyAn flow cytometer. 20,000 
relevant cells were collected for each run. 
 
3.14 Nascent protein synthesis quantification using Click chemistry 
The amount of nascent proteins produced by MV4-11 and HL-60 cells treated with GEN in 
comparison to the untreated cells was studied to understand the effects of GEN on protein 
synthesis. The Click-iT® Metabolic Labeling Reagents for Proteins and Click-iT® Cell 
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Reaction Buffer Kit (Molecular Probes, Invitrogen) were used for this purpose. Cells were 
treated with GEN and harvested at 24h, 48h and 72 h time points. The treatment was 
performed as explained in section 3.13. 
The click chemistry incorporates a new class of chemical reactions that use bio-orthogonal or 
biologically unique moieties to label and detect proteins using a two step procedure. In the 
first step, a biomolecule containing an azide- or alkyne is actively incorporated into the 
protein(s) of interest. This is followed by the detection step, wherein the chemoselective 
ligation or “click” reaction between an azide and an alkyne occurs. In the click reaction, the 
modified protein is detected with a corresponding azide- or alkyne-containing dye or hapten. 
The proteins thus labelled with the Click-iT® metabolic labelling reagent are detected using 
the Click-iT® Cell Reaction Buffer Kit by flow cytometry.  
The metabolic labelling reagent used was Click-iT® AHA (L-azidohomoalanine), a 
methionine alternative. The detection molecule used was Alexa Fluor 488 (alkyne). The effect 
of GEN on nascent protein synthesis is studied by assaying the incorporation of AHA in 
newly translated proteins. The AHA was solubilised with DMSO to make a 1000x stock 
solution, which was stored at -20˚C.  The cells were harvested and washed with 1PBS. The 
cells were depleted of their methionine reserves by incubating them in methionine-free RPMI 
for 45 min. The cells were then transferred to the normal growth medium. 50 µM of AHA 
was added to the growth medium and the cells were incubated for 2 hours. The cells were 
then harvested and fixed in 4% PFA for 15 min.  This was followed by permeabilisation with 
0.1% saponin for 15 min. 3% BSA was used to wash the cells. The Click-iT® reaction 
cocktail was prepared as shown in Table 3.7 (volumes indicated per reaction). 
0.5ml of the click-iT reaction cocktail was added to each sample and incubated for 30 min at 
room temperature. The cells were washed once with 3% BSA and the fluorescence was 
measured using a BD FACS Calibur flow cytometer, set to capture the fluorescence of Alexa 









Reaction components 1 reaction 
1x Click-iT reaction buffer 440 µl 
CuSO4 10 µl 
Click-iT cell buffer additive 50 µl 
Alexa Fluor 488 dye Add to 1-5 µM final concentration 




HIGH-THROUGHPUT CHARACTERISATION OF THE EFFECTS OF RAPA ON 
AML 
This chapter delves deep into the elucidation of the anti-proliferative effects of rapa on AML 
cell lines and attempts to explore the possible reasons for such a phenomenon. The chapter 
weaves a laconic justification for a combinatorial approach to study the transcriptome and 




Rapa, a macrolide antibiotic, is a potent FDA approved immunosuppressant, capable of 
reversing acute active allograft rejection and enhancing long-term donor-specific allograft 
tolerance (Calne, et al., 1989). Interestingly, it was found to exhibit anti-cancer effects. 
Studies pertaining to the anti-tumoral activity of rapa and its analogs (CCI-779, RAD001) and 
the possibility of using it as therapy for certain cancers are underway (Chan, et al., 2005; 
Galanis, et al., 2005; Mita, et al., 2008). Recent studies indicate that rapa controls the 
proliferation of AML cells (Récher, et al., 2005). Thus rapa is a prospective alternate therapy 
for AML. 
Rapa is a key regulator of the mTOR pathway which is responsible for cell growth and  
proliferation. Rapa arrests this critical pathway by binding to mTOR as a complex with 
FKBP12 and thus abrogating the phosphorylation of the downstream effectors S6K1 and 4E-
BP1 (Sehgal, 1998; Sehgal, 2003) . Rapa also represses the PI3K/Akt pathway in AML cells, 
which is activated in AML blasts (Martelli, et al., 2006) and is known to control AML 
survival (Xu, et al., 2003). This pathway lies upstream of mTOR and controls essential 
cellular processes such as cell growth, cell cycle progression, transcription and apoptosis 
(Song, et al., 2005). 
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Since all the previous studies pertaining to the anti-proliferative effects of rapa employed the 
traditional approach of investigating individual pathways, namely mTOR and PI3K/Akt, 
crucial information about the repercussions of rapa treatment on the cell as a whole is lacking. 
Hence we consider it imperative to study the effects of rapa on AML at the global level, by 
obtaining a bird‟s eye view of the modulations caused by the drug by employing a high-
throughput approach. 
We have profiled the transcriptomic and proteomic level changes induced by rapa in AML 
with the aid of microarray and iTRAQ™ techniques respectively. Transcriptomic techniques 
can survey the expression levels of thousands of genes and can capture even the low copy 
number transcripts. On the other hand proteomic strategies, although not as sensitive as their 
mRNA counterparts, have the advantage of mirroring the protein levels, the eventual products 
of mRNA translation. We have also performed functional studies to bolster the findings from 
the high-throughput technologies. Thus we present here for the first time, a comprehensive 
snapshot of the key functional pathways and networks regulated by rapa in AML.  
This chapter explicates the results obtained from the high-throughput study and the meaning 
derived from it. It proceeds to provide new evidence on novel activities of rapa and how it can 
be exploited for AML therapy. 
 
4.2 Results 
4.2.1 Rapa has cell line specific growth inhibitory effects on different AML cells 
The sensitivity of a spectrum of AML cell lines, namely MV4-11, THP-1, HL-60, Kasumi-1 
and HEL to rapa treatment was tested. The in vitro cytotoxicity assays were carried out in 96-
well plates using the MTS assay protocol as described in Chapter 3. 
Rapa was found to inhibit the growth of all the cell lines, but to varying degrees as inferred 
from their respective IC50 values (Table 4.1). MV4-11 was the most sensitive with an IC50 of 
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50nM. THP-1 was the least responsive with the inhibitory effect reaching a plateau at around 
500nM (IC50 755nM, estimated value) (Figure 4.1). This implies a static effect in the 
cytotoxicity of THP-1 to rapa treatment beyond a certain threshold. Nevertheless it is still 
sensitive enough to respond to drug treatment. MV4-11 and THP-1 cell lines were used as 
models for all further studies. 
 
 







*= Estimated value 
All cell lines were treated with increasing dosages of rapa and the cytotoxicity was analysed 
using the MTS assay. The IC50 values were calculated using the CalcuSyn software. All 
values are mean of triplicate experiments. 
  
Cell Line AML subclass (FAB) IC50, nM 
MV4-11 M5 50 
Kasumi-1 M2 87 
HEL M6 97 
HL-60 M2 173 







Figure 4.1: Dose-response curves of cell lines after 48 h of rapa treatment  
Dose-response curves for MV4-11 and THP-1, the most and the least rapa-sensitive cell lines 
are shown. The inhibitory effect of rapa was studied by growing the cells with increasing 
dosages of the drug. All cell lines were treated with increasing dosages of rapa and the 
cytotoxicity was analysed using the MTS assay. The IC50 values were calculated using the 





4.2.2 Gene expression profiles of AML cells treated with rapa 
The key to understanding the real mechanism of action of the drug is to analyse the molecular 
level changes orchestrated by it on the AML cells. Hence, the transcriptome of the MV4-11 
cells treated with 50nM and 500nM of rapa, and THP-1 cells treated with 500nM of rapa were 
profiled. The Affymetrix GeneChip based cDNA microarray was the technology of choice. It 
offered several advantages such as wide coverage, ease of application, standardised 
downstream analysis, etc. The technology is described in detail in Chapters 1 and 3. 
The samples were run as biological duplicates. Performing the experiment in replicates 
increases the confidence in the data due to increased sample size and reduces the chances of 
error due to chance. The Control samples in this study were cells which were not treated with 
the drug. However the control samples were treated with the same quantity of DMSO used in 
the dilution of the drug. This process subtracts the background observed due to DMSO. 
The data obtained from the study was analysed using Genespring™ 7.3.1 software. 
Transcriptome analysis indicated a significant similarity and yet a profound contrast in the 
expression patterns of the two cell lines (Figure 4.2). The expression profiles of the MV4-11 
cells treated with 50nM and 500nM concentrations of rapa do not show major differences. 
The two treatment conditions showed an overlap of 201 up-regulated genes and 186 down-
regulated genes, reiterating the fact. Hence elevated levels of rapa do not significantly alter 
the transcriptome of AML cells. However, we could observe marked deviations in the profiles 
of MV4-11 cells and THP-1 cells which might explain the reason for their differential 
sensitivity to the drug. Only 35 up-regulated genes and 32 down-regulated genes were 








Figure 4.2: Venn Diagrammatic comparison of transcriptome profiles of MV4-11 and 
THP-1  
Venn diagrammatic comparison of the (i) Up-regulated genes (ii) Down-regulated genes, of 
MV4-11 and THP-1, which cleared the p-value cut-off and fold-change cut-off.  
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The fold-change cut-off of 1.5 was used to filter the genes and identify those regulated by 
rapa treatment (Table 4.2).  
 
Table 4.2: Rapa regulates a large number of genes in AML 
Sample Number of up-regulated genes Number of down-regulated genes 
MV4-11 50nM 263 298 
MV4-11 500nM 251 236 
THP-1 500nM 179 204 
 
The genes were filtered on flags and fold-change (cut-off 1.5). The genes were then subjected 




The expression profiles of the two cell lines were subjected to hierarchical clustering using 
Genespring. The profiles clustered in accordance to the cell line type and treatment conditions 
(Figure 4.3). The MV4-11 samples clustered together and the THP-1 samples formed another 
subgroup. Among the MV4-11 samples, the treated samples clustered closer to each other and 
branched away from the control. This indicates a stark difference between the control and 





Figure 4.3: Hierarchical clustering of transcriptomic profiles of microarray data 
Hierarchical clustering of the transcriptomic profiles indicate that samples cluster according 
to cell type and dosage. Thus MV4-11 samples cluster together, away from THP-1 samples.  
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4.2.3 Mapping the alterations in the proteome using iTRAQ labelling  
Rapa treatment had a pronounced effect on the proteome of AML cells. The proteomic study 
was conducted on a 4-plex iTRAQ platform. The samples were labelled as described the in 
the Chapter 3, section 3.5.1. The study identified 24 proteins with altered levels in MV4-11 
and 73 in THP-1. All proteins with Total Score C.I % of greater than 99 and a change in 
expression of at least 1.24 folds are listed in the Table 4.3.  
 
Table 4.3: Proteins regulated by rapa in (A) MV4-11, (B) THP-1, as identified from the 
iTRAQ study 
(A) MV4-11 
Protein Name Accession 
Number 
Avg iTRAQ 
ratio * (115/114) 
 IMMT Isoform 3 of Mitochondrial inner membrane protein IPI00470829 1.642439636 
 FEN1 Flap endonuclease 1 IPI00026215 1.521590774 
 SERPINB6 serine (or cysteine) proteinase inhibitor, clade B 
(ovalbumin), me 
IPI00749398 1.385402845 
 MARCKS Myristoylated alanine-rich C-kinase substrate IPI00219301 1.347752825 
 GSN Isoform 2 of Gelsolin precursor IPI00646773 1.309421037 
 RPS27 40S ribosomal protein S27 IPI00513971 1.298915161 
 GPX1 glutathione peroxidase 1 isoform 2 IPI00398780 1.289065272 
 RAB5B Ras-related protein Rab-5B IPI00017344 1.288308742 
 GNAI2 Galphai2 protein IPI00465121 1.284414535 
 NARS 33 kDa protein IPI00643900 1.241839687 
 AHSA1 Activator of 90 kDa heat shock protein ATPase 
homolog 1 
IPI00030706 0.803412596 
 CYB5B Hypothetical protein DKFZp686M0619 IPI00641334 0.801761495 
 FUBP1 69 kDa protein IPI00644386 0.801565742 
 HIST1H4G H4 histone family, member L IPI00020618 0.793182978 
 CYC1 Cytochrome c1 heme protein, mitochondrial precursor IPI00029264 0.79034019 
 UBQLN1 Isoform 1 of Ubiquilin-1 IPI00099550 0.783455955 
 XTP3TPA CDNA: FLJ21190 fis, clone CAS12333 IPI00012197 0.778186963 
 VASP Vasodilator-stimulated phosphoprotein IPI00301058 0.77590876 
 BCLAF1 Isoform 2 of Bcl-2-associated transcription factor 1 IPI00413671 0.745287285 
 ATP5J ATP synthase, H+ transporting, mitochondrial F0 
complex, subunit F6 i 
IPI00456008 0.730890893 
 FAM10A5 Protein FAM10A5 IPI00168839 0.715983233 
 LSP1 50 kDa protein IPI00554652 0.696898312 
 MTDH Protein LYRIC IPI00328715 0.61510525 





Protein Name Accession 
Number 
Avg iTRAQ 
ratio * (117/116) 
 GSN Isoform 2 of Gelsolin precursor IPI00646773 1.879134992 
 NUCKS1 Isoform 1 of Nuclear ubiquitous casein and cyclin-
dependent kinases  
IPI00022145 1.780701265 
 TMSB4X Thymosin beta-4 IPI00220828 1.551528455 
 MARCKS Myristoylated alanine-rich C-kinase substrate IPI00219301 1.539001055 
 IMMT Isoform 3 of Mitochondrial inner membrane protein IPI00470829 1.529509401 
 - 20 kDa protein IPI00397828 1.519899869 
 COX17 11 kDa protein IPI00796062 1.460314786 
 TKT Transketolase variant (Fragment) IPI00788802 1.4074547 
 ATP6V1G1 Vacuolar ATP synthase subunit G 1 IPI00025285 1.390577733 
 TMSB10 Thymosin beta-10 IPI00220827 1.38045995 
 DPP7 Dipeptidyl-peptidase II variant (Fragment) IPI00555697 1.359279234 
 RAB11A Ras-related protein Rab-11A IPI00429190 1.316931985 
 CAPG Macrophage-capping protein IPI00027341 1.304971846 
 TPP1 Isoform 3 of Tripeptidyl-peptidase 1 precursor IPI00554538 1.304063292 
 GARS Glycyl-tRNA synthetase IPI00783097 1.302716562 
 HCLS1 Hematopoietic lineage cell-specific protein IPI00026156 1.297388367 
 DDB1 127 kDa protein IPI00784120 1.29624959 
 VASP Vasodilator-stimulated phosphoprotein IPI00301058 1.295950569 
 CSE1L Isoform 3 of Exportin-2 IPI00219994 1.295364442 
 ANXA5 Annexin A5 IPI00329801 1.293687483 
 SOD2 manganese superoxide dismutase isoform B precursor IPI00607577 1.287521235 
 CA2 Carbonic anhydrase 2 IPI00218414 1.286970854 
 DBNL Isoform 2 of Drebrin-like protein IPI00396437 1.275614289 
 CYC1 Cytochrome c1 heme protein, mitochondrial precursor IPI00029264 1.262771413 
 PTPRC Protein tyrosine phosphatase, receptor type, C IPI00306325 1.254756992 
 CD44 Isoform CD44 of CD44 antigen precursor IPI00305064 1.247395793 
 SERPINB6 serine (or cysteine) proteinase inhibitor, clade B 
(ovalbumin), me 
IPI00749398 1.243512064 
 NUCB2 Nucb2 splice variant IPI00746961 1.24329333 
 AHNAK 313 kDa protein IPI00555610 1.240159991 
 RPS21 Ribosomal protein S21 IPI00387084 0.80516512 
 EIF4G1 eukaryotic translation initiation factor 4 gamma, 1 
isoform 2 
IPI00384463 0.804817869 
 PRMT1 HRMT1L2 protein IPI00215734 0.803250774 
 RPS29 ribosomal protein S29 isoform 2 IPI00639942 0.80307878 
 DUT Isoform DUT-N of Deoxyuridine 5'-triphosphate 
nucleotidohydrolase, mito 
IPI00375015 0.800780657 
 TCP1 T-complex protein 1 subunit alpha IPI00290566 0.800773139 
 EIF3S7 Eukaryotic translation initiation factor 3 subunit 7 IPI00006181 0.800393334 
 RPL27A 60S ribosomal protein L27a IPI00456758 0.797303968 
 ACAT1 ACAT1 protein IPI00440499 0.7970036 
 LOC732066;LOC730004 similar to 60S ribosomal protein L22 IPI00787417 0.796638334 
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 MCM5 DNA replication licensing factor MCM5 IPI00018350 0.794889315 
 PCNA Proliferating cell nuclear antigen IPI00021700 0.794596819 
 - 140 kDa protein IPI00829641 0.793113132 
 YARS Tyrosyl-tRNA synthetase, cytoplasmic IPI00007074 0.791402626 
 MCM6 DNA replication licensing factor MCM6 IPI00031517 0.790651597 
 LOC143244 similar to eukaryotic translation initiation factor 
5A 
IPI00218084 0.784781249 
 EIF4G3 Isoform 1 of Eukaryotic translation initiation factor 4 
gamma 3 
IPI00646377 0.783896456 
 KHSRP KH-type splicing regulatory protein IPI00479786 0.782626467 
 S100A9 Protein S100-A9 IPI00027462 0.775027952 
 HSP90AB1 Heat shock protein HSP 90-beta IPI00414676 0.768882981 
 EIF3S9 Isoform 2 of Eukaryotic translation initiation factor 3 
subunit 9 
IPI00719752 0.763462937 
 SSBP1 Single-stranded DNA-binding protein, mitochondrial 
precursor 
IPI00029744 0.762615947 
 MCM3 DNA replication licensing factor MCM3 IPI00013214 0.757531381 
 IRF2BP2 interferon regulatory factor 2 binding protein 2 
isoform B 
IPI00646970 0.755749949 
 TRAP1 57 kDa protein IPI00646055 0.753481402 
 DDOST dolichyl-diphosphooligosaccharide-protein 
glycosyltransferase precurs 
IPI00297084 0.742141434 
 TOMM22 Mitochondrial import receptor subunit TOM22 
homolog 
IPI00024976 0.739267539 
 hCG_1983058 similar to eukaryotic translation elongation 
factor 1 beta 2 
IPI00414723 0.738043368 
 RPS27 40S ribosomal protein S27 IPI00513971 0.737534975 
 CSTB Cystatin-B IPI00021828 0.735548498 
 PA2G4 41 kDa protein IPI00794875 0.734318582 
 CDC37 Hsp90 co-chaperone Cdc37 IPI00013122 0.730410383 
 HSPH1 Heat shock 105kDa/110kDa protein 1 IPI00513743 0.730409178 
 - Eukaryotic translation elongation factor 1 alpha-like 3 IPI00472724 0.727433009 
 COX6C Cytochrome c oxidase polypeptide VIc precursor IPI00015972 0.720914829 
 G3BP2 Isoform B of Ras GTPase-activating protein-binding 
protein 2 
IPI00179890 0.719958259 
 S100A8 Protein S100-A8 IPI00007047 0.719737255 
 NUDC 24 kDa protein IPI00646767 0.712462089 
 SSR4 Protein IPI00646864 0.697726854 
 HNRPF Heterogeneous nuclear ribonucleoprotein F IPI00003881 0.69545242 
 EEF1G 50 kDa protein IPI00747497 0.66634367 
 hCG_1644239 similar to ribosomal protein L31 IPI00243278 0.609338211 
 SAE1 33 kDa protein IPI00640965 0.592283434 
 LYZ Lysozyme C precursor IPI00019038 0.589455535 
 
The proteins listed above cleared the fold-change cut-off of +/- 1.24 with a confidence of 




4.2.4 Rapa regulates a variety of pathways in AML 
Ingenuity Pathway Analysis software was employed to analyse the microarray and iTRAQ 
data and hence unearth the variety of canonical pathways regulated by rapa in AML. In the 
MV4-11 microarray study, 542 genes mapped to the Ingenuity Knowledge Database and 407 
genes were deemed network eligible, while in the iTRAQ analysis, 24 proteins mapped and 
10 were found to be network eligible. Among the genes showing regulation by rapa in the 
THP-1 cell line, in the microarray study, 372 mapped to the Ingenuity Knowledge database 
and 279 genes were classified as network eligible, while in the iTRAQ study for this cell line, 
66 proteins mapped to the database and 27 of them were network eligible.    
The biological functions regulated by the drug are a reflection on the key processes targeted 
by the drug. The major functions modulated hence by the drug are cancer, cell cycle, cellular 




Table 4.4: Biological functions regulated by rapa in AML 
Functions Number of Molecules regulated 
 
Significance of the pathway: p-
value score 
 
# of genes- 
from 
microarray 







































































































Comparison of data from microarray and iTRAQ study. The microarray data and iTRAQ data 
of both the cell lines were merged and compared to obtain the overall picture. 
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Canonical pathways are well studied established pathways. They include signalling as well as 
metabolic pathways. The most important and relevant pathways regulated by rapa in AML as 
identified from the microarray study include IGF-1 signalling, PI3K/Akt, insulin receptor 
signalling, cell cycle: G1/S checkpoint regulation, death receptor signalling, hypoxia 
signalling, FGF signalling and protein ubiquitination (Table 4.5).  
Networks are key regulatory interactions between genes/proteins. Although they do not 
constitute a standardised pathway, they influence key functions. The 50nM dosage of rapa 
regulated 42 networks in MV4-11 and the 500nM dosage modulated 41 networks. In the case 




Table 4.5: Key canonical pathways regulated by rapa in AML 
Pathway Sample Genes regulated (fold change) 
Cell cycle G1/S arrest MV4-11- Rapa 50nM  ATM (1.744), RBL2 (1.833), SKP2 (-2.507), SUV39H1 (-1.557) 
MV4-11- Rapa 500nM ATM (1.5), E2F3 (1.626), SKP2 (-2.063) 
THP-1- Rapa 500nM CDK4 (-1.622), SKP2 (-1.594) 
Death receptor signalling MV4-11- Rapa 50nM  CFLAR (1.676), HTRA2 (-1.648), MAP3K5 (1.544), TNF (2.606), TNFSF10 (-2.078) 
 MV4-11- Rapa 500nM CFLAR (1.663), HTRA2 (-1.530), TNF (3.066), TNFSF10 (-2.496) 
 THP-1- Rapa 500nM MAP3K5 (1.741), TNFRSF1B (1.947) 
IGF-1 signaling 
 
MV4-11- Rapa 50nM  BAD (-1.563), FOXO3 (1.658), IGFBP2 (-3.024), IGFBP7 (-1.580) 
 MV4-11- Rapa 500nM FOS (1.781), FOXO3 (1.674), IGFBP2 (-2.419), IGFBP7 (-1.533) 
 THP-1- Rapa 500nM ATF4 (-1.619), HGF (-1.745), MAP2K3 (1.662), MAP3K5 (1.741) 
Insulin receptor signalling MV4-11- Rapa 50nM  BAD (-1.563), CRK (-1.528), FOXO3 (1.658), INPPL1 (-1.617), PPP1R12A (1.638), 
PPP1R14B (-1.767), VAMP2 (2.237) 
 MV4-11- Rapa 500nM FOXO3 (1.674), FOXO4 (-1.649), PPP1R12A (1.533), PPP1R14B (-1.592), VAMP2 
(2.075) 
 THP-1- Rapa 500nM BAD (-1.583), EIF2B3 (-1.671), FOXO1 (-2.100), FOXO4 (-2.809), GRB10 (-1.781) 
FGF signalling MV4-11- Rapa 50nM  ATF4 (-1.585), CREB3 (-1.873), CRK (-1.528), MAP3K5 (1.544) 
 MV4-11- Rapa 500nM ATF4 (-1.628), CREB3 (-1.833) 
 THP-1- Rapa 500nM ATF4 (-1.619), HGF (-1.745), MAP2K3 (1.662), MAP3K5 (1.741) 
Protein ubiquitination MV4-11- Rapa 50nM  PSMC2 (1.566), PSMD3 (-1.605), SKP2 (-2.507), UBE2E3 (-1.501), UBE2M (-1.676), 
USP1 (1.839), USP12 (1.780), USP15 (1.913) 
 MV4-11- Rapa 500nM PSMC2 (1.802), SKP2 (-2.063), USP1 (1.848), USP12 (1.704) 
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 THP-1- Rapa 500nM HLA-C (1.753), HLA-G (2.032), PSMC3 (-1.573), SKP2 (-1.594), UBE2I (-1.503) 
Hypoxia signalling MV4-11- Rapa 50nM  ATF4 (-1.585), ATM (1.744),  
CREB3 (-1.873), UBE2E3 (-1.501), UBE2M (-1.676) 
 MV4-11- Rapa 500nM ATF4 (-1.628), ATM (1.500),  
CREB3 (-1.833) 
 THP-1- Rapa 500nM ATF4 (-1.619), UBE2I (-1.503), VEGFA (-1.602) 
Selenoamino acid metabolism MV4-11- Rapa 50nM  AHCYL1 (1.517), CTH (-2.734), FTSJ1 (-1.508), PAPSS2 (-20.990), SEPHS1 (-1.730) 
 MV4-11- Rapa 500nM AHCYL1 (1.763), PAPSS2 (-8.694), SEPHS1 (-1.543) 
 THP-1- Rapa 500nM CTH (-1.636), PAPSS2 (-2.466), SCLY (-1.877) 
 
Some of the interesting canonical pathways modulated by rapa and the genes regulated in each pathway, as identified from the microarray study, are listed. 
The genes highlighted in bold italics indicate ones that are commonly regulated in all the three samples, while the ones in bold represent the genes which are 
common to both the MV4-11 samples. The genes in italics are the ones common to THP-1 and one of the MV4-11 samples.  
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4.2.5 Validation of the microarray data by quantitative real-time PCR  
The change in expression of a chosen set of genes was quantified by real-time PCR. The 
selected genes were key members of canonical pathways and/or networks. These genes were 
found to be significantly regulated by rapa in the AML samples and the direction and level of 
regulation could help explain the observed anti-proliferative effect of rapa. Real-time PCR 
analysis was performed using the SYBR green technology and the fold-changes were 
calculated hence. The fold-change values obtained from this study were compared with the 
levels indicated by the microarray (Table 4.6). Linear regression analysis showed very good 
correlation between the microarray and real-time PCR data with a R
2
 value of 0.8575 (Figure 
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Figure 4.4: Linear regression analysis of fold-changes of regulated genes identified from 
microarray and real-time PCR studies 
Linear regression indicated an R
2 
value of 0.8575, which indicates high correlation between 
the microarray and real-time data.  
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4.2.6 Rapa causes G1 arrest in AML  
Cell cycle: G1/S checkpoint regulation is one of the major pathways found regulated in both 
the cell lines. Previous studies have shown that G1 arrest is a major mechanism of growth and 
proliferation arrest employed by rapa. The flow cytometry analysis revealed that upon 
treatment with rapa, the number of cells in the G1 phase increased with time and peaked at 16 
h in both MV4-11 and THP-1 (Figure 4.5). There was a gradual decline in the percentage of 







Figure 4.5: Rapa induces time dependent G1 arrest in (a) MV4-11 (b) THP-1 
Maximum accumulation of cells in G1 phase was observed at 16 h in both cases. The control 
was grown for 48 h without drug treatment.  
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4.2.7 Analysis of the change in the level of cell cycle proteins upon rapa treatment 
Dissection of the cellular events orchestrated by rapa to cause such a time dependent G1 
arrest was performed using western blotting analysis of the proteins involved in cell cycle: 
G1/S progression. We found a time dependent decrease in the levels of the Cdk 2 and Cdk 4 
and an increase in p27 levels upon rapa treatment in both MV4-11 and THP-1 cells (Figure 
4.6). The Cdk 2 and Cdk 4 levels show maximum repression at 16h. The Cdks (cyclin 
dependent kinases) are essential for the progression of the cell cycle. Hence cell cycle arrest is 
the direct consequence of their repression. Rapa treatment was also observed to induce up-
regulation of the p27 protein, which is a Cdk inhibitor. Thus the decrease in the Cdk levels 
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Figure 4.6: Western blots of cell cycle proteins regulated by rapa 
Immunoblotting of cell cycle related proteins was done for lysates from both the cell lines (A) MV4-11 and (C) THP-1. The protein levels were 
compared by densitometry (B) MV4-11 and (D) THP-1.  
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Interestingly, we found protein ubiquitination among the pathways regulated by rapa. 
Concurrently, we also observed a down-regulation of Skp2 protein in the microarray study, 
which was confirmed by real-time PCR (Table 4.6).  
 
4.2.8 Rapa represses Skp2 and hence up-regulates p27 leading to G1 arrest 
Skp2 is the specific substrate-recognition subunit of a SCF type ubiquitin ligase complex 
which is responsible for the ubiquitin-mediated proteolysis of p27 (Yang, et al., 2002; 
Hershko, et al., 2001). Thus the down-regulation of Skp2, observed in the microarray study, 
was very intriguing. The observation was validated using western blot analysis, which 
indicated a down-regulation of Skp2 which correlated with the increased p27 levels and 
decreased levels of Cdk 2 and Cdk 4. Such a correlation is very significant as the previous 
reports establish the link between p27 and its regulation by Skp2.  
This finding establishes that rapa induces G1 arrest in AML cells through the repression of 
Skp2 and hence up-regulation of p27, which subsequently causes down-regulation of Cdk 2 
and Cdk 4. Hence the results indicate that such a regulation in AML forms the crux of the 
anti-proliferative activity of rapa. 
 
4.2.9 Confirmation of mTOR arrest by rapa 
mTOR has been known to be the prime target of rapa. This is well established and has been 
discussed at length in Chapter 1, Section 1.4.4. We set about to confirm this effect of rapa on 
our AML models. As the Figure 4.7 shows, rapa had a potent inhibitory effect on the 




4.2.10 Rapa regulates the IGF-1 pathway and inhibits IGFBP2- a novel discovery 
A number of genes and proteins belonging to the IGF-1 signalling pathway and insulin 
receptor signalling pathway were found to be significantly regulated by rapa. The microarray 
and real-time PCR data indicated down-regulation of IGFBP2, an important member of the 
IGF-1 pathway (Table 4.6). We analysed the protein levels of IGFBP2 and as the western blot 
indicates, rapa down-regulates IGFBP2 in both the MV4-11 and THP-1 cells (Figure 4.7). 
This is a very novel and interesting finding as there have been absolutely no reports about 
such an inhibitory effect of rapa on IGF-1 signalling pathway and IGFBP2 in AML, which 
lies upstream of mTOR pathway. 




                          
Figure 4.7: Rapa inhibits IGFBP2 and mTOR  
(A) Rapa down-regulates expression of IGFBP2 (B) Rapamycin is an mTOR inhibitor. 
Actin was used as control to compare the IGFBP2 expression change, while 
unphosphorylated    4EBP-1 served as the control for its phosphorylated counterpart.  
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4.2.11 Rapamycin does not induce apoptosis in AML  
The Annexin V-FITC staining and Caspase-Glo® 3/7 assay results indicate that rapa did not 
induce apoptosis in AML (Figure 4.8). The Annexin-V-FITC study was conducted at a 48 h 
time point. The caspase levels were assayed at 12h and 20h time points to probe for early 
onset of apoptosis. Both the MV4-11 and THP-1 cells did not exhibit significant increase in 
the percentage of apoptotic cells upon rapa treatment in any of the time points studied. Hence 
apoptosis does not play a major role in the anti-proliferative effect of rapa. It can thus be 
concluded that rapa is a cytostatic drug. 
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Figure 4.8: Assaying for apoptosis using (a) Annexin-V-FITC (b) Caspase 3/7 assay 
 Both MV4-11 and THP-1 cells were subjected to rapa treatment and apoptosis was assayed 
using two different techniques. (A) Cells treated with rapa for 48 h were assayed by Annexin 
V- FITC method using a flow cytometer. (B) Cells subjected to 12 h and 20 h treatments were 
assayed for apoptosis using the Caspase-Glo® Reagent. Rapa did not significantly induce 






In this study, we have shown that the potent inhibitory effect of rapa on a variety of AML cell 
lines is the consequence of the regulation of a multitude of pathways and that mTOR is not its 
only target as thought of before. 
 
4.3.1 Advantages of the approach 
In order to study the mechanism of action of rapa in its totality, we decided that it would be 
more feasible to adopt a top-down systems biology approach. The use of the microarray 
technology to study the mode of drug action is a well established high-throughput and robust 
approach. iTRAQ, though a relatively new technology, has proven to be a useful tool for 
proteomic research as it captures the relative protein levels and can label multiple samples 
simultaneously. The Ingenuity Pathway Analysis (IPA) is an application that enables the 
mining and subsequent discovery of molecular interaction networks in expression data. It is 
supported by a large Ingenuity Pathway Analysis Knowledge Base- a curated database. The 
combination of microarray and iTRAQ techniques yielded profiling data, which when 
analysed with IPA divulged vital clues about the pathways and networks modulated by rapa 
in AML. 
In this era of „omics‟, the fact that such a comprehensive profile of the cellular events can be 
obtained using a high-throughput technologies such as microarrays is a welcome boon to 
researchers. The efficacy and advantages of such an approach is well established by number 
of studies  (Clarke, et al., 2004; Comuzzi and Sadar, 2006; Hattori, et al., 2006; Qian, et al., 
2008).  
Functional characterisation of individual pathways is essential to elucidate the intricate role of 
each molecule involved in the process. Hence an optimal strategy to study the mechanism of 
action of drugs should obtain a snapshot of the cellular events coordinated by the drug using a 
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high-throughput approach and use these clues to examine individual pathways in greater 
detail.  
The IPA analysis of the microarray and proteomics data identified a number of canonical 
pathways to be regulated by rapa treatment as listed in Table 4.5. The power of high-
throughput technologies is emphasised by the fact that such a diverse repertoire of regulated 
pathways and the genes which constitute them could be mapped out using this approach, 
which would otherwise be impossible.  
 
4.3.2 The cell cycle: G1/S checkpoint regulation pathway 
The cell cycle arrest is an interesting target pathway regulated by rapa treatment. Previous 
studies have shown that rapa induced G1 arrest (Récher, et al., 2005). A number of genes 
involved in cell cycle checkpoint control were regulated in the microarray study. 
Additionally, both the iTRAQ and microarray data showed that cell cycle was a major 
biological function targeted by the drug.  
This prompted us to hypothesise that cell cycle arrest might be a prominent feature of the 
anti-proliferative property of rapa. In accordance to our thought process the flow cytometry 
based propidium iodide staining results showed that rapa indeed arrested the MV4-11 and 
THP-1 cells in the G1 phase of the cell cycle. We also observed that such an effect is time 
dependent. The peak effect occurred at 16h. This is a very interesting observation. Our MTS 
assay results indicate a 50% killing effect of rapa at 48h. Thus we can conclude that the arrest 
of AML cells occurs at 16h and the effect manifests at 48h, wherein we observe the reduced 
cell numbers.  
In order to confirm our observation we analysed the levels of some of the important proteins 
involved in G1 checkpoint regulation. These include certain key components such as the 
cyclins, Cyclin dependent kinases (Cdks) and Cdk inhibitors as indicated in the Figure 4.9.  
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Cdks are a family of serine /threonine protein kinases that are activated at specific points of 
the cell cycle. The Cdk levels remain constant during the cell cycle unlike that of their cyclin 
counterparts. Cyclin protein levels rise and fall during the cell cycle.  Thus they periodically 





Figure 4.9: Stages of the cell cycle 
The cyclins and Cdks work in combination with each other. They tend to form specific pairs.   
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Progression through the cell cycle and cellular proliferation is under the control of the cyclin-
cdk complexes. Each of these cyclin/cdk complexes is activated at a specific point during G1 
and has a specific set of substrates. The stage of activity of the Cyclin-Cdk complex is listed 
in Table 4.7. Thus the Cyclin E- Cdk 2 and Cyclin D- Cdk 4 complexes were chosen as 
indicators of G1 arrest.  
 
Table 4.7: Cyclin-Cdk protein complexes and their stage of activity 
 
Cdk Cyclin Cell cycle phase activity 
Cdk 4 Cyclin D1, D2, D3 G1 phase 
Cdk 6 Cyclin D1, D2, D3 G1 phase 
Cdk 2 Cyclin E G1/S phase transition 
Cdk 2 Cyclin A S phase 
Cdk 1 Cyclin A G2/M phase transition 
Cdk 1 Cyclin B Mitosis 




The cyclin-Cdk activity can be countered by molecules called Cdk inhibitors (CDKI). The 
Cip-Kip family of CDKI includes members such as p21 and p27. These inhibitors inactivate 
Cdk-cyclin complexes. They are active against the G1 Cdk-cyclin complexes, and the Cdk1-
cyclin B complexes. The increase in CDKI levels leads to cell cycle arrest at the G1 phase. 
Hence we chose to study the levels of p27, a quintessential CDKI. 
The experiment was conducted on a time-course basis. The idea was to understand the 
dynamics of cell cycle regulation. Hence studying the cell cycle distribution of the cells over 
a series of time points would provide a lucid idea about the progression of the cells through 
the various stages and the effects of rapa on such an event. The PI staining of the cells made it 
very clear that time is a key player in the G1 arrest exerted by rapa. Hence the western blots 
were done on protein samples extracted from rapa treated samples extracted at various time 
points. The protein levels were in complete accordance with the flow cytometry results. The 
Cdk 2 and Cdk 4 showed maximum down-regulation compared to their control counterparts 
at 16h. The levels of p27 also showed up-regulation at the same time point as expected. Thus 
the dynamics of the cell cycle regulation by rapa are explained by the expression pattern of 
the key determinants. 
 
4.3.3 Linking Protein Ubiquitination to G1 arrest through Skp2 regulation 
In our high-throughput study we observed that protein ubiquitination was a major pathway 
regulated by rapa. This pathway is responsible for the targeted degradation of proteins and the 
control of protein turnover. The IPA analysis of the microarray data suggested that a number 
of genes belonging to this pathway showed significant regulation by rapa. Out of these genes, 
the F-box protein S-phase kinase-associated protein 2 (Skp2) is of particular interest.  
Progression through the cell cycle is orchestrated mainly by ubiquitin-mediated proteolysis of 
cyclins and CDKI. Ubiquitin ligases are special enzymes which function in the last step of a 
three-enzyme cascade, leading to covalent tagging of ubiquitin or polyubiquitin chains to Lys 
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residues of substrates. Two types of ubiquitin ligases, SCF complexes and the anaphase-
promoting complex/cyclosome (APC/C), ubiquitynate many cell-cycle regulators and are 
essential for cell-cycle progression. SCF-type ubiquitin ligases are composed of three 
invariable subunits, Skp1, Cul1 and Rbx1, and one of about 70 different F‑box proteins 
(Ecker and Hengst, 2009). One such important F-box protein is Skp2.  
Among the various substrates of Skp2, p27 is the foremost. Overexpression of Skp2 leads to 
increased proteolysis of p27 causing deregulation of the cell cycle checkpoint (Hershko, et al., 
2001). Skp2 is a proto-oncogene in this respect (Ecker and Hengst, 2009). Skp2 has been 
found to be up-regulated in several cancers ( Kawakami, et al., 2007; Yang, et al., 2002). 
Increase in Skp2 levels and subsequent loss of p27 have been associated with reduced 
recurrence free survival in prostate cancer (Yang, et al., 2002). An elevated Skp2 has been 
observed and implicated in AML progression too (Min, et al., 2004).  
In our microarray study we observed that Skp2 is down-regulated by rapa at the 
transcriptional level in both the cell lines at all the dosages. Real-time PCR analysis validated 
this result. Western blot analysis showed that the Skp2 protein was indeed down-regulated by 
rapa especially at 16h. This is a remarkable observation as this paves the way for explaining 
the mechanism of cell cycle arrest orchestrated by rapa in AML. This is a completely novel 
effect of rapa. 
Recent reports suggest that Akt mediates the regulation of Skp2 in cancer cells (Ecker and 
Hengst, 2009; Gao, et al., 2009). Cancer cells which usually have elevated Akt levels have 
increased Skp2 activity, as Akt protects Skp2 from degradation. Rapa is a known inhibitor of 
PI3K/Akt pathway. Thus we can conclude that this effect of rapa has far reaching effects on 
the protein ubiquitination pathway. The decrease in Akt levels by rapa treatment leads to 
reduction of Skp2 protein. Thus there is an elevation in the levels of p27, as they are not 
targeted for proteolysis by Skp2. The increase in p27 levels in turn leads to G1 arrest and 
accumulation of cells in this phase of the cell cycle.  
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Hence the down-regulation of Skp2 by rapa is a key determinant of the cell cycle arrest that it 
mediates in AML. 
 
4.3.4 The IGF-1 signalling pathway modulation and down-regulation of IGFBP2 
The growth and proliferation of cells are highly dependent on the availability of nutrients and 
growth factors. In this respect it is important to note that pathways such as FGF signalling and 
IGF-1 signalling were affected by rapa treatment. This suggests that the modulation of these 
pathways have a causal effect on the cell cycle arrest induced by rapa. 
IGF-1 pathway is a very important signalling pathway which lies upstream of PI3K/Akt and 
mTOR. This pathway was one of the highly regulated pathways in both the cell lines studied. 
It has been implicated in a number of tumours including breast, colon and prostate cancer 
prompting the development of anti-IGF-IR therapy to combat cancer (Mitsiades, et al., 2004; 
Yasui, et al., 2006). 
Insulin like growth factor binding proteins (IGFBPs) are key members of the IGF-1 pathway 
which modulate the availability and biological action of the IGFs (Mohnike, et al., 1996). 
Among this class of six proteins, IGFBP2 is of particular interest since elevated levels of 
IGFBP2 have been observed in leukemia patients (Mohnike, et al., 1996), and are associated 
with increased relapse risk and negative prognosis (Dawczynski, et al., 2006). The elevated 
levels of IGFBP2 are increasingly being associated with AML progression. Interestingly, in 
our study we found that rapa down-regulates the expression of IGFBP2 in both MV4-11 and 
THP-1 cells at the transcriptional (microarray, real-time PCR) and translational (western blot) 
levels. We hypothesize that the repression of IGFBP2 levels strongly contributes to the anti-
leukemic activity of rapa.  
A previous study has shown that IGFBP2 is regulated through the PI3K/Akt/mTOR axis in 
breast cancer cells (Martin and Baxter, 2007). This is in line with our theory since rapa is a 
known inhibitor of both the PI3K/Akt and mTOR pathway as discussed before. Thus it is 
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reasonable to suggest a link between the IGFBP2 repression and the mTOR arrest by rapa in 
AML. This is a very significant finding because there have been no previous reports on such a 
direct effect of rapa on IGFBP2 in AML. 
 
4.3.5 Rapa is cytostatic- not cytotoxic 
Once we established that rapa caused G1 arrest and worked out the underlying molecular 
mechanism of the cell cycle arrest, we proceeded to investigate whether rapa induced 
apoptosis in AML cells. We suspected that rapa would indeed induce apoptosis as it had a 
potent anti-proliferative effect on the AML cells as vouched for by the MTS assays. Also the 
„Death receptor signalling pathway‟, which leads the cells to apoptosis, was among the 
pathways identified from the IPA analysis. Additionally „Cell death‟ was also one of the 
major functions affected by rapa treatment. Hence it was important to analyse the cytotoxic 
effects of the drug. 
However, the caspase 3/7 and annexin V-FITC staining assays indicated that there was no 
significant increase in apoptosis observed in the rapa treated cells (Figure 4.8). Thus apoptosis 
is not a major player in the anti-leukemic effect of rapa.  Hence we conclude that rapa is not a 
cytotoxic drug. Yet, the reason why many apoptosis related genes and proteins were found to 
be regulated is ambiguous and needs to be studied in greater detail. One possible reason might 
be that these genes are regulated as part of a greater anti-proliferative effect, but do not 
translate into cytotoxicity. 
 
4.3.6 Hypoxia signalling regulation by rapamycin 
Hypoxia signalling was another pathway modulated by rapa. The critical molecular mediators 
of this pathway, hypoxia-inducible factors (HIFs), regulate tumour formation, progression and 
response to drug treatment (Rankin and Giaccia, 2008). This pathway has been known to 
control cell growth and proliferation by influencing the mTOR signalling (Simon, et al., 
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2008), indicating that this pathway could be another upstream signal which contributes to the 
cell cycle arrest induced by rapa.  
 
4.3.7 Conclusion and Key findings 
This is the first comprehensive study to adopt a top-down approach to study the global effects 
of rapa on AML. The key findings from the study are highly significant. We have established 
that rapa has potent anti-proliferative effects against AML. It regulates a wide range of 
pathways ranging from mTOR signalling, IGF-1 signalling, FGF signalling, hypoxia 
signalling to cell cycle G1 arrest and protein ubiquitination. Thus, the microarray and iTRAQ 
approaches complement each other and bolster the confidence in the data obtained. Real-time 
PCR analyses of selected genes indicate high convergence in the fold-change values with 
their microarray counterparts. 
Rapa induced time-dependent cell cycle arrest in both the MV4-11 and THP-1 cells. The peak 
arrest was achieved at 16h. The classical pathways leading to cell cycle regulation were 
modulated by rapa. These include PI3K/Akt, mTOR and Protein ubiquitination. Rapa causes 
down-regulation of Skp2, a SCF-type ubiquitin ligase, leading to p27 elevation. This in turn 
causes inhibition and concurrent down-regulation of Cdk 2 and Cdk 4 culminating in the 
arrest of cells in the G1 phase of the cell cycle. Rapa down-regulates IGFBP2, a key member 
of the IGF-1 signalling pathway, which is known to be elevated in AML. IGF-1 pathway lies 
upstream of mTOR. IGFBP2 expression portends poor prognosis and increased 
leukemogenesis. Hence the inhibitory effect of rapa on this key protein is of high 
significance. 
Rapa does not induce apoptosis in AML and is hence a cytostatic drug. The cytostasis 
induced by rapa on AML is the cumulative effect of its regulation of the PI3K/Akt, mTOR, 
IGF-1 signalling, FGF signalling, hypoxia signalling and protein ubiquitination pathways. 
The study strongly endorses the use of high-throughput approaches in partnership with 
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functional characterisation in deciphering the mode of action of drugs in cancer. The wealth 
of data generated hence, would greatly help in the selection of combinatorial agents which 
could synergise the anti-leukemic effects of rapa. Thus, we have proposed a model for the 
mode of action of rapa based on our study (Figure 4.10).  
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Figure 4.10: Summary of the proposed mechanism of cell growth arrest employed by rapa 
The study provides a model for the anti-leukemic effect of rapa based on the findings from the high-throughput studies and functional studies.  




PROTEOMIC INVESTIGATION OF THE ANTI-LEUKEMIC ACTIVITY OF GEN 
This chapter briefly describes the necessity for a proteomic study of the effects of genistein on 
AML cells and moves on to describe the results obtained from such a study. The chapter 
encompasses a detailed analysis of the results leading to an interpretative discussion to 
elucidate the mechanism of action of GEN.  
  
5.1 Introduction 
GEN is a soybean derivative belonging to the isoflavone family of phytochemicals. The fact 
that GEN has anti-leukemic activity, was identified in the beginning of the previous decade 
(Traganos, et al., 1992). It is now well established that GEN holds a lot of promise as a 
potential therapy for AML. 
GEN is a multi-targeted receptor tyrosine kinase inhibitor. This interesting characteristic 
makes it a promising anti-cancer drug candidate, while also leading us to believe that it has a 
profound effect on the proteome of cancer cells. This has made the study of its mechanism of 
action a challenge, spawning a number of studies in this direction. Yet the conclusions drawn 
from these studies are insufficient to map the exact mechanism of action of GEN and leave 
much to be desired.  
We have adopted a proteomic approach to characterise the anti-proliferative activity of GEN 
in AML cells, using two different cell lines. Although there has been a previous attempt by 
Zhang et al , wherein they have employed a 2D gel based approach to study the proteome 
level changes orchestrated by GEN in leukemia cells, it is not conclusive as the method is 




We have used two different cell lines in our study, one containing an inherent FLT3-ITD 
mutation and one with the wild-type gene. GEN‟s effect on the cell lines with FLT3-ITD 
mutations hasn‟t been characterised yet. However it is very important to look for this 
connection, considering the fact that most drugs for AML exert FLT3 status-specific 
inhibitory effects. A drug which can exert potent anti-leukemic effects irrespective of FLT3 
status would be a revolution of sorts, leading to generic AML therapy, without any concerns 
about the patient sensitivity. The fact that GEN is a known PTK inhibitor provides the 
reasoning behind our speculation that it might be a FLT3 inhibitor (Akiyama, et al., 1987).  
The objective of the study is to identify the various pathways that the drug modulated and 
piece up the puzzle to accurately pinpoint to its mechanism of functioning. We have used an 
8-plex iTRAQ based approach to achieve this goal. The clues obtained from the iTRAQ 
analysis were followed up and a hypothetical model was formulated to describe GEN‟s 
action. The model was empirically validated.  
This chapter describes in great detail the results gleaned from the high-throughput proteomic 
investigative study. The chapter also illustrates the analysis of this data and the subsequent 
functional assays performed to buttress the claims made by the study. 
 
5.2 Results 
5.2.1 Genistein exerts strong anti-proliferative effects on AML cell lines 
The anti-leukemic activity of GEN was studied using two AML cell lines, namely, MV4-11 
and HL-60 as models. The two cell lines in this case differ in the status of the FLT3 gene 
mutation. While HL-60 has a wild-type FLT3 gene, MV4-11 possesses a mutant version 
comprising an ITD mutation, which renders its protein product constitutively phosphorylated 
and hence activated. In many cases this is the primary cause of leukemogenesis. Such a 
choice of cell lines provides scope for a broader and more inclusive analysis. 
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GEN exhibited inhibitory effects on the proliferation of both MV4-11 and HL-60 cells in 
vitro. The effect increased with dosage levels as illustrated in Figure 5.1a. The cytotoxicity of 
GEN increased with time as observed in Figure 5.1b. While the IC50 dosage at 48 h for MV4-
11 cells was found to be 20 µM, it was close to 30 µM in the case of HL-60 cells. The cells 









Figure 5.1: Anti-proliferative activity of GEN (a) Dose dependent inhibitory effects at 
48h and (b) Time dependent inhibitory effects at 20µM dosage for MV4-11 and 30 µM 
dosage for HL-60.  
The total number of cells at each dosage was counted using trypan blue exclusion staining and 
the inhibitory effect of GEN was quantified hence. The results show that GEN had an 
enhanced effect on MV4-11 as compared to HL-60. The IC50 dosage was found to be 
approximately 20µM for MV4-11 and 30 µM for HL-60 at 48h. The data shown is an average 




























Dose dependent inhibitory effects of GEN  
Time dependent inhibition by GEN 
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5.2.2 GEN is a FLT3 inhibitor 
The inhibitory effect of GEN on PTKs logically led us to examine its effect on FLT3, a 
tyrosine kinase. Western blotting studies using an antibody specific to the phosphorylated 
tyrosine residue 591 of the FLT3 gene showed that GEN in fact had a potent inhibitory effect 
on the phosphorylation status of FLT3 in the MV4-11 cells, which contain the ITD mutation. 
GEN down-regulated the phosphorylation of FLT3 as indicated in Figure 5.2. This proves that 
GEN is a FLT3 inhibitor. In the case of HL-60, phosphorylated FLT3 was not detected, 
consistent with its wild-type status. 
Both the cell lines showed positive response to the drug, making it all the more interesting to 
understand the mechanism of action of GEN in both cases. In order to achieve this, the 













Figure 5.2: GEN is a FLT3 inhibitor 
GEN down-regulates the constitutive phosphorylation of FLT3 in the MV4-11 cells and is 
hence a FLT3 inhibitor. In the case of HL-60, due to the absence of FLT3-ITD mutation, this 




5.2.3 8-plex iTRAQ based profiling of the proteome level changes induced by genistein  
The optimal dosage of GEN required to kill 50% of the cells was hence determined to be 20 
µM for MV4-11 and 30 µM for HL-60 cells at 48h and these fixed dosages were used for all 
future experiments. Proteomic profiling of the cells was performed by employing the 8-plex 
iTRAQ strategy. The cells were treated with GEN and proteins were extracted and quantified 
as described in Chapter 3. The samples were prepared as biological replicates. 100 µg of each 
sample was used for iTRAQ analysis. Each of the trypsin digested samples was labelled with 
a unique isobaric tag. The peptides were then identified and quantified by LC/MS/MS 
analysis. The protein identification performed using the ProteinPilot™ software yielded 
several hits. A short summary of the results is shown in Table 5.1. An aggregate FDR of 1% 
was used as the accepted value. This corresponded to an unused score of 2. This was hence 




Table 5.1: Summary of LC/MS/MS results obtained from the iTRAQ study  
 
  Protein level data 
Critical Value Number of Proteins identified 
Accepted FDR Aggregate FDR 
1.0 % 609 
5.0 % 774 
Peptide level data 
Critical Value Number of Peptides identified 
Accepted FDR Aggregate FDR 
1.0 % 2907 
5.0 % 4171 
Spectra level data  
Critical Value Number of  Spectra identified 
Accepted FDR Aggregate FDR 
1.0 % 3511 
5.0 % 4975 
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5.2.3.1 Statistical significance of the iTRAQ data 
Since the samples were run as biological duplicates, it is critical to assess the reproducibility 
of the data. A high level of concordance between the duplicates would bolster the confidence 
in the data and also lend credibility to the sample preparation methodology and the 
downstream mass spectrometric analysis. The scatter plot analysis of the duplicates was 
performed and the R
2
 value of the trendline was used as a measure of reproducibility. As the 
Figure 5.3 shows, the duplicates exhibited high level of conformity, validating the soundness 














Figure 5.3: Scatter plot analysis of the proteomics data 
Comparison of the area under the curve of the spectral profiles of the duplicate pairs indicated 
high reproducibility. This is justified by the R
2
 values of the trendlines. A value of 1 indicates 




5.2.3.2 Comparison of the profiles of the two cell lines 
Once the veracity of the data was established, it was scrutinised for biological meaning. The 
data was analysed using the ProteinPilot™ software as mentioned earlier. The fold-changes of 
the identified proteins in the treated samples, compared to the control samples were 
calculated. Proteins were considered significantly regulated if they had a fold-change value 
greater than or equal to +/- 1.3. The ratios of the biological replicates were computed and the 
average value was taken. Those proteins which exhibit opposite levels of regulation in the 
replicates were disregarded.  
There were more proteins found regulated in MV4-11. Figure 5.4 compares the profiles of 
proteins regulated in both the cell lines. There was a large percentage of overlap between the 
two cell lines, indicating a significant similarity in the mechanism of action. However there 
were still some proteins which were not regulated in the same manner or extent in both cell 




        
  (a) Up-regulated proteins                                       
 
 
 (b) Down-regulated proteins 
 
Figure 5.4: Venn Diagrammatic comparison of the regulated proteins identified from 
the proteomic study 
The intersection represents the proteins commonly up/down regulated in both the cell lines. 
The data implies a high degree of overlap between the two cell lines, while also signifying 















5.2.4 Genistein regulates crucial pathways in MV4-11 and HL-60 cells 
Pathway analysis was performed on the proteomics data using the IPA software. The analysis 
unearthed some very interesting results. A number of signalling and metabolic pathways were 
found to be regulated by GEN, in line with the fact that GEN is a multi-targeted protein 
kinase inhibitor. A lot of these pathways, such as mTOR, Akt, protein synthesis, etc have 
previously not been known to be modulated by GEN. 
GEN was found to alter the expression of proteins involved in both signalling and metabolism 
alike. This implies that the effects of GEN are much more profound and deeper than what is 
originally known. The top 20 functions regulated in MV4-11 and HL-60 are shown in Figures 











Figure 5.5: Biological functions regulated by GEN in (a) MV4-11 (b) HL-60  
       (b)  HL-60 
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As the figure clearly indicates, a number of functions are common to both the cell lines. 
Protein synthesis was the top function targeted by GEN. PTM, cellular movement, cell death, 
carbohydrate/lipid metabolism and haematological disease were among the most regulated 
functions in both the cell lines.  
Although it is important to look at the functions, it is more pertinent and informative to 
consider the canonical pathways regulated by GEN more closely. Hence we analysed the 
canonical pathways regulated by GEN using IPA. The Table 5.2 lists the pathways which 
were regulated in the cell lines. As can be seen, GEN regulated both signalling and metabolic 
pathways in AML. Only the pathways which cleared the p-value cut-off are shown.  
The pathways regulated were of course reflective of the functions found modulated by GEN. 
There were significant similarities between the two cell lines, indicating a consistent 
mechanism of action of GEN. However there was significantly more number of pathways 
regulated in MV4-11 as evidenced by the Table 5.2. 
It was interesting to see that GEN regulated mTOR pathway, in both the cell lines, a 
previously unknown effect. Such a consistent regulation in both the cell lines indicates that 




Table 5.2: Canonical Pathways regulated by GEN in (a) MV4-11 (b) HL-60 
(a) MV4-11  
Pathway -log (p-value) 
Signalling pathways 
Polyamine Regulation in Colon Cancer 4.81E00 
 Mitochondrial Dysfunction 2.56E00 
 mTOR Signaling 2.49E00 
 Induction of Apoptosis by HIV1 2.46E00 
 Actin Cytoskeleton Signaling 2.2E00 
 Reelin Signaling in Neurons 2.11E00 
 RAN Signaling 1.92E00 
 Leukocyte Extravasation Signaling 1.9E00 
 Protein Ubiquitination Pathway 1.9E00 
 Regulation of Actin-based Motility by Rho 1.9E00 
 Integrin Signaling 1.84E00 
 ATM Signaling 1.78E00 
 Death Receptor Signaling 1.63E00 
 Myc Mediated Apoptosis Signaling 1.61E00 
 Regulation of eIF4 and p70S6K Signaling 1.6E00 
 RhoA Signaling 1.56E00 
 IL-8 Signaling 1.51E00 
 PI3K/AKT Signaling 1.47E00 
Metabolic pathways 
Oxidative Phosphorylation 2.94E00 
 Purine Metabolism 2.27E00 
 Phenylalanine Metabolism 2.19E00 
 Methane Metabolism 1.92E00 
 One Carbon Pool by Folate 1.65E00 
 Stilbene, Coumarine and Lignin 
Biosynthesis 
1.58E00 
 Glutathione Metabolism 1.54E00 










The canonical pathways regulated are segregated as signalling and metabolic pathways for 
easier comprehension. 
  
Pathway -log (p-value) 
Signalling pathways 
Polyamine Regulation in Colon Cancer 4.67E00 
 PI3K/AKT Signaling 3E00 
 Reelin Signaling in Neurons 2.83E00 
 mTOR Signaling 2.68E00 
 Regulation of eIF4 and p70S6K Signaling 2.28E00 
 Leukocyte Extravasation Signaling 2.15E00 
 Protein Ubiquitination Pathway 2.15E00 
 AMPK Signaling 1.95E00 
 CTLA4 Signaling in Cytotoxic T Lymphocytes 1.68E00 
 SAPK/JNK Signaling 1.66E00 
 ERK/MAPK Signaling 1.54E00 
 p70S6K Signaling 1.35E00 
 IL-2 Signaling 1.32E00 
Metabolic pathways  
Aminoacyl-tRNA Biosynthesis 2.63E00 
 Purine Metabolism 1.79E00 
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5.2.5 Genistein modulates mTOR pathway- an erstwhile unknown arrow in genistein‟s 
quiver 
Immunoblotting analysis of 4EBP-1, the downstream effector of the mTOR pathway was 
performed to ascertain the regulatory effect of GEN on this pathway, which is crucial to cell 
growth and protein synthesis. The western blots showed that GEN inhibited the 
phosphorylation of 4EBP-1, hence indicating a shutdown of the mTOR pathway (Figure 5.6).   
Such a modulation of the mTOR pathway is a novel effect of GEN which has not been 
observed or even suspected to happen before! This is however very consistent with the fact 
that in both MV4-11 and HL-60, protein synthesis is the top function regulated by GEN, since 

























Figure 5.6: Western blot validation of certain key proteins regulated by GEN in AML 
The immunoblotting studies indicated that GEN had profound effect on the mTOR and 
PI3K/Akt pathways in AML. Actin served as the loading control.  
132 
 
5.2.6 Protein synthesis mechanism- an important target of genistein 
Considering the strong causal link between the mTOR pathway and protein translation, the 
rate of nascent protein synthesis was probed. As surmised in the Figure 5.7, GEN was found 
to severely curtail the rate of protein synthesis in both the MV4-11 and HL-60 cells by a 
factor of nearly 4-5 folds. Such an emphatic response to GEN is a very interesting observation 
which is previously unreported. 
The experimental procedure adopted is described in detail in the Methods section (Chapter 3). 
The procedure accommodated an inherent negative control in the form of the cells grown in 
media containing normal methionine. Such cells technically do not take part in the „Click 
chemistry‟ and would hence account for the basal fluorescence of the cells. 
However it is important to note that the effect was manifested at different time points in both 
the cell lines. MV4-11 cells were quick to react to GEN and exhibited a drop in protein 
synthesis levels as early as 24h after drug treatment, sustaining the reduction in the levels up 
to 72h.  However the HL-60 cells showed prolific reduction only at 72h, with little or no 









Figure 5.7: GEN arrests protein synthesis in MV4-11 and HL-60. 
The dynamics of the inhibitory effect differs between the two cell lines. While there is an 
immediate and consistent drop in the synthesis rates in the MV4-11 cells treated with 20µM 











































5.2.7 Akt regulation- One stop solution to many questions?  
The IPA analysis strongly pointed to the regulation of the PI3K/Akt axis in both the cell lines. 
Hence western blot analysis was performed to characterise the role of GEN in Akt regulation. 
As seen in Figure 5.6 GEN strongly up-regulated the levels of the Akt protein in both the cell 
lines. This is very puzzling as Akt is known to promote tumourigenesis and cellular 
proliferation. Hence such an effect of GEN on this vital pathway is contrary to expectations 
and is thus intriguing. 
However in recent times it has been seen that increase in Akt levels leads to production of 
reactive oxygen species (ROS). ROS accumulation beyond a certain threshold has been 
known to promote apoptosis and cell death in a lot of cancer tissues and cells (Simon, et al., 
2000; Wei, et al., 2010). It is hence essential to probe this link between Akt and ROS levels to 
establish a mechanism for the mode of cell death induced by GEN in AML. 
 
5.2.8 Genistein increases ROS levels in leukemia cells 
ROS levels were measured using the cell permeant ROS detection indicator carboxy-
H2DCFDA.  
As shown in Figure 5.8, GEN caused an accumulation of ROS in the AML cells over time. 
There was a difference in the pattern of ROS accumulation between the two cell lines. In the 
case of MV4-11, ROS accumulation followed a uniform upward trend with time, while in 
HL-60 it exhibited a non-linear pattern. In HL-60 cells, GEN caused a dip in the ROS levels 










Figure 5.8: GEN induces ROS accumulation in MV4-11 and HL-60.  
GEN induces ROS generation in both the cell lines over time. However, while in the MV4-11 
cells the trend of ROS accumulation is linear, in the HL-60 it peaks at 72h, with a mild dip at 











































5.2.9 Mechanism of cell death caused by genistein 
5.2.9.1 GEN induces apoptosis in AML cells 
Increase in ROS levels have been known to induce apoptosis and cell death. In order to 
determine whether such a phenomenon occurs in GEN treatment of AML cells, the cells were 
assayed for apoptosis using the flow cytometry based Annexin-V FITC staining method. This 
method involves double staining of the cells with the fluorescent dyes P.I and FITC.  GEN 
was found to induce apoptosis in both the cell lines. The cells which stain positively for FITC, 
but are negative for P.I are considered apoptotic cells. As the Figure 5.9 indicates, an 










Figure 5.9: GEN causes apoptosis in (a) MV4-11 (b) HL-60.  
GEN treatment caused an increase in the proportion of the apoptotic and dead cells in both the 
cell lines. As is the case with the other observations, the apoptotic response in the MV4-11 
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It was also observed that the drug caused an increase in the dead cell population. These cells 
stain positively for both PI and FITC. However in this subpopulation of cells, it is not 
possible to discern between those which died via apoptosis and those which died by necrosis.  
More apoptotic/dead cells were observed at 72h than the other time points, which is 
concurrent with our in vitro cytotoxicity assays, which indicated a peak effect for GEN at 72h 
in both the cell lines (Figure 5.1). Thus it is apparent that GEN induces apoptosis in both the 
cell lines, in correlation with the increase in ROS levels. 
 
5.2.9.2 Contrast in the mechanisms of apoptosis in MV4-11 and HL-60 
In order to understand the mechanism of apoptosis caused by GEN in AML, the caspase 3/7 
levels of AML cells treated with GEN were assayed. Caspase activation is a major mode of 
apoptosis induction in cells.  
Interestingly enough, the results (Figure 5.10) showed that while there was more than a two-
fold increase in the activated caspase levels in the HL-60 cells upon treatment with GEN, 
such a phenomenon does not occur in MV4-11. The dramatic increase in activated caspase 
levels in HL-60 occurs at 72h, which is consistent with the Annexin-V-FITC results, showing 
highest degree of apoptosis at the same time point. Such a pattern of regulation is in 
accordance to the elevation in the ROS levels at 72h. 
Yet, in the MV4-11 cells, the activated caspase levels do not conform to the observed increase 
in apoptosis. The results expound that the apoptosis induction by GEN in MV4-11 is ROS 





Figure 5.10: GEN exerts a duality in its apoptotic mechanism. 
GEN adopts a caspase mediated approach to apoptosis in the HL-60 cells as implied by the 
increase in the caspase levels. However in the MV4-11 cells, GEN does not have any effect 






5.2.10 Deciphering the mode of cell cycle arrest caused by GEN 
Cell cycle arrest is one of the essential features of inhibition of cellular proliferation by drugs. 
Cell cycle was among the biological functions regulated by GEN in both the AML cell lines. 
Hence PI staining of the DNA was performed to study the cell cycle progression of the cells 
treated with GEN in comparison to the untreated cells. The cell cycle analysis result depicted 
in Figure 5.11 clearly elucidates that GEN induces G2/M arrest in HL-60 cells. The drug 
causes a relative accumulation of cycling cells in the G2/M phase with time, thereby blocking 
cell division and cellular proliferation.  
However in the case of the MV4-11 cells, a different phenomenon is observed. The cell cycle 
of MV4-11 does not show a prolific sensitivity to GEN. The cells show an accumulation in 
the G1/S phase at 24h, in stark contrast to the observation in the HL-60 cells. This reveals a 
fundamental difference in the cell cycle regulation by GEN in the two cell lines. This is 
profoundly significant in the wake of the previous finding that MV4-11 cells undergo caspase 
independent apoptosis. The results put together indicate that GEN employs a different mode 
of action to induce growth arrest and cellular death in the AML cells studied, which might be 
correlated with the difference in their genetic background, namely the presence of wild-type 




                










Figure 5.11: Cell cycle regulation by GEN in (a) MV4-11 (b) HL-60 
Propidium iodide based flow cytometric assay of cell cycle indicated divergent effects of GEN on MV4-11 and HL-60 cells. The phase and time-points at 




5.3 Discussion- Piecing together the puzzle! 
5.3.1 Significance of GEN‟s FLT3 inhibitory effect 
The anti-proliferative effect of GEN on tumour cells has been widely reported and is hence 
well established.  There have been many studies characterising the effects of GEN on cancer 
cells and proposing it as a therapeutic strategy to cure cancer. GEN has been effective in 
inhibiting the proliferation of AML cells. Various studies have attempted to elucidate the 
mechanism of action of GEN in AML such as the one by Shen, et al., 2007. However all the 
studies have restricted themselves to looking at the effects of GEN on just one subset of AML 
cells. AML is a multifactorial disease and about 24% of the AML cases are exemplified by 
the presence of an internal tandem duplication in the juxtamembrane of the FLT3 gene, a 
receptor tyrosine kinase. The presence of this mutation has been known to cause drug 
resistance and portend to poor prognosis. Hence it is imperative to address the effects of GEN 
on AML cells containing the FLT3-ITD mutation, in addition to those possessing the wild-
type gene, in order to obtain a comprehensive picture of the mechanism of action of GEN on 
AML cells in its totality. 
This is the first high-throughput proteomic study which attempts to characterise the effects of 
the isoflavone on AML cells, using the cell line MV4-11, containing FLT3-ITD mutation and 
HL-60, sans the mutation as models. The in vitro cytotoxicity assays demonstrated the potent 
inhibitory effect of GEN on both the cell lines. The MV4-11 cells were seen to be a shade 
more responsive than HL-60, as typified by the lower IC50 dosage values. More interesting is 
the observation that at 72h, there was nearly 90% inhibition in case of MV4-11. This is all the 
more significant because there are no previous reports pertaining to GEN‟s effect on MV4-11 
in specific and FLT3-ITD positive cells in general.  
The tyrosine kinase inhibitory activity of GEN has been very well characterised decades ago 
and is hence very well established. This interesting property of GEN formed the basis for our 
hypothesis that GEN might have a regulatory effect on the FLT3 protein. Indeed, as seen in 
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Figure 5.2 GEN inhibited the constitutive phosphorylation of FLT3 in MV4-11. This is a 
landmark discovery as such an effect of GEN is previously unknown and is completely novel. 
This shows that GEN has an anti-proliferative effect on AML cells, irrespective of the 
mutational status of their FLT3 gene. 
Developing drugs which selectively target leukemia cells containing the FLT3 mutation has 
been a critical part of therapeutic research in the recent years. A number of FLT3 inhibitors 
are currently under clinical trials. Thus the fact that GEN can cure both FLT3 dependent and 
independent leukemia is a highly significant discovery! FLT3 inhibitors have been found to 
have highly specific cytotoxic effects towards cells harbouring the FLT3 mutation. Drugs 
such as ABT-869, currently in clinical trials as a FLT3 inhibitor, have little or no effect on 
cells containing wild-type FLT3 gene (Shankar, et al., 2007; Levis, et al., 2001). In such a 
climate, the efficacy of GEN on both subsets of AML is remarkable. This widens the scope 
and application of GEN, which has a directed action, with little side effects, owing to it being 
a natural product. It is also indicative of a divergent effect of the drug on FLT3 positive and 
negative cells. 
Thus, to study the mechanism of action of GEN on a comprehensive scale a high-throughput 
proteomic approach was employed. We profiled the proteome of MV4-11 and HL-60 cells 
treated with the IC50 dosage of GEN and compared them with the untreated cells. The iTRAQ 
platform used for the study was designed in such a manner as to accommodate the labelling of 
8 samples in parallel. This allowed us to label each of the samples in duplicate, thus 
enhancing the statistical power and hence the veracity of the data. 
 
5.3.2 High-throughput study and the story that it presents 
High-throughput studies are powerful methods to obtain a large amount of data. However at 
the end of the day, we would in fact be sitting on a mountain pile of data, completely 
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overwhelmed by its sheer magnitude. Hence we adopted an IPA based strategy to make sense 
of our data.  
The IPA analysis helped unearth a lot of pathways of considerable significance in explaining 
GEN‟s anti-leukemic effects. The pathways identified as regulated by GEN in both the MV4-
11 and HL-60 showed significant similarity and correlated well with the biological functions 
identified. MV4-11 had more number of regulated proteins than HL-60. This might be 
because of the fact that GEN doubles up as a FLT3 inhibitor in MV4-11. As a consequence of 
the down-regulation of the phosphorylation of FLT3, a PTK, a host of its downstream targets 
such as STAT5, RAS/MAPK and PI3K/Akt would be modulated (Gilliland and Griffin, 
2002). On the other hand, in the case of HL-60, this action is rendered obsolete due to the 
absence of the relevant mutation on FLT3. 
 
5.3.2.1 Inhibitory effect of GEN on „Protein Synthesis‟ 
Delving deeper into the data, we observed that „Protein Synthesis‟ ranked consistently as the 
top function in both the cell lines. This might be indicative of the arrest of protein synthesis 
by GEN leading to the inhibition of cellular growth and proliferation. In accordance with our 
hypothesis, mTOR signalling and PI3K/AKT Signalling were found to be regulated by GEN 
in both the cell lines. In addition to this, metabolic pathways such as Phenylalanine 
Metabolism, Tyrosine Metabolism in MV4-11 cells and Aminoacyl-tRNA Biosynthesis in 
HL-60 cells were significantly regulated. These pathways are directly implicated in the 
protein synthesis events. 
Western blotting of p-4EBP-1, the downstream effector of mTOR validated the inhibitory 
effect of GEN on the mTOR signalling axis. This is a completely novel discovery and to the 
best of our knowledge there have no previous studies which have reported such an effect of 
GEN. A detailed description of this pathway is presented in the section 2.4.3.2, Chapter 2. 
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Among the many functions regulated by this pathway, protein translation and cellular growth 
are of special significance in explaining the anti-leukemic property of GEN. 
Previous studies have reported that targeting translation demonstrated a marked anti-leukemic 
potential in AML. The phosphorylation of 4EBP-1 was essential for the control of translation 
initiation (Tamburini, et al., 2009). There are suggestions for development of therapeutic 
strategies that directly target the eIF4F translation initiating complex in AML, of which 
4EBP-1 is an integral component (Tamburini, et al., 2009). Interestingly, GEN exhibited 
inhibitory effects on protein synthesis in leukemia cells mediated by eIF2α kinase (Ito, et al., 
1999).  
Thus there is growing evidence to suggest that GEN caused a decrease in the synthesis of 
proteins mediated by arrest of the mTOR pathway. In order to confirm this, we employed a 
flow cytometry based approach involving Click-iT® chemistry to study the rate of nascent 
protein synthesis in cell treated with GEN in comparison to untreated cells at various time 
points. It is critical to incorporate a series of time points in order to spot the onset of the 
inhibitory effect at its earliest. This information would help map the events in a sequential 
fashion. GEN was found to drastically reduce the protein synthesis rate in MV4-11 cells at all 
time points. In the case of HL-60 the effect was most pronounced at 72h, with the other time 
points displaying milder reduction in the protein synthesis rates.  
The fact that purine metabolism was one of the highly regulated metabolic pathway in both 
the cell lines indicates that GEN might exert a considerable influence on the transcriptional 
control too. Such an effect on the nucleic acid biosynthesis needs to be probed further. 
Additionally GEN has also been reported to down-regulate the proteosome complex in 
tumour cells leading to proliferation arrest (Kazi, et al., 2003). Protein Ubiquitination was 
also among the top functions regulated by GEN in AML. This leads us to speculate that GEN 




5.3.2.2 Reactive oxygen species levels 
The mTOR pathway is downstream of an important signalling axis- PI3K/Akt. The IPA 
analysis indicated a regulation of the PI3K/Akt pathway and the related p70S6K signalling 
axis. Hence we probed the protein levels of Akt in the whole cell lysates in order to glean 
empirical evidence on this effect. The result was baffling GEN was found to increase the Akt 
levels in both the cell lines. Genistein has been known to cause repression of Akt activity by 
the down-regulation of its phosphorylation (Shen, et al., 2007; Zhao, et al., 2009). However in 
our study we found an increase in the levels of total Akt upon GEN treatment, contrary to all 
previous observations.  
 
5.3.2.2.1 Akt increases ROS accumulation 
The phosphoinositide 3-kinase (PI3-kinase) signalling pathway plays a key role in the 
regulation of cell survival and proliferation. Activated Akt is then responsible for the 
phosphorylation of a number of downstream targets, regulating apoptosis and survival, cell 
growth and the cell cycle. Elevated levels of Akt have long been associated with 
tumourigenesis and metastasis. Increase in Akt levels is a biomarker for cancer progression 
(Grandage, et al., 2005). In fact, the PI3K/Akt pathway is an attractive target for several new 
drugs for various tumour types including leukemia (Martelli, et al., 2006). Hence it is indeed 
puzzling to see that GEN elevates the expression levels of Akt in our study! However, a 
recent study reported that Akt stimulated the accumulation of oxygen radicals, which can be 
exploited to selectively kill cancer cells (Nogueira, et al., 2008; Dolado and Nebreda, 2008). 
The study terms this property of Akt to generate ROS as the “Achilles‟ heels of Akt”. ROS 
production by AKT was found to sensitise primary mouse and human fibroblasts to 
replicative senescence and apoptosis. Replicative senescence is the process by which cells 
stop dividing after a limited number of passages in culture. The study proposes that the 
increase in ROS by Akt might be due to a two pronged strategy. Akt stimulates oxidative 
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metabolism in the mitochondria concurrent with enhanced oxygen consumption, which 
indirectly increases intracellular ROS. They also found that although the increased Akt level 
promoted proliferation and inhibited apoptosis in cancer cells, it was ineffective against ROS 
mediated apoptosis. Thus this study suggests that the increased levels of Akt can actually be 
exploited to induce the cells to undergo apoptosis.  
 
5.3.2.2.2 ROS mediates apoptosis 
ROS plays important roles in cell proliferation, ageing, and cancer development. The reactive 
chemical properties of ROS may cause a variety of tissue injury in a wide range of human 
diseases. An excessive amount of ROS can lead to cell death by apoptosis or necrosis. The 
fact that increased levels of ROS can cause apoptosis is now well established. There is now 
considerable interest in drugs such as β-phenylethyl isothiocyanate (PEITC) and arsenic 
trioxide which increase the intrinsic ROS levels of the cells beyond a certain threshold and 
hence cause apoptosis (Trachootham, et al., 2006; Zhou, et al., 2003). ROS generation was 
the primary mechanism of cell death induced by 2-methoxyestradiol in AML cells (She, et al., 
2007). 
GEN is known to cause ROS accumulation in other studies (Salvi, et al., 2002).  It is also 
known to potentiate arsenic trioxide mediated apoptosis in leukemia cells by ROS generation 
(Sánchez, et al., 2008). 
 
5.3.2.2.3 GEN induces ROS mediated apoptosis by elevating the Akt levels in AML cells 
The IPA analysis of the proteomics data showed that Oxidative Phosphorylation and 
Glutathione Metabolism were among the metabolic pathways highly regulated by GEN in 
MV4-11 and Mitochondrial Dysfunction was one of the top signalling pathways modulated 
by the drug. The same pathways were regulated in HL-60 cells too, although they did not 
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clear the stringent p-value threshold set for the study. This data strongly alludes to a ROS 
mediated activity by GEN. 
Hence we investigated the levels of ROS production in the cells treated with GEN in 
comparison to the untreated cells. The assay, performed using the carboxy-H2DCFDA 
reagent, indicated an elevated ROS production in both MV4-11 and HL-60 cells. The 
maximum production was at 72h- consistent with the observation that maximum apoptosis 
occurs at this time point. This is a completely novel finding and adds a completely new 
dimension to the treatment of AML by GEN, opening up a multitude of possibilities for 
combinative therapies. 
The pattern of ROS increase was linear in the case of MV4-11. This is in concert with the 
pattern of decrease in the protein synthesis rate observed in this cell line. However in the case 
of HL-60, the ROS level increased sharply at 72h and showed minor decrease upon GEN 
treatment at earlier timepoints. This was again in line with the observed drop in protein 
synthesis in the HL-60 cells.  
 
5.3.3 The tale of two modes of “death” 
5.3.3.1 ROS accumulation culminates in apoptosis 
The aforementioned arguments based on empirical data obtained from the proteomic study 
and functional assays indicate that GEN induces apoptosis in both the MV4-11 and HL-60 
cells. The IPA analysis unearthed several pathways related to apoptosis in both the cell lines. 
Pathways related to cell death such as Induction of Apoptosis by HIV1, Death Receptor 
Signalling and Myc Mediated Apoptosis Signalling were found regulated in both the cell 




Apoptosis was assayed using Annexin-V-FITC staining, a technique which has the capability 
to specifically differentiate between apoptotic and necrotic cells. As the results in Figure 5.9 
elucidate, GEN induced apoptosis in both MV4-11 and HL-60 cells, with the effect peaking at 
72h. This observation is further backed up by the trypan blue counting results, which 
demonstrate the cytotoxic effect of GEN in AML. 
Thus we can conclusively say that GEN potentiated the cells to cell death by shutting down 
the protein translational machinery, leading to protein synthesis arrest and caused apoptosis in 
AML cells via ROS mediated mechanism. 
 
5.3.3.2 Caspase dependency paradigm 
Apoptosis is the main mode of cell death employed by GEN. We decided to probe deeper into 
the mechanism of apoptosis initiated by the drug. 
Caspase activation is a hallmark of apoptosis. They are so named as they are „cysteine‟ 
proteases that cleave after an „aspartate‟ residue in their substrates. They constitute a 
conserved family of enzymes that irreversibly commit a cell to death. These enzymes 
participate in a cascade that is triggered in response to proapoptotic signals and culminates in 
cleavage of a set of proteins, resulting in disassembly of the cell (Thornberry and Lazebnik, 
1998). Although there are at least 14 caspases in humans, only a subset of these enzymes is 
detectably proteolytically activated by various distinct death stimuli in different cell types. 
Caspase 3 is one of the most important and well studied of this family and is a frequently 
expressed death protease (Porter and Jänicke, 1999). Caspase 3 and 7 belong to the family of 
effector caspases, the increased levels of which signal the onset of apoptosis.  
The caspase 3/7 levels were assayed in cells treated with GEN. The results were very 
interesting. We found that while HL-60 cells exhibited a nearly two-fold increase in activated 
caspase levels upon GEN treatment, while MV4-11 cells showed no such increase. In spite of 
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the fact that both cell lines underwent apoptosis, caspase activation was restricted to HL-60 
cells alone! This shows that MV4-11 cells undergo apoptosis by a caspase independent 
mechanism. 
Several apoptotic mechanisms, independent of caspases have been identified. One such 
mechanism implicates mitochondria in the release of proapoptotic proteins. The caspase 
dependent and independent mechanisms can act in tandem in cells (Lorenzo and Susin, 2004).  
It is important to note that the MV4-11 cells undergo cell death by caspase independent 
apoptosis and not necrosis as evidenced by the Annexin V FITC staining. Thus there is a 
duality in the apoptotic effect of GEN in AML. Such a difference arises probably due to the 
inherent FLT3-ITD mutation in the MV4-11 cells. 
 
5.3.4 Divergent effects of GEN on Cell Cycle Progression 
GEN has been known to arrest the cell cycle progression of AML cells and hence inhibit the 
growth and proliferation of cells (Shen, et al., 2007; Sánchez, et al., 2009). This is 
characteristic of anti-tumour drugs which cause accumulation of cells in a particular phase of 
the cell cycle in order to curb the growth of cancer cells. 
Literature suggests that GEN effected a G2/M arrest in AML cells, and HL-60 in particular. 
In our study too, we found that GEN caused a G2/M arrest in HL-60 cells. However in the 
case of MV4-11, this phenomenon was absent. In fact there was a G1/S arrest at 24 h in 
MV4-11, in complete contrast to HL-60. This observation is in keeping with the difference in 
the mode of apoptosis, patterns of ROS increase and protein synthesis decrease observed in 
the two cell lines.  
Thus G2/M arrest induced by GEN is not a generic effect on all AML cells as thought of 
before. The difference in the FLT3 status of the two cell lines might explain the divergent 
effects on cell cycle regulation. There have been previous instances of drugs exerting 
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contradicting effects on the cell cycle based on the presence and absence of FLT3-ITD 
mutations. In a study conducted on series of AML cells with and without this mutation, it was 
found that the drug PKC412, a FLT3 inhibitor, arrested the cells with the mutation at the G1 
phase and those without the mutation at the G2/M phase of the cell cycle (Odgerel, et al., 
2008; Furukawa, et al., 2007). PKC412 was highly cytotoxic to cells containing the mutation, 
but not very effective against the ones with wild-type FLT3 gene. Thus it is highly possible 
that the FLT3 mutational status determines to a large degree regulatory effect of GEN on the 
cell cycle. 
 
5.3.5 Summarising the effects of GEN on AML 
Thus, we have studied the effects of GEN on AML in its totality using a two-cell line model. 
The results are summarised in a tabular form (Table 5.3). The effects of GEN on MV4-11 and 
HL-60 cells were similar in many ways. The drug generated ROS by elevating the levels of 
Akt and inhibited protein synthesis by the shutdown the mTOR pathway. These in turn led to 
cell cycle arrest and apoptosis. However the modes of cell death and growth arrest were 
divergent in the two cell lines. The processes which differ in the two cell lines by a high 
degree are highlighted by solid lines and those that differ only by the time of onset are 





Table 5.3: Tabular comparison of effects of GEN on the two AML models 
EFFECT MV4-11 HL-60 REMARKS 
Cytotoxicity IC50  20 µm IC50  30 µm In the case of MV4-11, GEN exhibits more prolific cytotoxicity 
FLT3 status Abrogates 
phosphosphorylation of 
FLT3 
p-FLT3 absent This specific effect on MV4-11 might have a bearing on the downstream 
effects 
mTOR  Down-regulated Down-regulated Leads to protein translation arrest 
Akt  Up-regulated Up-regulated Might lead to increase in ROS levels 
ROS levels Up-regulated 
(consistently) 
Up-regulated (at 72 h, 
down-regulated or no 
change at other time 
points) 
HL-60 shows a dip in the ROS levels but bounces back at 72 h. MV4-11 
shows an upward trend in the ROS levels consistently 




at 72 h, down-regulated 
or no change at other 
time points) 
 
Protein synthesis drop dramatically at 72 h in case of HL-60. In MV4-11‟s 
case there is a consistent drop in the rate at all time points 
Apoptosis – Annexin 
V FITC assay 
Increase in apoptosis Increase in apoptosis Consistent with increase in ROS  
Caspase assay No increased caspase 
activation 
More than two-fold 
increase in activated 
caspase levels 
Mechanism of apoptosis in MV4-11 is caspase independent 
Cell cycle analysis G1 arrest at 24 h  G2/M arrest Differences in the mode of cell cycle arrest 
 
 
Compilation of GEN‟s effects indicated certain key differences in the mode of action of the drug on the two cell lines. The blue dotted line represents those 




5.3.6 Examining the role of FLT3 in the story 
In spite of the apparent similarity in the overall mechanism of action of GEN in the two 
model cell lines, the inherent differences surface when we probe in depth. The fact that the 
two cell lines differ by a mutation in the FLT3 gene, which by itself is capable of 
leukemogeneis and cancer progression is very significant. Our results prove beyond that the 
PTK inhibitor GEN is also an effective FLT3 kinase inhibitor and this effect is manifested in 
the MV4-11 cell line. HL-60 cells are devoid of this mutation and hence such an effect is 
irrelevant in their context.  Hence it is very tempting to view the observed differences through 
the prism of FLT3 inactivation. 
The general mechanism of action of GEN is similar in both the cell lines. Processes such as 
ROS generation and protein synthesis arrest are common to both cell lines. The causal factors 
such as mTOR arrest and Akt elevation are also shared by both. However the degree of 
regulation and time of onset are different for the two models. Previous literature indicates that 
GEN induces cell cycle arrest and apoptosis in AML. Our study corroborates this fact. 
However it is very important to note that we found a major difference in the mode of cell 
cycle regulation and mechanism of apoptosis between the cell lines.  
Although baffling, such a difference in the effects of GEN can be explained by incorporating 
its inhibitory effect on the phosphorylation status of FLT3 in MV4-11. This powerful weapon 
in GEN‟s arsenal equips it with an additional method to arrest proliferation of cells. Since 
FLT3 is a very important kinase for cell growth and proliferation, it has a number of 
downstream effectors such as STAT5 and RAS/MAPK. Thus a modification to its 
constitutively activated status would elicit several downstream responses. Such responses 
would obviously be unique to MV4-11 which contains the mutated FLT3 gene and would not 
be observed in HL-60 which has the wild-type version.  
It is possible that the inhibitory effect of GEN on the FLT3 phosphorylation in MV4-11 
makes the cell highly responsive to cytotoxic effects of the drug and hastens the biological 
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processes such as ROS generation and protein synthesis arrest. The differential effect of drugs 
on the cell cycle of AML cells with and without FLT3-ITD has been observed previously in a 
number of studies as cited before (Furukawa, et al., 2007; Odgerel, et al., 2008). The studies 
also establish that FLT3 inhibitors induce apoptosis in cells with FLT3-ITD cells and not in 
wild type-FLT3. In our study GEN was effective in inducing apoptosis against both the 
subsets of AML, albeit by differing mechanisms. Thus the fact that GEN acts as a FLT3 
inhibitor in AML adds new meaning to all the observations and provides a plausible 
explanation to the divergent effects exerted by GEN on certain biological processes in these 
cell lines. 
 
5.4 Significance and Concluding Remarks 
In summary, it is pertinent to note the key findings of this study. GEN exerts anti-proliferative 
effects on AML cells. It has a novel FLT3 kinase inhibitory function and acts by inhibiting 
the constitutive phosphorylation of the FLT3 protein in FLT3-ITD cells. Thus, GEN has 
cytotoxic effects on both the subsets of AML and can hence be used as a generic anti-
leukemic drug which would be effective against all patient types irrespective of their 
mutational status. The drug targets specific functions in AML such as Protein Synthesis, Cell 
death and Cell growth arrest. It had novel regulatory effects on mTOR (down-regulates); 
PI3K/Akt (up-regulates); apoptosis related pathways; amino acid biosynthesis pathways, etc. 
It decreased the protein synthesis levels in both the cell lines. GEN causes ROS mediated 
apoptosis in AML cells. The apoptosis in MV4-11 cells (FLT3-ITD) was caspase independent 
while that in HL-60 (wild-type FLT3) was caspase dependent. GEN induced G2/M arrest in 
the HL-60 cells; it caused G1 arrest in the MV4-11 cells. Hence the drug exhibits a duality in 
its mode of cell cycle arrest which is dependent on the FLT3 mutational status. Thus with an 
overall similarity in its mode of action, the dynamics varied between the two cell lines 
studied. Based upon the empirical data gleaned, we have proposed a mechanism of action of 
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Figure 5.12: Summary of the effects of GEN on AML 
Proposed model for the mechanism of action of GEN in AML, based on empirical evidence. 
Legend:  
   Down-regulation 
    Up-regulation 
                       





The future augurs well for the development of targeted therapies for AML, which have 
reduced side-effects, increased cytotoxicity sans drug resistance. Our study helps understand 
the mechanism of action of two such promising drugs- rapa and GEN. We have used high-
throughput methodologies to characterise the anti-leukemic effects of these drugs and have 
demonstrated the efficacy of such an approach. Hence our study would serve as a template for 
future studies in this direction. Our investigation provides fresh perspectives to AML therapy 
and has the potential for further exploration. 
 
6.1 Rapamycin based AML treatment- What lies ahead? 
Rapa has far reaching effects on the signalling axis of AML. The fact that its effects are not 
restricted to just the mTOR pathway is a revelation, paving the way for several future 
directions. 
 Rapa is primarily a cytostatic drug in the context of AML. Hence there are several 
potential combinatorial strategies that can be tried. Rapa can be coupled to 
chemotherapeutic agents and apoptosis inducing agents to maximise the anti-cancer 
effects. Rapa would arrest the cells at the G1 phase and prepare them for cell death by 
the agent in combination. 
 
 The profiling studies could be carried out on patient samples and primary cells to 
fathom the effects of rapa in a more fundamental fashion. 
 
 Once the right combinatorial strategy is identified and optimised, clinical trials should 
be mooted to test its efficacy on patients so that targeted AML therapy can actually 
become a reality. 
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6.2 Genistein- Novelties abound and an exciting future! 
The discovery that GEN has potent FLT3 inhibitory properties opens the door to a plethora of 
possibilities.  
 Since GEN is primarily a PTK inhibitor which causes reversal of FLT3 
phosphorylation, it is imperative to profile the phosphoproteome of the cells treated 
with the drug. Such a study would throw light on the effects of GEN on the PTM 
(post-translational modification) of proteins. This would provide more clues to the 
functional mechanism of the drug as it adds a new dimension to our understanding. 
We propose to proceed with this set of experiments using a HAMMOC (aliphatic 
hydroxy acid-modified metal oxide chromatography) technology based mass 
spectrometric approach (Sugiyama, et al., 2008). The proteins would be labelled 
intracellularly by SILAC for quantification.  
 
 As the proteomic data implied, metabolic pathways such as oxidative 
phosphorylation, mitochondrial dysfunction, amino acid biosynthesis and regulation, 
purine metabolism, etc were highly regulated by GEN. Thus a profile of the 
metabolites regulated by GEN in AML could pave the way to the understanding of 
the metabolic functions regulated by the drugs. This would in turn enable the 
discovery of the intricate link between the signalling and metabolic aspects of the 
anti-cancer mechanism.   
 
 The metabolic profile thus obtained could be specifically investigated for the 
regulation of glycolysis, gluconeogenesis and TCA pathways to comprehend the 
oxygen cycling and energy production dynamics of the cells treated with GEN.  
 
 There is an interesting link between GEN and transcriptional control which needs to 
be investigated in greater detail. GEN‟s inhibitory effect on protein translation could 
imply a similar effect on transcription. Added to this, our observation that purine 
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metabolism was highly regulated and pentose phosphate pathway was moderately 
regulated by GEN in both the AML cell lines, bolsters our hypothesis that 
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TABLE A: Proteins significantly regulated in HL-60 cells upon GEN treatment as identified by 8-plex iTRAQ 
ACCESSION # NAME HL-60-
AVERAGE 
RATIO 
IPI00515061.3 HIST1H2BJ Histone H2B type 1-J 0.213825 
IPI00926977.1 PSMC6 proteasome 26S ATPase subunit 6 0.266575 
IPI00816460.2 DST Isoform 2 of Bullous pemphigoid antigen 1, isoforms 1/2/3/4/5/8 (Fragment) 0.26945 
IPI00291764.5 HIST1H2AH;HIST1H2AI;HIST1H2AK;HIST1H2AJ;HIST1H2AG;HIST1H2AL;HIST1H2AM 
Histone H2A type 1 
0.27375 
IPI00032460.3 LSM2 U6 snRNA-associated Sm-like protein LSm2 0.281825 
IPI00748149.2 CDC20B Isoform 1 of Cell division cycle protein 20 homolog B 0.301425 
IPI00908443.1 DYSF Isoform 2 of Dysferlin 0.3435 
IPI00941730.1 ARHGAP1 cDNA FLJ60782, highly similar to Rho-GTPase-activating protein 1 0.38385 
IPI00885176.1 C3orf77 Uncharacterized protein C3orf77 0.3853 
IPI00019927.2 PSMD7 26S proteasome non-ATPase regulatory subunit 7 0.3934 
IPI00290460.3 EIF3G Eukaryotic translation initiation factor 3 subunit G 0.437 
IPI00010402.2 SH3BGRL3 Putative uncharacterized protein 0.4979 
IPI00026546.1 PAFAH1B2 Platelet-activating factor acetylhydrolase IB subunit beta 0.510225 
IPI00873383.1 ST6GALNAC3 Putative uncharacterized protein ST6GALNAC3 (Fragment) 0.5439 
IPI00746438.2 RPL11 Isoform 2 of 60S ribosomal protein L11 0.551725 
IPI00946481.1 MBNL1 Protein 0.5601 
IPI00301058.5 VASP Vasodilator-stimulated phosphoprotein 0.57225 
IPI00456758.4 RPL27A 60S ribosomal protein L27a 0.6046 
IPI00940423.1 LCK Isoform Long of Proto-oncogene tyrosine-protein kinase LCK 0.610275 
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IPI00291419.6 ACAT2 cDNA FLJ53975, highly similar to Acetyl-CoA acetyltransferase, cytosolic 0.6127 
IPI00645339.2 HP1BP3 39 kDa protein 0.62615 
IPI00219446.5 PEBP1 Phosphatidylethanolamine-binding protein 1 0.62995 
IPI00216047.3 SMARCC2 Isoform 1 of SWI/SNF complex subunit SMARCC2 0.6314 
IPI00945507.1 SUCLG2 48 kDa protein 0.63535 
IPI00011913.1 HNRNPA0 Heterogeneous nuclear ribonucleoprotein A0 0.638275 
IPI00917298.1 RPL31 Putative uncharacterized protein RPL31 0.641925 
IPI00397571.1 NSFL1C Isoform 3 of NSFL1 cofactor p47 0.645225 
IPI00900327.2 PCBP2 cDNA FLJ58339, highly similar to Poly(rC)-binding protein 2 0.650025 
IPI00942600.1 EIF4B 70 kDa protein 0.671575 
IPI00922415.1 SSBP1 cDNA FLJ51825, highly similar to Single-stranded DNA-binding protein, mitochondrial 0.6737 
IPI00217950.5 HMGN2 Non-histone chromosomal protein HMG-17 0.67555 
IPI00010270.1 RAC2 Ras-related C3 botulinum toxin substrate 2 0.676325 
IPI00217030.10 RPS4X 40S ribosomal protein S4, X isoform 0.687875 
IPI00106491.3 MRTO4 mRNA turnover protein 4 homolog 0.69085 
IPI00216659.1 RBM8A Isoform 2 of RNA-binding protein 8A 0.69115 
IPI00872379.1 ANXA5 Putative uncharacterized protein ANXA5 (Fragment) 0.692525 
IPI00176637.5 LOC728350;EIF2S2 Eukaryotic translation initiation factor 2 subunit 2-like protein 0.69385 
IPI00412607.6 RPL35 60S ribosomal protein L35 0.7008 
IPI00068430.1 SNRPEL1 Putative small nuclear ribonucleoprotein polypeptide E-like protein 1 0.7014 
IPI00014263.1 EIF4H Isoform Long of Eukaryotic translation initiation factor 4H 0.7031 
IPI00220503.9 DCTN2 dynactin 2 0.712225 
IPI00005966.6 NDUFA12 13kDa differentiation-associated protein variant (Fragment) 0.714525 
IPI00026665.2 QARS cDNA FLJ75085, highly similar to Homo sapiens glutaminyl-tRNA synthetase (QARS), 
mRNA 
0.714575 
IPI00420108.5 DLST;DLSTP Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate 
dehydrogenase complex, mitochondrial 
0.720325 
IPI00099550.1 UBQLN1 Isoform 1 of Ubiquilin-1 0.721625 
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IPI00026781.2 FASN Fatty acid synthase 0.727575 
IPI00004839.1 CRKL Crk-like protein 0.7385 
IPI00794978.1 MRPL47 Isoform 2 of 39S ribosomal protein L47, mitochondrial 0.73905 
IPI00879531.1 - 9 kDa protein 0.744025 
IPI00219622.3 PSMA2 Proteasome subunit alpha type-2 0.74715 
IPI00903204.1 RPS24 15 kDa protein 0.748 
IPI00647915.1 TAGLN2 24 kDa protein 0.7486 
IPI00873466.1 HPRT1 Putative uncharacterized protein HPRT1 0.7586 
IPI00940950.1 RPL10 Ribosomal protein L10 (Fragment) 0.759 
IPI00872814.1 MSN Putative uncharacterized protein MSN (Fragment) 0.761975 
IPI00643317.3 HMGB3 21 kDa protein 0.767075 
IPI00006658.4 PIN4 Isoform 2 of Peptidyl-prolyl cis-trans isomerase NIMA-interacting 4 0.768525 
IPI00945691.1 PRPS1 Ribose-phosphate pyrophosphokinase (Fragment) 0.769625 
IPI00303882.2 PLIN3 Isoform B of Mannose-6-phosphate receptor-binding protein 1 0.772075 
IPI00908543.1 PPP2R1A cDNA FLJ56133, highly similar to Serine/threonine-protein phosphatase 2A 65 kDa 
regulatory subunit A alpha isoform 
1.3003 
IPI00815770.2 SNX3 Isoform 1 of Sorting nexin-3 1.301825 
IPI00000816.1 YWHAE 14-3-3 protein epsilon 1.303925 
IPI00878984.1 DDT 14 kDa protein 1.31175 
IPI00947458.1 PCMT1 protein-L-isoaspartate (D-aspartate) O-methyltransferase 1 1.31645 
IPI00947554.1 RP6-213H19.1 cDNA FLJ90669 fis, clone PLACE1005519, moderately similar to Homo 
sapiens STE20-like kinase 3 (mst-3) mRNA 
1.319175 
IPI00412737.1 WARS tryptophanyl-tRNA synthetase isoform b 1.321975 
IPI00002569.3 EIF4EBP1 Eukaryotic translation initiation factor 4E-binding protein 1 1.322325 
IPI00165393.1 ANP32E Acidic leucine-rich nuclear phosphoprotein 32 family member E 1.32335 
IPI00853163.1 TYMP 46 kDa protein 1.34025 
IPI00399142.5 SURF4 Surfeit 4 1.36515 
IPI00789285.1 TXNDC17 11 kDa protein 1.366775 
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IPI00375380.4 PSMD13 proteasome 26S non-ATPase subunit 13 isoform 2 1.374175 
IPI00026833.4 ADSS Adenylosuccinate synthetase isozyme 2 1.376875 
IPI00893362.1 RYR3 Putative uncharacterized protein RYR3 1.3773 
IPI00556451.2 ETFB Isoform 2 of Electron transfer flavoprotein subunit beta 1.3788 
IPI00783982.1 COPG Coatomer subunit gamma 1.383225 
IPI00395617.5 ARID1B Isoform 2 of AT-rich interactive domain-containing protein 1B 1.40015 
IPI00007163.1 LSM7 U6 snRNA-associated Sm-like protein LSm7 1.4041 
IPI00788055.3 THAP4 Isoform 1 of THAP domain-containing protein 4 1.40415 
IPI00032313.1 S100A4 Protein S100-A4 1.4077 
IPI00003419.1 C11orf58 Small acidic protein 1.411175 
IPI00657724.1 NPTN Isoform 3 of Neuroplastin 1.412625 
IPI00383680.3 RPN2 ribophorin II isoform 2 precursor 1.4145 
IPI00939431.1 RELN 368 kDa protein 1.4183 
IPI00795292.1 NME2;NME1-NME2 Isoform 3 of Nucleoside diphosphate kinase B 1.420875 
IPI00028004.2 PSMB3 Proteasome subunit beta type-3 1.421425 
IPI00910593.1 CNN2 cDNA FLJ52765, highly similar to Calponin-2 1.425425 
IPI00059139.1 ATP6V1E2 V-type proton ATPase subunit E 2 1.43245 
IPI00015602.1 TOMM70A Mitochondrial import receptor subunit TOM70 1.439425 
IPI00927101.1 RPSAP15;RPSA 30 kDa protein 1.440125 
IPI00177728.3 CNDP2 Isoform 1 of Cytosolic non-specific dipeptidase 1.456575 
IPI00894213.1 RTN4 Isoform 6 of Reticulon-4 1.4684 
IPI00013122.1 CDC37 Hsp90 co-chaperone Cdc37 1.4926 
IPI00418169.3 ANXA2 Isoform 2 of Annexin A2 1.51015 
IPI00744851.2 HMGA1 cDNA FLJ54188, moderately similar to High mobility group protein HMG-I/HMG-Y 1.514425 
IPI00940656.1 ANP32A;LOC723972 Putative uncharacterized protein ANP32A 1.529875 





IPI00009950.1 LMAN2 Vesicular integral-membrane protein VIP36 1.558975 
IPI00871954.2 LARS cDNA FLJ58466, highly similar to Leucyl-tRNA synthetase, cytoplasmic 1.56735 
IPI00939523.1 DDX46 117 kDa protein 1.63585 
IPI00646241.1 CIRBP 18 kDa protein 1.650375 
IPI00304925.5 HSPA1A;HSPA1B Heat shock 70 kDa protein 1 1.680575 
IPI00299404.1 LAMB3 Laminin subunit beta-3 1.688175 
IPI00465211.1 PPP3R1;WDR92 HZGJ 1.740825 
IPI00942171.1 PRPSAP2 cDNA FLJ52829, highly similar to Phosphoribosyl pyrophosphatesynthetase-
associated protein 2 
1.76285 
IPI00939315.1 - 37 kDa protein 1.76625 
IPI00872855.1 EWSR1 Isoform EWS of RNA-binding protein EWS 1.83685 
IPI00012382.3 SNRPA U1 small nuclear ribonucleoprotein A 1.8451 
IPI00395939.4 PITPNB Phosphatidylinositol transfer protein, beta, isoform CRA_a 1.853325 
IPI00550069.3 RNH1 Ribonuclease inhibitor 1.879725 
IPI00746770.4 LOC728129 Putative LRRC3-like protein ENSP00000367157 1.88255 
IPI00941900.1 CALU Isoform 1 of Calumenin 1.977975 
IPI00328754.6 ZFHX4 zinc finger homeodomain 4 2.0119 
IPI00943889.1 LOC100129103 similar to hCG2038970 2.15715 
IPI00027409.1 PRTN3 Myeloblastin 2.186275 
IPI00293276.10 MIF Macrophage migration inhibitory factor 2.292175 
IPI00847759.2 DENND4B DENN domain-containing protein 4B 2.3784 
IPI00385250.1 PRSS3 Protease serine 4 isoform B 2.698 
IPI00218448.4 H2AFZ Histone H2A.Z 2.74285 
IPI00793234.1 - 395 kDa protein 2.750125 
IPI00009030.1 LAMP2 Isoform LAMP-2A of Lysosome-associated membrane glycoprotein 2 2.87545 
IPI00031489.1 EIF1B Eukaryotic translation initiation factor 1b 2.97935 
IPI00941463.1 NAP1L4 Nucleosome assembly protein 1-like 4 3.3569 
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IPI00022630.1 AIF1 Allograft inflammatory factor 1 3.977825 
IPI00031696.4 FASTKD3 FAST kinase domain-containing protein 3 5.4235 
IPI00644529.1 ZNF615;ZNF432 Isoform 1 of Zinc finger protein 615 6.91355 
IPI00477040.1 NUP188 Isoform 1 of Nucleoporin NUP188 homolog 6.931175 
IPI00479186.7 PKM2 Isoform M2 of Pyruvate kinase isozymes M1/M2 10.38615 
 
 
TABLE B: Proteins significantly regulated in MV4-11 cells upon GEN treatment as identified by 8-plex iTRAQ 
ACCESSION # NAME MV4-11-
AVERAGE 
RATIO 
IPI00926977.1 PSMC6 proteasome 26S ATPase subunit 6 0.232475 
IPI00291764.5 HIST1H2AH;HIST1H2AI;HIST1H2AK;HIST1H2AJ;HIST1H2AG;HIST1H2AL;HIST1H2AM 
Histone H2A type 1 
0.25295 
IPI00515061.3 HIST1H2BJ Histone H2B type 1-J 0.292025 
IPI00816460.2 DST Isoform 2 of Bullous pemphigoid antigen 1, isoforms 1/2/3/4/5/8 (Fragment) 0.368725 
IPI00885176.1 C3orf77 Uncharacterized protein C3orf77 0.374425 
IPI00216659.1 RBM8A Isoform 2 of RNA-binding protein 8A 0.4275 
IPI00619914.2 U2AF1 U2 small nuclear RNA auxillary factor 1 isoform b 0.431375 
IPI00010414.4 PDLIM1 PDZ and LIM domain protein 1 0.438025 
IPI00004839.1 CRKL Crk-like protein 0.44925 
IPI00793205.1 SFRS9 cDNA FLJ56571, highly similar to Splicing factor, arginine/serine-rich 9 0.45385 
IPI00019927.2 PSMD7 26S proteasome non-ATPase regulatory subunit 7 0.460175 
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IPI00908443.1 DYSF Isoform 2 of Dysferlin 0.46565 
IPI00299254.3 EIF5B Eukaryotic translation initiation factor 5B 0.468225 
IPI00301058.5 VASP Vasodilator-stimulated phosphoprotein 0.472225 
IPI00008418.6 DIABLO Diablo homolog, mitochondrial precursor 0.47235 
IPI00909453.2 HSPB1 cDNA FLJ52243, highly similar to Heat-shock protein beta-1 0.484375 
IPI00301561.1 TRIP6 Thyroid receptor-interacting protein 6 0.497025 
IPI00783862.2 BLVRB Flavin reductase 0.50615 
IPI00414684.7 SEMG1 Isoform 2 of Semenogelin-1 0.51215 
IPI00946481.1 MBNL1 Protein 0.52285 
IPI00017342.1 RHOG Rho-related GTP-binding protein RhoG 0.537975 
IPI00026546.1 PAFAH1B2 Platelet-activating factor acetylhydrolase IB subunit beta 0.5461 
IPI00942600.1 EIF4B 70 kDa protein 0.566325 
IPI00604710.2 LOC442497;SLC3A2 Isoform 1 of 4F2 cell-surface antigen heavy chain 0.569 
IPI00900327.2 PCBP2 cDNA FLJ58339, highly similar to Poly(rC)-binding protein 2 0.576725 
IPI00221035.4 BTF3 Isoform 1 of Transcription factor BTF3 0.593775 
IPI00005537.2 MRPL12 39S ribosomal protein L12, mitochondrial 0.595375 
IPI00843996.1 SFRS3 Splicing factor, arginine/serine-rich 3, isoform CRA_a 0.60135 
IPI00026519.1 PPIF Peptidyl-prolyl cis-trans isomerase, mitochondrial 0.602825 
IPI00746438.2 RPL11 Isoform 2 of 60S ribosomal protein L11 0.603275 
IPI00450855.1 HMGA1 HMGA1 protein 0.61485 
IPI00748149.2 CDC20B Isoform 1 of Cell division cycle protein 20 homolog B 0.6159 
IPI00412492.3 PLXND1 Isoform 1 of Plexin-D1 0.617675 
IPI00219953.5 CMPK1 UMP-CMP kinase 1 isoform a 0.62145 
IPI00217950.5 HMGN2 Non-histone chromosomal protein HMG-17 0.6233 
IPI00008986.1 SLC7A5 Large neutral amino acids transporter small subunit 1 0.6301 
IPI00011913.1 HNRNPA0 Heterogeneous nuclear ribonucleoprotein A0 0.631225 
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IPI00016513.5 RAB10 Ras-related protein Rab-10 0.632825 
IPI00301434.4 BOLA2;BOLA2B BolA-like protein 2 0.634425 
IPI00221224.6 ANPEP Aminopeptidase N 0.640525 
IPI00420108.5 DLST;DLSTP Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate 
dehydrogenase complex, mitochondrial 
0.654725 
IPI00219446.5 PEBP1 Phosphatidylethanolamine-binding protein 1 0.6565 
IPI00026314.1 GSN Isoform 1 of Gelsolin 0.658975 
IPI00922914.1 EPB41L3 cDNA FLJ58675, highly similar to Band 4.1-like protein 3 0.6629 
IPI00853163.1 TYMP 46 kDa protein 0.668325 
IPI00941730.1 ARHGAP1 cDNA FLJ60782, highly similar to Rho-GTPase-activating protein 1 0.66885 
IPI00106491.3 MRTO4 mRNA turnover protein 4 homolog 0.669 
IPI00025019.3 PSMB1 Proteasome subunit beta type-1 0.670975 
IPI00031801.4 CSDA Isoform 1 of DNA-binding protein A 0.67155 
IPI00787306.1 RCC1 regulator of chromosome condensation 1 isoform b 0.6721 
IPI00013297.1 PDAP1 28 kDa heat- and acid-stable phosphoprotein 0.672275 
IPI00456925.3 DBNL Isoform 1 of Drebrin-like protein 0.67765 
IPI00006052.3 PFDN2 Prefoldin subunit 2 0.678725 
IPI00002569.3 EIF4EBP1 Eukaryotic translation initiation factor 4E-binding protein 1 0.68335 
IPI00935729.1 HBXIP Hepatitis B virus X-interacting protein 0.68905 
IPI00375531.2 NME1 Isoform 2 of Nucleoside diphosphate kinase A 0.690675 
IPI00021840.1 RPS6 40S ribosomal protein S6 0.692025 
IPI00872952.1 UQCRH Ubiquinol-cytochrome c reductase hinge protein, isoform CRA_c 0.6942 
IPI00412607.6 RPL35 60S ribosomal protein L35 0.70145 
IPI00916535.1 P4HA1 prolyl 4-hydroxylase, alpha I subunit isoform 3 precursor 0.702575 
IPI00456758.4 RPL27A 60S ribosomal protein L27a 0.70735 
IPI00021924.1 H1FX Histone H1x 0.707575 
IPI00290460.3 EIF3G Eukaryotic translation initiation factor 3 subunit G 0.7103 
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IPI00815642.1 TMSB4X TMSB4X protein (Fragment) 0.71265 
IPI00220487.4 ATP5H Isoform 1 of ATP synthase subunit d, mitochondrial 0.71605 
IPI00940263.1 LPXN 44 kDa protein 0.71715 
IPI00015891.1 PFDN4 Prefoldin subunit 4 0.717875 
IPI00945507.1 SUCLG2 48 kDa protein 0.7207 
IPI00010270.1 RAC2 Ras-related C3 botulinum toxin substrate 2 0.721275 
IPI00942171.1 PRPSAP2 cDNA FLJ52829, highly similar to Phosphoribosyl pyrophosphatesynthetase-
associated protein 2 
0.722425 
IPI00303882.2 PLIN3 Isoform B of Mannose-6-phosphate receptor-binding protein 1 0.722825 
IPI00027834.3 HNRNPL Heterogeneous nuclear ribonucleoprotein L 0.725125 
IPI00176637.5 LOC728350;EIF2S2 Eukaryotic translation initiation factor 2 subunit 2-like protein 0.72895 
IPI00217236.4 TBCA Tubulin-specific chaperone A 0.731425 
IPI00873383.1 ST6GALNAC3 Putative uncharacterized protein ST6GALNAC3 (Fragment) 0.73335 
IPI00025273.1 GART Isoform Long of Trifunctional purine biosynthetic protein adenosine-3 0.7336 
IPI00005260.4 PSME4 Isoform 1 of Proteasome activator complex subunit 4 0.737675 
IPI00936284.1 LOC100291317 hypothetical protein XP_002346735 0.737725 
IPI00011200.5 PHGDH D-3-phosphoglycerate dehydrogenase 0.740125 
IPI00014263.1 EIF4H Isoform Long of Eukaryotic translation initiation factor 4H 0.740525 
IPI00647915.1 TAGLN2 24 kDa protein 0.74235 
IPI00218319.3 TPM3 Isoform 2 of Tropomyosin alpha-3 chain 0.74525 
IPI00025086.4 COX5A Cytochrome c oxidase subunit 5A, mitochondrial 0.746925 
IPI00031708.1 FAH Fumarylacetoacetase 0.7485 
IPI00219445.1 PSME3 Isoform 2 of Proteasome activator complex subunit 3 0.7494 
IPI00941907.1 STRAP Serine-threonine kinase receptor-associated protein 0.749525 
IPI00003419.1 C11orf58 Small acidic protein 0.75335 
IPI00794978.1 MRPL47 Isoform 2 of 39S ribosomal protein L47, mitochondrial 0.75475 
IPI00298547.3 PARK7 Protein DJ-1 0.7586 
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IPI00011569.2 ACACA Isoform 1 of Acetyl-CoA carboxylase 1 0.758975 
IPI00010402.2 SH3BGRL3 Putative uncharacterized protein 0.75905 
IPI00013452.10 EPRS Bifunctional aminoacyl-tRNA synthetase 0.75935 
IPI00643317.3 HMGB3 21 kDa protein 0.75965 
IPI00413611.1 TOP1 DNA topoisomerase 1 0.7599 
IPI00386119.4 SF1 Isoform 5 of Splicing factor 1 0.76005 
IPI00647786.1 ARHGEF1 Isoform 1 of Rho guanine nucleotide exchange factor 1 0.7623 
IPI00879531.1 - 9 kDa protein 0.76255 
IPI00337541.3 NNT NAD(P) transhydrogenase, mitochondrial 0.7628 
IPI00219034.3 NDUFA8 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 8 0.765725 
IPI00026105.1 SCP2 Isoform SCPx of Non-specific lipid-transfer protein 0.766575 
IPI00220362.5 HSPE1 10 kDa heat shock protein, mitochondrial 0.766825 
IPI00021266.1 RPL23A 60S ribosomal protein L23a 0.76865 
IPI00879702.2 RBBP7 Retinoblastoma binding protein 7 0.76875 
IPI00376005.2 EIF5A Isoform 2 of Eukaryotic translation initiation factor 5A-1 0.770075 
IPI00798025.1 C21orf33 Protein 0.770875 
IPI00783982.1 COPG Coatomer subunit gamma 1.311425 
IPI00789457.1 KPNA2 Karyopherin alpha 2 1.3168 
IPI00847759.2 DENND4B DENN domain-containing protein 4B 1.319025 
IPI00939174.1 OTUB1 Isoform 1 of Ubiquitin thioesterase OTUB1 1.320725 
IPI00479191.2 HNRNPH1 51 kDa protein 1.324325 
IPI00646241.1 CIRBP 18 kDa protein 1.3329 
IPI00220503.9 DCTN2 dynactin 2 1.334425 
IPI00009950.1 LMAN2 Vesicular integral-membrane protein VIP36 1.345175 
IPI00478410.2 ATP5C1 Isoform Liver of ATP synthase subunit gamma, mitochondrial 1.357275 
IPI00007244.1 MPO Isoform H17 of Myeloperoxidase 1.36145 
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IPI00220301.5 PRDX6 Peroxiredoxin-6 1.365 
IPI00007163.1 LSM7 U6 snRNA-associated Sm-like protein LSm7 1.36535 
IPI00641334.3 CYB5B Putative uncharacterized protein DKFZp686M0619 1.3658 
IPI00375380.4 PSMD13 proteasome 26S non-ATPase subunit 13 isoform 2 1.3667 
IPI00293655.3 DDX1 ATP-dependent RNA helicase DDX1 1.36765 
IPI00943215.1 BID 22 kDa protein 1.377575 
IPI00790115.1 SLC25A3 cDNA FLJ90278 fis, clone NT2RP1000325, highly similar to Phosphate carrier 
protein, mitochondrialprecursor 
1.381575 
IPI00759715.1 FH Isoform Cytoplasmic of Fumarate hydratase, mitochondrial 1.3822 
IPI00945846.1 PRSS1 28 kDa protein 1.392275 
IPI00927101.1 RPSAP15;RPSA 30 kDa protein 1.393575 
IPI00894213.1 RTN4 Isoform 6 of Reticulon-4 1.396275 
IPI00639819.1 TARDBP TAR DNA binding protein 1.4045 
IPI00878984.1 DDT 14 kDa protein 1.413525 
IPI00023542.6 TMED9 Transmembrane emp24 domain-containing protein 9 1.41695 
IPI00945622.1 NAT13 15 kDa protein 1.42115 
IPI00939315.1 - 37 kDa protein 1.422875 
IPI00893362.1 RYR3 Putative uncharacterized protein RYR3 1.42985 
IPI00023302.2 SYN2 Isoform IIa of Synapsin-2 1.4363 
IPI00328754.6 ZFHX4 zinc finger homeodomain 4 1.44505 
IPI00827658.1 CD44 Isoform 7 of CD44 antigen 1.448625 
IPI00910419.1 DDOST cDNA FLJ52929, highly similar to Dolichyl-diphosphooligosaccharide--
proteinglycosyltransferase 48 kDa subunit 
1.448975 
IPI00003217.3 PSMB7 Proteasome subunit beta type-7 1.458875 
IPI00903204.1 RPS24 15 kDa protein 1.461875 
IPI00872855.1 EWSR1 Isoform EWS of RNA-binding protein EWS 1.469025 
IPI00795292.1 NME2;NME1-NME2 Isoform 3 of Nucleoside diphosphate kinase B 1.474 
IPI00220416.3 UQCRB Cytochrome b-c1 complex subunit 7 1.4765 
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IPI00514530.5 ACTA1 Putative uncharacterized protein ACTA1 1.493825 
IPI00013122.1 CDC37 Hsp90 co-chaperone Cdc37 1.498125 
IPI00000816.1 YWHAE 14-3-3 protein epsilon 1.50145 
IPI00940656.1 ANP32A;LOC723972 Putative uncharacterized protein ANP32A 1.513525 
IPI00027409.1 PRTN3 Myeloblastin 1.515325 
IPI00550917.3 TWF2 Twinfilin-2 1.51825 
IPI00910593.1 CNN2 cDNA FLJ52765, highly similar to Calponin-2 1.519975 
IPI00744851.2 HMGA1 cDNA FLJ54188, moderately similar to High mobility group protein HMG-I/HMG-Y 1.533025 
IPI00007188.5 SLC25A5 ADP/ATP translocase 2 1.5607 
IPI00420014.2 SNRNP200 Isoform 1 of U5 small nuclear ribonucleoprotein 200 kDa helicase 1.5767 
IPI00219525.10 PGD 6-phosphogluconate dehydrogenase, decarboxylating 1.584975 
IPI00105598.3 PSMD11 Proteasome 26S non-ATPase subunit 11 variant (Fragment) 1.586 
IPI00015602.1 TOMM70A Mitochondrial import receptor subunit TOM70 1.58615 
IPI00059139.1 ATP6V1E2 V-type proton ATPase subunit E 2 1.59565 
IPI00743626.1 MTHFD2 Methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, 
methenyltetrahydrofolate cyclohydrolase, isoform CRA_b 
1.622525 
IPI00908424.1 CDC2 cell division cycle 2 isoform 3 1.64165 
IPI00550069.3 RNH1 Ribonuclease inhibitor 1.645675 
IPI00657659.1 BNC2 Basonuclin 2 1.66475 
IPI00399142.5 SURF4 Surfeit 4 1.667925 
IPI00893258.1 SMC1B Isoform 3 of Structural maintenance of chromosomes protein 1B 1.70635 
IPI00293276.10 MIF Macrophage migration inhibitory factor 1.71975 
IPI00514622.2 RANBP6 Ran-binding protein 6 1.732075 
IPI00383680.3 RPN2 ribophorin II isoform 2 precursor 1.7333 
IPI00031411.3 FAT1 507 kDa protein 1.8685 
IPI00022246.1 AZU1 Azurocidin 1.890675 
IPI00914061.1 TCOF1 Treacher Collins-Franceschetti syndrome 1 isoform e 1.92545 
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IPI00746770.4 LOC728129 Putative LRRC3-like protein ENSP00000367157 1.926975 
IPI00013163.1 MNDA Myeloid cell nuclear differentiation antigen 2.036625 
IPI00220271.3 AKR1A1 Alcohol dehydrogenase [NADP+] 2.043675 
IPI00793234.1 - 395 kDa protein 2.087575 
IPI00006377.4 POMP Proteasome maturation protein 2.0987 
IPI00759542.1 TTN Isoform 8 of Titin 2.102375 
IPI00022643.2 TRIM36 E3 ubiquitin-protein ligase TRIM36 2.183625 
IPI00385250.1 PRSS3 Protease serine 4 isoform B 2.197475 
IPI00937077.1 hCG_2011852 hypothetical protein LOC643677 2.2041 
IPI00218448.4 H2AFZ Histone H2A.Z 2.251175 
IPI00939523.1 DDX46 117 kDa protein 2.2599 
IPI00009030.1 LAMP2 Isoform LAMP-2A of Lysosome-associated membrane glycoprotein 2 2.269725 
IPI00941463.1 NAP1L4 Nucleosome assembly protein 1-like 4 3.0814 
IPI00939431.1 RELN 368 kDa protein 3.17255 
IPI00022630.1 AIF1 Allograft inflammatory factor 1 3.278075 
IPI00031696.4 FASTKD3 FAST kinase domain-containing protein 3 4.0252 
IPI00644529.1 ZNF615;ZNF432 Isoform 1 of Zinc finger protein 615 6.2289 
IPI00477040.1 NUP188 Isoform 1 of Nucleoporin NUP188 homolog 6.65625 
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